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RIASSUNTO 
 
 
Base scientifica del progetto  
Biocatalisi e glicosidasi 
Le biocatalisi rappresentano uno strumento ampiamente utilizzato nel campo delle 
biotecnologie. Un valore aggiunto in tale ambito viene fornito dall’utilizzo di enzimi 
come catalizzatori, i quali possono aumentare la selettività delle reazioni, la resa dei 
prodotti desiderati ed il cui utilizzo comporta una diminuzione dell’utilizzo di sostanze 
chimiche inquinanti. Tra gli enzimi utilizzati, le glicosidasi risultano particolarmente 
interessanti, soprattutto nella produzione di detergenti (cellulasi ed amilasi), di 
bioetanolo a partire dalla biomassa vegetale, di soft-drinks ad alto contenuto 
zuccherino ecc. Tra le glicosidasi, negli ultimi anni grande attenzione è stata dedicata 
alle α-L-ramnosidasi (α-RHA), enzimi che catalizzano l’idrolisi di un residuo di ramnosio 
in un’ampia varietà di composti presenti in natura, come i flavonoidi, e che sono 
prodotte da tessuti di origine animale, da piante, funghi e batteri. Nell’ultimo decennio 
le α-RHA hanno attirato un grande interesse per il loro utilizzo come biocatalizzatori 
nell’industria alimentare, farmaceutica e nei processi di chimica industriale. In 
particolare, questi enzimi vengono utilizzati nell’industria alimentare per esaltare gli 
aromi dei vini attraverso l’idrolisi enzimatica dei glicosidi terpenici contenenti L-
ramnosio, e per dolcificare e chiarificare i succhi di frutta ottenuti da agrumi. 
Nonostante le applicazioni finora descritte, ad oggi solo poche α-L ramnosidasi di 
origine batterica sono state caratterizzate e attualmente un numero estremamente 
esiguo di strutture tridimensionali è depositato in banca dati.  Tutto questo rende le α-
L ramnosidasi una classe di enzimi ancora poco caratterizzata e con un interessante 
potenziale biotecnologico ancora da esplorare. 
 
L’immobilizzazione degli enzimi 
L’utilizzo di enzimi in applicazioni industriali è spesso limitato dalla loro instabilità, dal 
loro elevato costo di purificazione e dall’impossibilità di disporne in grande quantità. 
Tutte queste problematiche trovano una loro soluzione nell’immobilizzazione degli 
enzimi su diversi supporti, approccio che può aumentare sia la stabilità di un enzima 
che la sua attività enzimatica, avvantaggiando l’avanzamento delle reazioni e 
aumentando la rese dei prodotti desiderati. Diverse tipologie di supporti per 
l’immobilizzazione sono state fino ad ora utilizzate e studiate ma, negli ultimi anni, di 
particolare interesse si è rivelato l’utilizzo di nanobiomateriali. In particolare, la ricerca 
si è recentemente focalizzata sull’isolamento di nanoparticelle di origine biologica quali 
le Outer Membrane Vesicles (OMVs) originate da batteri gram-negativi e le 
Extracellular Vesicles (EVs), secrete invece da cellule eucariotiche. 
-Outer Membrane Vesicles (OMVs) e Extracellular Vesicles (EVs) 
Le OMVs sono proteo-liposomi con un diametro di circa 20-200 nm, prodotte dai batteri 
gram-negativi durante il loro ciclo vitale. Sembra che la loro funzione possa essere 
quella di veicolare tossine, molecole segnale, nutrienti e attività enzimatiche di vario 
genere, e che siano quindi implicate in svariati processi. Queste nanostrutture possono 
essere interessanti in campo biotecnologico sia per l’immobilizzazione di enzimi, sia 
per creare nuovi supporti per il “drug-delivery”. Ad oggi le OMVs maggiormente 
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studiare derivano da batteri gram-negativi patogeni; al contrario, le OMVs secrete da 
batteri non patogeni, che dovrebbero essere più indicate in campo farmaceutico, 
risultano invece essere ancora poco studiate e caratterizzate. Per quanto riguarda le 
EVs, si tratta di particelle di grandezza variabile tra i 30 e i 2000 nm secrete da gran 
parte delle cellule eucariotiche, classificate, in base alla loro differente origine, in due 
principali categorie: esosomi e microparticelle (MP). Tali nanostrutture sono implicate 
in diversi processi fisiologici quali ad esempio la coagulazione, e sembrano avere un 
ruolo nell’insorgenza delle patologie cardiovascolari e del cancro [4,6,7 star]; in campo 
biotecnologico potrebbero avere un grande potenziale nell’ambito della progettazione 
di nuovi farmaci. Ciò che rende le EVs più idonee delle OMVs batteriche nel campo 
del drug-delivery deriva dal fatto che tali nanovescicole, essendo di origine eucariotica, 
dovrebbero essere meno immunogeniche. Le EVs possiedono inoltre uno specifico 
meccanismo di “cell-targeting”, che permetterebbe una veicolazione del farmaco 
mirata ad uno specifico tessuto. 
 
Novosphingobium sp. PP1Y 
Nel laboratorio in cui ho svolto il seguente progetto di dottorato, è stato recentemente 
isolato, dalle acque superficiali di una piccola baia all’interno del porto di Pozzuoli, un 
α-proteobatterio gram-negativo: Novosphingobium sp. PP1Y (N.sp. PP1Y). N.sp. 
PP1Y appartiene all’ordine degli sfingomonadali ed è in grado di utilizzare un numero 
sorprendentemente ampio di idrocarburi aromatici mono- e policiclici come unica fonte 
di carbonio e di energia, con un efficace adattamento alla crescita su miscele 
complesse di molecole aromatiche disciolte in fasi non polari (come il gasolio e la 
benzina). Considerate le sue peculiari caratteristiche, N.sp. PP1Y risulta essere molto 
interessante per l’isolamento sia di nuove attività enzimatiche sia di OMVs. L’interesse 
per l’isolamento di nuove glicosidasi di interesse biotecnologico da tale batterio nasce 
dalla considerazione che l’analisi del suo genoma, completamente annotato, ha 
evidenziato un’abbondanza unica di geni codificanti per glicosil-idrolasi (53 ORFs) e 
glicosil-trasferasi (57 ORFs); tra questi sono stati identificati 8 geni codificanti per 
proteine con attività ramnosidasica. 
Altro aspetto interessante è il fatto che PP1Y mostra un complesso dimorfismo 
planctonico/sessile ed è in grado di colonizzare superfici idrofobiche o interfacce 
acqua/gasolio. Dati preliminari hanno inoltre mostrato la capacità di PP1Y di formare, 
in soluzione, flocculi amorfi o un biofilm strutturato. Queste caratteristiche morfologiche 
e metaboliche, oltre ad evidenziare la potenzialità dello stesso biofilm per applicazioni 
industriali nelle biotecnologie dei materiali e del biorisanamento, suggerirebbero la 
produzione di OMVs per l’acquisizione di nutrienti e la comunicazione cellulare. 
 
Obiettivi del progetto di ricerca 
Sulla base delle considerazioni descritte nella sezione precedente, le α-L-
rhamnosidasi, le OMVs e le EVs sono considerate interessanti elementi per il 
miglioramento dei processi biocatalitici nelle industrie biotecnologiche.  
Lo scopo di questa tesi è stato quello di: i) caratterizzare una nuova α-L-rhamnosidasi 
da Novosphingobium sp. PP1Y, un microorganismo gram-negativo recentemente 
isolato nel porto di Pozzuoli; ii) Isolare e caratterizzare OMVs da Novosphingobium sp. 
PP1Y ed EVs da macrofagi murini.  
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Risultati 
 
Isolamento e caratterizzazione di una nuova α-L-rhamnosidasi da 
Novosphingobium sp. PP1Y 
Nel laboratorio in cui ho svolto il mio progetto di dottorato, è stata recentemente 
identificata un’attività α-L-ramnosidasica nell’estratto crudgrezzoo del batterio 
Novosphingobium sp. PP1Y, cresciuto in presenza di 0.3 mM naringina. Il gene 
codificante per tale enzima è stato clonato in un vettore di espressione pET22b(+), e 
la proteina è stata espressa in maniera ricombinante in cellule di E. coli BL21(DE3). I 
primi tentativi di espressione hanno evidenziato la presenza della proteina nella sola 
porzione insolubile; di conseguenza, la temperatura di induzione è stata diminuita da 
37 a 23 °C e la crescita batterica è stata effettuata in terreno LB ad alte concentrazioni 
di NaCl e in presenza di Betaina e Sorbitolo, due molecole che possono agire da 
“chaperon molecolari”, consentendo un miglioramento del folding della proteina 
stessa. La proteina è stata quindi espressa nelle condizioni ottimizzate e la 
purificazione è stata effettuata seguendo tre passaggi cromatografici, al termine dei 
quali la resa ed il fattore di purificazione risultavano però non soddisfacenti. La 
sequenza amminoacidica di rRHA-P, un monomero di 101,500 ± 5,000 Da, è stata 
verificata per spettrometria di massa. La successiva caratterizzazione dal punto di 
vista biochimico di rRHA-P, ha evidenziato una KM inferiore rispetto alle altre α-RHA 
riportate in letteratura, suggerendo una maggiore affinità di rRHA-P per il substrato 
sintetico utilizzato. Per valutare l’effettivo potenziale biotecnologico di rRHA-P, sono 
state inoltre determinate le condizioni ottimali di attività enzimatica in diverse condizioni 
sperimentali. In particolare, rRHA-P presenta proprietà leggermente basofile con 
un’attività ottimale a pH 6.9 e a 40.9 °C, conservando una certa stabilità fino a 50°C. 
L’enzima possiede inoltre una moderata tolleranza ai solventi organici, quali etanolo e 
DMSO; i risultati ottenuti indicano che rRHA-P mostra diverse caratteristiche di 
interesse biotecnologico. È stata a tal proposito valutata la capacità di rRHA-P di 
idrolizzare alcuni flavonoidi naturali, la cui solubilità è più elevata in condizioni di pH 
basico, alte temperature e in presenza di solventi organici. I risultati ottenuti hanno 
mostrato che rRHA-P è in grado di convertire, dopo 3h di incubazione, di 
completamente la naringina nei corrispondenti prunina e ramnosio, e parzialmente 
rutina e neoesperidina. Tali dati supportano ulteriormente l’utilizzo dell’enzima in 
processi di bioconversione. Le analisi di spettrometria di massa ed il sequenziamento 
N-terminale effettuati sulla proteina rRHA-P purificata hanno evidenziato l’assenza dei 
primi 23 aminoacidi codificati dal gene, il che ha suggerito la presenza di un peptide 
segnale, successivamente allontanato in seguito a modifiche post-traduzionali della 
stessa. Tale peptide possiede delle caratteristiche peculiari e, da dati presenti in 
letteratura, sembra essere coinvolto nel “sorting” della proteina nello spazio 
periplasmatico. Tale ipotesi è stata confermata da esperimenti di espressione analitica, 
in cui la frazione periplasmatica evidenzia un’attività ramnosidasica 400 volte maggiore 
rispetto alla frazione citoplasmatica.  Considerando la bassa resa di purificazione di 
rRHA-P, si è deciso di clonare e di esprimere in maniera ricombinante la proteina fusa 
con un his-tag, e di utilizzare, come primo step di purificazione, l’estrazione della 
frazione periplasmatica. Seguendo il protocollo appena descritto, è stato necessario 
un solo step di purificazione attraverso una cromatografia di affinità che ha permesso 
di ottenere, con una resa del 25%, una proteina molto pulita caratterizzata da una 
minima percentuale di contaminanti. Saggi di attività sulla proteina purificata non 
hanno mostrato una significativa influenza del tag di istidine nè sulla attività specifica, 
né sull’efficienza catalitica dell’enzima. Per implementare l’utilizzo biotecnologico di 
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rRHA-P, sono stati effettuati esperimenti di mutagenesi per ottenere una preliminare 
identificazione degli ipotetici residui amminoacidici responsabili dell’attività catalitica 
dell’enzima. È stato quindi effettuato, in primo luogo, un allineamento della sequenza 
della proteina rRHA-P con sequenze di ramnosidasi della stessa famiglia GH106, già 
presenti in banca dati. Successivamente, individuati i 5 residui maggiormente 
conservati (D504, E506, D552, E644 e D763), si è proceduto con un approccio di 
mutagenesi sito specifica in cui i residui di interesse sono stati sostituiti con alanina ed 
è stata valutata la loro influenza sull’attività specifica di rRHA-P. Le mutazioni in 
posizione 504, 506 e 644 sembrano portare ad una totale inattivazione dell’attività 
catalitica, mentre le mutazioni in posizione 552 e 763 hanno mostrato una ritenzione 
dell’attività enzimatica di rRHA-P compresa tra il 6 e il 12%. Tali dati suggeriscono un 
effetto differenziale dei residui amminoacidici individuati dall’allineamento e pongono 
le basi per futuri interventi di mutagenesi finalizzati al fine-tuning dell’attività enzimatica 
su substrati di interesse biotecnologico. 
 
Isolameto di vescicole batteriche e eucariotiche  
Per ottimizzare l’utilizzo degli enzimi come biocatalizzatori, oltre all’ingegnerizzazione, 
molto utile può essere la loro immobilizzazione su diversi tipi di supporti. In particolare, 
al fine di sviluppare supporti biocompatibili, sono stati recentemente studiati sistemi di 
immobilizzazione composti da membrane di origine biologica. Durante la seconda 
parte del mio periodo di dottorato, mi sono quindi occupata della caratterizzazione di 
due possibili sistemi di immobilizzazione, uno di origine batterica (Outer Membrane 
Vesicles OMVs) ed uno di derivazione eucariotica (Extracellular Vesicles EVs). 
 
Isolamento e caratterizzazione di OMVs da Novosphingobium sp. PP1Y 
Le OMVs sono state isolate da N. sp. PP1Y, un batterio gram-negativo non patogeno. 
Analisi di microscopia elettronica (SEM) e a forza atomica (AFM) hanno evidenziato, 
durante la crescita in terreno minimo, una significativa attività di vescicolazione in tarda 
fase esponenziale, evidenza che spiegherebbe la vescicolazione di N. sp. PP1Y come 
possibile strategia per l’acquisizione di nutrienti. Le OMVs identificate sono state quindi 
purificate attraverso una serie di ultracentrifugazioni e la loro analisi strutturale ha 
evidenziato una forma sferica e un diametro di ≈ 130-150 nm, in linea con le OMVs 
descritte in letteratura. Le OMVs da N. sp. PP1Y, risultano inoltre avere una peculiare 
composizione biochimica sia per quanto riguarda le proteine che per quanto concerne 
gli acidi grassi. L’analisi proteomica ha infatti evidenziato la presenza di una 
preponderanza di enzimi idrolitici rispetto alle cellule del ceppo PP1Y. Ancor più 
interessante risulta il fatto che la maggior parte delle proteine maggiormente presenti 
sulle OMVs, non lo è invece nelle cellule di PP1Y; in particolare le OMVs risultano 
avere, al contrario delle cellule, una elevata percentuale di proteine di membrana ed 
enzimi idrolitici ed una quasi totale assenza di enzimi deputati al metabolismo cellulare. 
Anche la composizione in acidi grassi sembra essere fortemente regolata nelle OMVs, 
che infatti presentano una grande percentuale di acidi grassi saturi, rispetto alla 
membrana delle cellule; questo aspetto suggerisce una specifica selezione degli acidi 
grassi durante la vescicolazione, che avverrebbe in zone della membrana batterica più 
“rigide” rispetto al resto della cellula.  
I dati ottenuti incrementano fortemente l’interesse delle OMVs nel campo delle 
biotecnologie anche se un limite nel loro utilizzo è rappresentato dalla loro 
immunogenicità verso le cellule eucariotiche, dovuta alla presenza di LPS sulla 
membrana esterna. In questo contesto, N. sp. PP1Y sembra essere un buon candidato 
in quanto la sua membrane esterna non presenta LPS. Infatti, il trattamento di cellule 
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di cheratinociti umani con concentrazioni crescenti di OMVs, non ha mostrato una 
significativa diminuzione della vitalità cellulare rispetto al controllo; tale dato suggerisce 
una potenziale biocompatibilità delle OMVs per le cellule eucariotiche, che necessita 
chiaramente di ulteriori indagini effettuate su altre linee cellulari. 
 
Isolamento e caratterizzazione di EVs da macrofagi 
 Una valida alternativa alle OMVs batteriche per il drug-delivery è rappresentata dalle 
vescicole isolate da cellule eucariotiche: EVs. Tali nanostrutture sono classificate, in 
base alla loro origine e dimensione, in Microparticelle (MPs), che hanno una grandezza 
di ≈ 400-2000 nm ed esosomi, di ≈ 50-200 nm. Tali vescicole originano da diversi tipi 
di cellule eucariotiche, il che le rende meno immunogeniche per le stesse e quindi più 
attraenti per il drug-delivery; inoltre, grazie alla presenza di specifici recettori di 
membrana, le EVs possono avere uno specifico cell-targeting che può aumentare 
l’efficienza di veicolazione di un farmaco. Nell’ultima parte del mio progetto di dottorato 
mi sono quindi occupata della caratterizzazione e della valutazione dell’effetto 
immunogenico di EVs isolate da macrofagi murini. Per l’isolamento delle EVs sono 
stati valutati differenti stimoli, tra cui l’utilizzo di LPS, acido oleico e acido palmitico, i 
quali incrementano la vescicolazione rispetto alle cellule non stimolate. Tali vescicole, 
dopo opportuna purificazione tramite ultracentrifugazione, sono risultate essere 
omogenee in taglia e conformi rispetto a quelle descritte in letteratura. La valutazione 
dell’effettivo utilizzo delle EVs in campo biotecnologico passa necessariamente 
attraverso la determinazione dell’effetto di tali nanostrutture sulle cellule eucariotiche. 
In particolare, negli ultimi anni è stata riscontrata una correlazione tra le EVs isolate 
da macrofagi e l’instaurazione di uno stato di infiammazione. Per tale motivo, nelle EVs 
isolate da cellule sottoposte a stimoli di vescicolazione, è stata valutata l’espressione 
di Nlrp3, un complesso proteico definito “infiammosoma” responsabile dell’attivazione 
della gran parte dei processi infiammatori. In particolare, la stimolazione dei macrofagi 
con LPS e acido palmitico aumenta significativamente l’espressione di Nlpr3, 
suggerendo un’effettiva differenza anche nell’effetto delle diverse EVs su altre cellule. 
In particolare, essendo le cellule vascolari le prime coinvolte nell’infiammazione, 
l’effetto pro-infiammatorio delle EVs, sia MPs che esosomi, è stato valutato su cellule 
muscolari lisce vascolari (VSMC). In questo modello sperimentale è stato evidenziato 
un significativo aumento dell’espressione della caspasi-1 attivata in seguito a 
trattamento delle VSMC con MPs ed esosomi isolate da macrofagi stimolati con LPS 
e acido palmitico, mentre si è osservato un aumento dell’espressione della caspasi-8 
soltanto dopo trattamento con esosomi isolati da macrofagi stimolati con LPS e acido 
palmitico.  
In conclusione, in questo lavoro di dottorato è stato messo a punto un sistema di 
espressione ricombinante e di purificazione di una nuova α-RHA, il cui potenziale 
biotecnologico è stato analizzato e discusso. Inoltre, questo progetto di dottorato ha 
permesso di caratterizzare due possibili sistemi di immobilizzazione e di veicolamento 
di attività enzimatiche e/o di piccole molecole organiche, di origine batterica (OMVs) 
ed eucariotica (EVs). Tutti i sistemi analizzati in questo progetto di dottorato risultano 
essere molto interessanti dal punto di vista biotecnologico e applicabili in diversi campi.  
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ABSTRACT 
 
 
Biocatalysis represents a versatile and valuable tool for industrial biotechnologies. The 
use of enzymes as biocatalysts has reached its present industrial level, due to their 
optimal reaction selectivity, high reaction rates, high product purity, and a significant 
decrease in the generation of chemical waste. The use of enzymes in industrial 
applications has been limited by several factors, mainly the high cost of enzymes, their 
instability, and their availability in small amounts. To overcome these problems, the 
quest for new catalytic activities and the development of new technical approaches, 
such as enzyme immobilization, to improve their stability and practical applications, 
remain a central focus of the current biotechnological research. In this PhD thesis, the 
biotechnological potential of a novel bacterial glycosidase (α-RHA), and the 
characterization of two possible immobilization systems, bacterial OMVs and 
eukaryotic EVs is reported. 
More in detail, an optimized expression and purification procedure allowed to 
characterize a novel α-RHA from the microorganism Novosphingobium sp. PP1Y, 
which resulted to be appealing from a biotechnological point of view for its interesting 
catalytic behaviour. Moreover, mutagenesis experiments, allowed a preliminary 
identification of the amminoacidic residues responsible for the catalytic activity of 
rRHA-P, which could be further mutagenized to fine-tune rRHA-P catalytic efficiency 
on selected substrates. 
In addition, two different potential scaffolds from bacteria (OMVs) and from an 
eukaryotic cell line (EVs) were isolated and characterized. Both systems resulted to be 
appealing either for enzyme immobilization or for drug-delivery strategies. In particular, 
OMVs isolated from N. sp. PP1Y were characterized by a peculiar biochemical 
composition, which showed some differences with the originating whole cells. EVs 
isolated from human macrophages resulted to have differential effects on inflammation 
activation, and their potential as a valid alternative to bacterial OMVs for the 
development of novel delivery Biosystems is discussed. 
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ABBREVIATIONS 
 
α-RHA = α-L-rhamnosidase 
ABS = absorbance 
AFM = atomic force microscopy 
BSA = bovin serum albumin 
DLS = dynamic light scattering 
DMEM = Dulbecco modified Eagle’s medium 
DMSO = dimethyl sulfoxide 
EtOH = ethanol 
EVs = extracellular vesicles 
GC-MS = gas chromatography – mass spectrometry 
GFP = green fluorescent protein 
GHs = glycosyl hydrolases 
GTs = glycosyl transferases 
IPTG = isopropyl β-D-1-thiogalactopyranoside 
LB = Luria Bertani 
LC-MS = liquid chromatography – mass spectrometry 
LPS = lipopolysaccharide 
MOPS = morpholinopropansulphonic acid 
MPs = microparticles 
MUFA = monounsaturated fatty acid 
NTA = nano tracking particles analysis 
OA = oleic acid 
OD = optical density 
OM = outer membrane 
OMPs = outer membrane proteins 
OMVs = outer membrane vesicles 
ORF = open reading frame 
PA = palmitic acid 
PAHs = polycyclic aromatic hydrocarbons 
PBS = phosphate sulphate buffer 
PLs = phospholipids 
pNPR = para-nitrophenyl rhamnopyranoside 
ppb = parts per billion 
PPMM = potassium phosphate minimal medium 
PUFA = polyunsaturated fatty acid 
RT = room temperature 
SDS = sodium dodecyl sulphate 
SEM = scanning electron microscopy 
SFA = saturated fatty acid 
TLC = thin layer chromatography 
TLR4 = Toll-like receptor 4 
UFA = unsaturated fatty acid 
VSMC = vascular smooth muscle cells 
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CHAPTER I  
INTRODUCTION 
 
 
1.1 Biocatalysis and glycosidases 
 
Biocatalysis represents nowadays a versatile and valuable tool for industrial 
biotechnologies. The use of enzymes as biocatalysts gives invaluable advantages over 
conventional chemical technologies, for achieving high reaction selectivity, higher 
reaction rate, improved product purity, and a significant decrease in chemical waste 
generation. More in detail, in the fine chemical and pharmaceutical industries several 
advantages can be obtained from the use of biocatalytic processes, such as: 
- reduction of processing steps (improved productivity and lower costs); 
- transfer of processes from organic solvents to water (lower emissions, saving on raw 
materials and waste treatment); 
- use of eco-friendly mild reaction conditions (avoiding very high or very low 
temperatures, and therefore heating/refrigeration costs). 
Biocatalysts can be performed either with whole cells or purified enzymes, in solution 
or immobilized. 
Glycosidases are a class of enzymes particularly suited for biotechnological 
applications. These enzymes catalyse the hydrolysis of the glycosidic linkage, leading 
to the formation of a sugar hemiacetal or hemiketal and the corresponding free aglycon 
[1] (Fig. 1).  
 
 
 
Figure 1. Glycosidases reaction mechanism.  
 
 
Glycosidases (GH) are present in almost all living organisms [2] where they play 
different roles. Based on the amino acid sequence and folding and the diversity of the 
reactions catalysed, glycosidases have been classified in many different ways. 
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Recently, a new type of classification was proposed based on the amino acid similarity 
within the proteins; this classification is available in the Carbohydrate-Active Enzymes 
database (CAZy - http://www.cazy.org/) [2] and provides a direct relationship between 
sequence and folding similarities, which can be found in 130 amino acid sequence-
based families. In general, GHs belonging to the subfamilies of the same family share 
a common ancestor, a similar 3D structure and are characterized by an identical 
catalytic mechanism [2]. 
Despite all their natural functions, glycosidases are nowadays considered an attractive 
target for food, paper and pulp industries, as well as in organic chemistry, where 
glycosidases have proven to be efficient catalysts, able to hydrolize very stable 
glycosidic bonds in glycoconjugates, oligo- and poly-saccharides [3]. For this reason, 
glycosidases have wide and documented applications in several fields of 
biotechnology. Classical examples of industrial application of these enzymes include 
detergent formulations (cellulases and amylases) for the removal of glycan spots and 
fading of the denim color [4] pulp and paper bleaching (xylanases) [5], conversion of 
lignocellulosic plant biomass into bioethanol (cellulases, glucosidases, xylanases, etc. 
[6], production of High Fructose Corn Syrup for soft drinks (amylases and 
glucoamylases) [7], fruit juice processing (pectinases) [8], and many others. 
Glycosidases have recently attracted the attention of many pharmaceutical industries 
since they are involved in many biological processes such as cell-cell or cell-virus 
recognition, immune responses, cell growth, and viral and parasitic infections [9].  
In addition to the hydrolytic ability, GHs can also be used under appropriate conditions 
for the reverse reaction, thus promoting the formation of glycosidic linkages. These 
reactions are called transglycosylations [10] and generally require high substrate 
concentration. In this case, the glycosyl donor can be a monosaccharide, an 
oligosaccharide or an activated glycoside. This specific action of glycosidases, which 
work either as hydrolases or in the glycosynthetic mode [11], are of great interest for 
the production of functional foods and drugs, whose biological activities might be 
improved by either the removal or the addition of specific glycan moieties [12]. In 
conclusion, glycosidases are biotechnologically attractive for the preparation of 
structurally well-defined oligosaccharides compared to chemical processes that 
require instead, complex protection and deprotection steps. 
Continuous progress in the study of these enzymes and the application of molecular 
evolution and site-directed mutagenesis for better performance, is currently improving 
their potential use in oligosaccharide synthesis [13]. 
 
1.2 α-L-rhamnosidases 
 
α-L-Rhamnosidases (α-RHAs) are a subset of GHs that have gained much attention 
in recent years. These enzymes catalyse the hydrolysis of a terminal L-rhamnose from 
a large number of natural products [14].  
L- Rhamnose is widely distributed in plants as component of flavonoid glycosides, 
terpenyl glycosides, pigments, signalling molecules, and in cell walls as a component 
of complex heteropolysaccharides, such as rhamnogalacturonan and arabinogalactan-
proteins [15-18]. In bacteria, L-rhamnose appears to be included in membrane 
rhamnolipids [19-20] and polysaccharides [21]. According to the GHs classification, α-
RHAs are grouped in the CAZy (carbohydrate-active enzymes) database (www.cazy. 
org) into four different families: GH28, GH78, GH106, and NC (non-classified). 
 α-RHAs are produced by a large number of animal tissues, plants, fungi, bacteria and 
bacteriophages [16], but their physiological role is still not well understood. The 
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hypothesis can be advanced that the role of α-RHAs is linked to the broad distribution 
of L-rhamnose as a component in bacterial and plant cell walls, glycosides, biofilms 
and glycolipids [16,22]. 
In the last decade, α-RHAs have attracted a great deal of attention due to their potential 
application as biocatalysts in a variety of industrial processes and in particular in the 
food industry [1]. Among α-RHAs substrates, particularly interesting results natural 
flavonoids (Fig. 2), polyphenolic compounds generally characterized by a three-ring 
structure, which consists of two phenyl rings (A and B) and a heterocyclic ring (C). 
These molecules are naturally produced in plants in glycosylated forms, showing the 
presence of either a rutinoside (6-α-l-rhamnosyl-β-d-glucose) or a neohesperidoside 
(2-α-l-rhamnosyl-β-d-glucose) disaccharidic unit bound in different positions. These 
molecules are intriguing due to their potential antioxidant, antitumor and anti-
inflammatory properties [23-24]. In particular, naringin, hesperidin and rutin, flavanone 
glycosides found in grapefruit juices, lemons, sweet oranges and vegetables, have 
gained increasing recognition for their potential antioxidant, antitumor and anti-
inflammatory properties [25-28]. In humans, endogenous β-glucosidases are 
responsible for removing in the small intestine glucose (or possibly arabinose or 
xylose) moiety from flavonoids thus allowing their effective absorption; these enzymes, 
however, are not able to cleave terminal rhamnose units, thereby limiting the 
bioavailability of rhamnosylated flavonoids that are further converted by the colon local 
microflora [29-30]. Therefore, enzymatic rhamnose removal from potentially bioactive 
flavonoids might be the key point to improve their intestinal absorption and their 
beneficial properties on human health [31-32]. In addition, the ability to hydrolyze 
glycosylated flavonoids has been used, in the industrial field, to mitigate the bitterness 
of citrus juices, which is primarily caused by naringin [33-34]. Moreover, the 
corresponding de-rhamnosylated compound, prunin, is endowed with antimicrobial 
properties [28], and shows an improved intestinal assimilation when compared to 
naringin. Other applications of α-RHAs are gaining popularity in the oenological 
industry, where these enzymes are used to hydrolyze terpenyl glycosides and enhance 
aroma in wine, grape juices and derived beverages [35-37].  
 
 
 
 
Figure 2. Hydrolysis of naringin to prunin by α-L-rhamnosidase in the corrisponding product: prunin (a) 
and rhamnose. 
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Moreover, in their glycosynthetic mode of action α-L-rhamnosides can “decorate” 
flavonoids in fruit juices and wine, antibiotic and antitumoral drugs [38]. 
It is worth to note that the use of an α-RHA for the synthesis of rhamnose-containing 
chemicals by reverse hydrolysis was recently reported, suggesting a yet unexplored 
potential of these class of enzymes in the chemical and pharmaceutical industry [39]. 
Despite their potential as industrial biocatalysts, only a limited number of bacterial 
rhamnosidases have been extensively studied and characterized [40-44]. In fact, 
commercial preparations of α–RHAs, naringinases and hesperidinases available and 
currently used in oenology, are all isolated from fungal sources (Aspergillus niger and 
Penicillium decumbens) [45-47]. 
Different features of these two families of enzymes, especially pH optimum, suggest 
different applications for fungal and bacterial enzymes. As an example, fungal 
enzymes show more acidic pH optima compared to bacterial counterparts, for which 
neutral and alkaline optimal pH values have generally been reported [48-49]. This 
feature suggested that bacterial α-RHAs might be considered, for example, an 
alternative source of biocatalysts to use in basic conditions for the biotransformation 
of flavonoids such as naringin or hesperidin, whose solubility strongly increases at 
higher pH value [48-49]. Most importantly, few attempts have been described so far to 
engineer bacterial α-RHAs to unravel the molecular details concerning their catalytic 
mechanism, to modify their substrate specificity or to improve their catalytic efficiency 
towards different substrates [50]. A major stumbling is represented by the limited 
number of α-RHAs crystal structures currently available, with a consequent lack of 
structural data of these enzymes. To date, only two bacterial α-RHAs belonging to the 
GH106 family were described, one from Sphingomonas paucimobilis FP2001 [51] and 
the α-RHA BT0986 from Bacteroides thetaiotaomicron [52]. Moreover, only five crystal 
structures of bacterial α-RHA have been solved so far, which include the putative α-
RHA BT1001 from Bacteroides thetaiotaomicron VPI-5482 [53], the α-RHA B 
(BsRhaB) from Bacillus sp. GL1[54], α-RHA (SaRha78A) from Streptomyces 
avermitilis [55], and α-RHA (KoRha) from Klebsiella oxytoca [56]. All these enzymes 
belong to the GH78 group. Only one example of a GH106 α-RHAs crystal structure 
was recently reported and in the α-RHA BT096 expressed by Bacteroides 
thetaiotaomicron [52]. 
Therefore, it is evident that bacterial α-RHAs represent a yet unexplored reservoir of 
potential biocatalysts for which more functional and structural data are required.  
 
1.3 Enzyme immobilization 
The use of enzymes in industrial applications has been limited by several factors, 
mainly the high cost of the enzymes, their instability, and availability in small amounts. 
In addition, enzymes are soluble in aqueous media and it is difficult and expensive to 
recover them from reactor effluents at the end of the catalytic process. These limits the 
use of soluble enzymes to batch operations, followed by disposal of the spent enzyme-
containing solvent [57]. Over the last few decades, intense research in the area of 
enzyme technology has provided many approaches that facilitate their practical 
applications. Among these, technological developments in the field of immobilized 
biocatalysts resulted to be a very powerful tool to improve almost all enzyme 
properties, such as stability, activity, specificity selectivity, and enzyme inhibition [58]. 
Enzyme immobilization offers the possibility of a wider and more economical 
exploitation of biocatalysts in industry, waste treatment, drug delivery, and bioprocess 
monitoring devices, like biosensors [57]. Besides the application in industrial 
processes, immobilization techniques could be the basis for the developing a large 
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number of biotechnological devices with applications in diagnostics and biosensors 
[59].  
Immobilization means associating the biocatalysts with an insoluble matrix, so that it 
can be retained in a proper reactor geometry for its economic reuse under stabilized 
conditions (Fig.3) [60]. Immobilization helps in the development of continuous 
processes allowing more economic organization of the operations, automation, and 
investment/capacity ratio. Immobilized biocatalysts offer several other advantages 
such as, for example, the availability of the product in greater purity. Purity of the 
product is crucial, for example, in food processing and pharmaceutical industry since 
contamination could cause serious toxicological, sensory, or immunological problems 
[60]. 
Another major advantage includes greater control over enzymatic reaction, as well as 
high volumetric productivity, with lower residence time, which are of great significance 
in the food industry [57]. Moreover, compared to their free forms, immobilized enzymes 
are generally more stable and easier to handle [57]. In addition, reaction products are 
not contaminated with the enzyme (especially useful in the food and pharmaceutical 
industries), and in the case of proteases, the rate of the autolysis process can be 
dramatically reduced upon immobilization [61]. 
To date, more than one hundred techniques to immobilize enzymes have been 
developed, such as entrapment, adsorption, ionic binding, and disulphide bonds 
formation. Enzymes can be attached to the support by interactions, ranging from 
reversible physical adsorption and ionic linkages to stable covalent bonds (Fig.3) [62]. 
Ideal support properties include physical resistance to compression, hydrophilicity, 
inertness toward enzymes ease of derivatization, biocompatibility, resistance to 
microbial attack, and availability at low cost [62-64]. Supports can be classified as 
inorganic and organic according to their chemical composition, and organic supports 
can be subdivided into natural and synthetic polymers [65]. The most common are 
synthetic polymers, biopolymers (cellulose, starch, agarose, carragenans, and 
chitosan), inorganic supports (alumina, silica, zeolites), hydrogels and so on. 
 In this framework, nanobiotechnology is gaining much attention from the scientific 
community, and “Nanobiocatalysis” is one direct application of this growing field 
[66]. In early approaches to nanobiocatalysis, enzymes were immobilized on various 
nanostructured materials using conventional approaches, such as simple adsorption 
and covalent attachment. This approach was used by immobilizing enzymes onto 
nanostructured materials, such as nanoporous materials and magnetic nanoparticles 
[67]. Nanosized particles of noble metals, for example, were used due to their 
attractive electronic, optical, and thermal properties as well as catalytic properties 
and potential applications in the fields of physics, chemistry, biology, medicine, and 
material science [68]. Recently, new immobilization studies were performed by using, 
as immobilization systems, artificial or natural lipid bilayers of biological membranes. 
Lipid vesicles (liposomes) have been recently used for this purpose, despite the fact 
that the long-term stability of liposomes may be problematic [69]. Lipid vesicles, 
generally, are not thermodynamically stable and do not assemble ‘spontaneously’ 
(without input of external energy); they are only kinetically stable, and their physical 
properties may depend on how and under which conditions lipid vesicles have been 
prepared. To overcome all these limitations, a recent interest for the immobilization of 
enzymes and biocatalysts in general focuses on the isolation of bilayer membranes 
from both prokaryotic and eukaryotic sources. 
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http://www.easybiologyclass.com 
Figure 3. Enzyme immobilization examples. 
 
 
 
In this context, extracellular nanostructures, such as bacterial Outer Membrane 
Vesicles (OMVs) and eukaryotic Extracellular Vesicles (EVs), proteoliposomes of 20-
2000 nm diameter, have been recently investigated as biotechnological scaffolds 
alternative to liposomes [70-71].  
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1.3.1 Outer Membrane Vesicles 
 Outer membrane vesicles (OMVs) are nanoscale proteoliposomes of 20-200 nm 
diameter, naturally derived from the surface of some Gram-negative and Gram-positive 
bacteria as part of their natural growth cycle. In Gram-negative bacteria, OMVs are 
initially formed as a bulge arising from the outer membrane (Fig 4) [70]. Thus, they are 
generally surrounded by a single phospholipidic bilayer derived from the outer 
membrane and are primarily composed of lipopolysaccharides, membrane 
phospholipids (PLs) and outer membrane proteins (OMPs) [70-73]. In addition, a 
portion of periplasmic space is often enclosed in these vesicles, which includes 
proteins, toxins or effectors that are delivered to the environment to accomplish several 
biological functions (Fig 4).  
The production of OMVs has been reported from a large number of Gram-negative 
bacteria, [73-75] in a variety of environments, including planktonic cultures, fresh and 
salt water, biofilms, inside eukaryotic cells and within mammalian hosts [76-78]. Among 
OMV-producing Gram-negative bacteria, pathogenic microorganisms such as 
Escherichia coli, Helicobacter pylori, Pseudomonas aeruginosa, have been so far 
major targets for OMV studies [79-81]. The main interest towards pathogenic-OMVs 
was driven from their cargo proteins, identified as major virulence factors or agents of 
inflammatory responses. Some examples include E. coli cytolysin A (ClyA), E. coli heat 
labile enterotoxin (LT) [82]. However, OMVs functions are far from being limited to 
pathogenicity, and the role of these carrier structures has proven to be far more 
complex than what initially supposed. 
 
 
http://genesdev.cshlp.org/content/19/22/2645/F1.large.jpg 
Figure 4. OMVs example. LPS: lipopolysaccharide; OM: outer membrane; Pp: periplasm; Cyt: cytosol; 
IM: inner membrane. 
 
 
Indeed, it is currently well known that OMVs are also involved in interspecies 
communication and competition, biofilm formation, DNA lateral gene transfer, antibiotic 
resistance and nutrient acquisition [79,83-87]. This system allows signalling proteins 
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or effectors to be delivered, even over great distances, at high concentration in close 
proximity of an acceptor site. Ultimately, the binding specificity between surface-
exposed bacterial adhesins and environmental ligands or receptors guarantees a high 
target specificity. Several hypotheses on OMVs biogenesis have been proposed, 
although they are not fully comprehensive and often restricted to a few species of 
bacteria [74-75, 86, 88]. However, OMV production occurs at a constitutive level for a 
wide variety of bacteria, suggesting that this is a highly conserved process [74-75, 86]. 
Furthermore, vesiculation levels can be altered by factors such as temperature, 
nutrient availability, oxidation, quorum sensing and envelope- targeting antibiotics [86-
87, 89]. So far, only few examples of OMVs isolated from non-pathogen gram-negative 
bacteria have been reported. Some examples of non-pathogenic, environmental 
bacteria from which OMVs have been isolated include the halophilic marine bacterium 
Novosphingobium pentaromativorans US6-1, and the soil bacterium Pseudomonas 
putida K2440 [90-91]. These environmental OMV-producing bacteria are endowed with 
the ability to use various aromatic compounds, including polycyclic aromatic 
hydrocarbons (PAHs) and several other pollutants, as major carbon and energy 
sources. Little is still known about the vesicles produced by these organisms, however 
two main roles of these OMVs have been suggested. The first one involves the use of 
OMVs as carriers of hydrolytic enzymes, such as proteases and glycosidases, which 
play a role in the acquisition of nutrients from the surrounding environment [18]. This 
system would improve nutrient acquisition and thus bacterial survival, particularly in 
starving growth conditions [71, 90- 93]. The second hypothesis suggests that these 
structures might be involved in i) the formation of the biofilm matrix [20], ii) the onset 
and maintaining of biofilm communities [71, 83, 88, 93] and iii) the antibiotic resistance 
expressed by the biofilm bacterial community. Beyond a role in biofilm onset, OMVs 
might mediate interactions within and external to the biofilm through OMV-associated 
quorum-signalling molecules [88, 93-94].  
In recent years, a great deal of attention was also devoted to the study of OMVs for 
their potential use in biotechnological industry. Drug delivery, enzyme immobilization 
and construction of innovative biosensors are some of the major research fields of 
interest. Bacterial OMVs can be foreseen as platforms for the immobilization of 
proteins and enzymatic complexes and be employed as carriers for drugs and 
molecules, allowing these latter to be conveyed to a highly specific target site and in a 
protected environment [95-98]. By taking advantage of the unique feature to embed 
outer membrane proteins into OMVs, a wide range of functional proteins such as green 
fluorescence protein (GFP) and β-lactamase, have been genetically tethered to the 
surface of a hyper-vesiculating Escherichia coli strain- therefore to the corresponding 
OMVs- using the virulence factor cytotoxin ClyA as the surface anchor [95]. Unlike 
complex enzyme assembly onto liposomes or polymerosomes, these results indicate 
the feasibility of designing OMVs as synthetic nanoreactors, using only standard 
molecular biology techniques. This approach has been recently used for example, to 
immobilize three glycosidase activities on engineered E. coli OMVs [98]. A trivalent 
protein scaffold was genetically tethered onto the OMVs to enable the positional 
specific recruitment of three different cellulases. This work reported that the assembled 
enzyme complex, not only retained full activity, but also hydrolyzed cellulose 23-fold 
faster than non-complexed enzyme [98]. The biotechnological use of OMVs isolated 
from gram-negative bacteria, for example as drug delivery systems, is currently limited, 
among others, by the presence in their outer membrane of the immunogenic LPS. 
Several studies have in fact demonstrated how LPS is sensed by the Toll-like receptor 
4 (TLR4) complex, triggering a pro-inflammatory response and playing an important 
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role in septic shock [99]. As a consequence, much interest is currently devoted to 
vesiculating non-pathogen strains that do not produce LPS.  
 
1.3.2 Extracellular Vesicles 
Extracellular vesicles (EVs) are membrane-derived particles with a diameter size 
ranging from 30 nm to 2,000 nm, surrounded by a (phospho)lipid bilayer and released 
by cells in the human body [100]. EVs s are classified, based on their cellular origin, 
biological function or biogenesis, in three main groups: exosomes, microvesicles and 
apoptotic bodies [101]. Distinct processes responsible for vesicle release from cells 
have been identified; in particular, exosomes are derived from the multivesicular 
endosomal cell compartment [71. 101-103] whereas EVs originate by direct budding 
from the cell plasma membrane [102-106] Both extracellular vesicle types contain 
cytoplasmic proteins, certain lipid raft-interacting proteins and RNAs but, owing to their 
highly regulated biogenesis, exosomes typically accommodate some additional 
defined components [71]. Apoptotic bodies represent another type of membrane-
limited vesicle. These are larger than exosomes and EVs [108] and are formed 
exclusively during the late stage of apoptosis (Fig. 5). 
Within the past decade, extracellular vesicles have gained attention as important 
mediators of intercellular communication [108]. 
 Shedding of EVs is considered to be a physiological phenomenon that leads cell 
activation and growth. Many stimuli have been shown to increase vesicle secretion, 
including hypoxia, oxidative stress and inflammation [109-111]. These evidences 
suggested that EVs are implicated in physiological responses such as immune 
surveillance [112], blood coagulation [113], tissue repair [114] or in pathological 
disorders, for example cancer [115] and cardiovascular diseases [116]. 
 
 
Yamamoto S, Azuma E, Muramatsu M, Hamashima T, Ishii Y, Sasahara M. (2016) Significance of extracellular vesicles: 
pathobiological roles in disease. Cell Struct Funct 
 
Figure 5. EVs classification and origin. 
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EVs could also carry and deliver multiple information through lipids, proteins or 
nucleic acids transfer. Proteins sorting into shedding vesicles is selective; specific 
proteins may be included or excluded from membrane EVs, leading to the expression 
of proteins arrays that differ from those present on the surface of the cells from which 
they originated [117-118]. It is also possible that EVs may interact with specific target 
cells after their release. For example, EVs shed from platelets interact with 
macrophages and endothelial cells but not with neutrophils, [119] whereas EVs from 
neutrophils interact with platelets, macrophages, and dendritic cells [120-121]. Due to 
their specific targeting, the current biotechnological interest in EVs derives from their 
great potential as a new way, for innovative therapies, to deliver drugs to specific 
target cells [115]. Thus, EVs can be engineered to over-express different therapeutic 
proteins, mRNA or miRNA - by driving their synthesis from the relevant EV producing 
cells [122]. Indeed, EVs possess a lot of peculiarities that give them ideal drug-
delivery features. More specifically, EVs are stable within the body. EVs do not induce 
(ii) tumour generation [123], or (iii) immune rejection after allogenic administration 
[124]. In addition, EVs carrying proteins and/or nucleic acids can be easily modulated 
to confer them specific pharmacological functions [125]. 
EVs have been also studied, in particular from macrophages, for the identification of 
new potential therapeutic targets associated to inflammatory response and for the 
development of a new drug delivery strategy. All these features suggest that EVs, as 
well as bacterial OMVs, could be used for biotechnological purposes. The interest in 
using eukaryotic EVs rather than OMVs, lies in their specific drug delivery application. 
Indeed, the fact that EVs derives from eukaryotic cells, could make these latter less 
immunogenic than OMVs. Moreover, their composition can be physiologically 
determined or driven by exogenous modulations either on their origin cells or directly 
on purified EVs populations [126]. Another advantage in using EVs as novel natural 
bio-carriers, lies in their specific cell-targeting, which has already been described in 
literature [127-129]. For this reason, EVs appear to be a suitable alternative to 
traditional delivery systems currently in development, limiting inflammation processes 
and improving target-specific delivery.  
 
1.4 Novosphingobium sp. PP1Y: a novel microbial source of OMVs and 
glycosidases 
 
In the laboratory in which my PhD project has been developed, a novel gram-negative 
strain has been isolated and characterized, named Novosphingobium sp. PP1Y 
[99,120]. The microorganism was isolated from surface waters of a small dock bay in 
the harbour of Pozzuoli which is used for the storage of small boats and is 
characterized by a severe pollution of the water by mono-, poly- and heterocyclic 
aromatic hydrocarbons (Fig. 6) 
The microbiological analysis of the bacterium indicated that the microorganism belongs 
to the order of Sphingomonadales, a class of bacteria whose outer membrane is 
characterized by the presence of glycosphingolipids, instead of the more common 
lipopolysaccharides. 
This peculiarity makes the surface of their cells more hydrophobic than those of the 
other Gram-negative strains and has probably contributed to the ability of these 
microorganisms to degrade mono- and polycyclic aromatic hydrocarbons (PAHs). N. 
sp. PP1Y, however, shows different characteristics if compared to other members of 
the order, as it appears not only to be able to grow using, as the sole source of carbon 
and energy, a wide range of mono-and polycyclic aromatic substrates such as pyrene, 
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naphthalene and phenanthrene, but also to have evolved an effective adaptation to the 
growth on complex mixtures of aromatic molecules dissolved in non-polar phases such 
as diesel and gasoline. 
Due to its peculiar natural environment and metabolism, this strain might be considered 
a valuable reservoir of novel biotechnological tools. 
In particular, Sphingomonadales show the presence of a great abundance of both 
glycosyl hydrolases (GHs) and glycosyltransferases (GTs), activities that are probably 
involved in the biosynthesis of complex extracellular polysaccharides and microbial 
biofilms [130].  
The interest for Novosphingobium sp. PP1Y carbohydrate-active enzymes has grown 
as the sequencing and annotation of the whole genome, recently completed, has 
revealed peculiar biochemical and biotechnological properties, namely some 
metabolic pathways specifically involved in the degradation of several aromatic 
hydrocarbons, and the resistance to toxic compounds. A great number of genes 
encoding for both GHs (53 orfs) and GTs (57 orfs) were identified in this microorganism 
[99]. In particular, the number of GHs is remarkable when compared, respectively, to 
the 16 GHs and the 32 GHs of the closely related strains of Sphingomonas wittichii 
and Sphingobium chlorophenolicum. The 53 GHs of strain PP1Y are distributed among 
27 different families. The most represented families are GH3, GH13 and GH23 with 9, 
5 and 9 members respectively. Among these, there are 8 genes encoding for α-RHAs. 
A novel α-RHA activity in N. sp. PP1Y crude extract was recently described, which was 
used, among others, for bioconversion experiments on substrates such as naringin, 
rutin and hesperidin [131]. 
Strain PP1Y shows a very high propensity to adopt the sessile phenotype and 
efficiently colonise several types of hydrophobic surfaces including water/oil 
interfaces (Fig. 7) [99]. In addition to these features, strain PP1Y has a surprisingly 
high tolerance to diesel oil, which allows its growth in biphasic diesel oil/water 
cultures containing more oil than water. To the best of our knowledge, such behaviour 
has never been reported for a Sphingomonas. Sphingomonas sp. Ant 17, the sole 
Sphingomonads known to use fuels as a sole carbon and energy source, has been 
reported to grow in 1:1000 (v/v) fuel/water biphasic systems [131]. Several details 
suggested also the production of OMVs in strain PP1Y, which might play a potential 
role in biodegradation and nutrient supply in natural habitats, as well as being involved 
in cell-cell communication and genetic transfer. N. sp. PP1Y can grow as either 
planktonic free cells or sessile-aggregated macroscopic “flocks” of 1-10 mm long, with 
a composition in fatty acids similar to the cell membrane (Izzo V., unpublished results); 
noteworthy, this behaviour has already been described for other Sphingomonads, 
which show the so-called “planktonic/sessile dimorphism” [132-133]. Most importantly, 
cell free supernatants from cultures of N. sp. PP1Y were able to effectively stabilize 
paraffin drops, obtained by shaking a paraffin/water biphasic system, which remained 
stable for more than 1 week. These last data in particular suggested that strain PP1Y 
produced an extracellular emulsifier, and it was shown that secretion was dependent 
upon the presence of neither aromatic hydrocarbon nor an oil phase in the growth 
medium [133]. Interestingly, culture supernatants showed a low total carbohydrate 
level and no detectable polysaccharides [134].  
Thus, N. sp. PP1Y might be particularly appealing for OMVs isolation and 
characterization in order to shed light on vesiculation mechanisms related to 
environment adaptation. Noteworthy, the lack of LPS on the membrane surface of 
strain PP1Y, and the availability for this microorganism of a completely sequenced and 
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annotated genome [134], are extremely appealing to develop a novel molecular tool 
for drug delivery systems and enzyme immobilization. 
During my PhD work, specific aspects of the biotechnological potential of N. sp. PP1Y 
were investigated, focusing the attention on the use of this microorganism to isolate 
and characterize novel examples of i) α-RHA activities and ii) OMVs for industrial 
applications and biotechnological purposes.  
 
Figure 6. An overview of the harbour of Pozzuoli, where Novosphingobium sp. PP1Y was isolated. 
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Figure 7. Phase contrast microscopy analysis of coated diesel oil drops isolated from a culture of 
Novosphingobium sp. PP1Y grown using diesel oil as sole carbon and energy source. A) and B) Coated 
diesel oil drop after 2 days of incubation observed using visible light only or UV/visible light, respectively. 
C) Coated diesel oil drop after 2 days of incubation observed using UV/visible light. D) and E) Coated 
diesel oil drops after 10 days of incubation. F) Super-aggregates of coated drops. Bar = 10 μm.  
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AIMS OF THE THESIS 
 
 
Both α-L-rhamnosidases and extracellular vesicles are elements of great interest for 
the development and implementation of novel biocatalysis processes of 
biotechnological importance. A great deal of attention is being devoted by the biotech 
community to the use of these two systems for applications in the food and 
pharmaceutical industries. Main aim of this PhD project has been to characterize the 
biotechnological potential of a bacterial α-L-rhamnosidase isolated from 
Novosphingobium sp. PP1Y, and of novel examples of vesicles, Outer Membrane 
Vesicles (OMVs) isolated from the same microorganism and Extracellular Vesicles 
(EVs) from macrophages.  
This general aim has been pursued through the following activities:  
1. Purification and characterization of a novel α-L-rhamnosidases from N. sp. PP1Y;  
2a. Isolation, purification and characterization of OMVs from N. sp. PP1Y;  
2b. Isolation, purification and characterization of Extracellular Vesicles (EVs) from 
human macrophages.  
Tasks 1 and 2a were performed in the laboratory of Professor Alberto Di Donato, 
university of Naples, Federico II. The 2b task was developed, starting September 2016 
through March 2017, at INSERM (University of Angers, France) in the laboratories of 
the “Stress oxidant et patologies mètaboliques U1063” of Prof. Ramaroson 
Andriantsitohaina.  
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CHAPTER II  
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Generals 
N. sp. PP1Y was isolated from polluted seawater in the harbor of Pozzuoli (Naples, 
Italy) as already described []. Bacterial growth was followed by measuring the optical 
density at 600 nm (OD/mL, from now on referred to as OD600). Nanosize analysis for 
the determination of OMVs size was performed by IZON technical service using 
qNANO GOLD (http://www.izon.com). Protein quantification was performed using BCA 
kit assay purchased from Thermo Scientific. 
Protein concentration was measured using the Bio-Rad Pro- tein System [52] using 
bovine serum albumin (BSA) as standard. Polyacrylamide gel electrophoresis was 
carried out using standard techniques [53]. SDS–PAGE 15% Tris–glycine gels were 
run under denaturing conditions and proteins were stained with Coomassie brilliant 
blue G-250. “Wide range” (200–6.5 kDa) molecular weight standard was from Sigma 
(ColorBurstTM Electrophoresis Marker). 
 
2.2 Cloning of orf PP1YRS05470 and construction of the pET22b(+)/rha-p 
expression vector.  
Genomic DNA was extracted from a 50mL saturated culture of N. sp. PP1Y as 
described elsewhere [130]. OrfPP1Y RS05470 coding for the α-RHA activity was 
amplified in two contiguous fragments, owing to the considerable length of the orf (3441 
bp). The first fragment, named rha-up (1816 bp), was amplified using an internal 
downstream primer, RHA-Intdw (5′- AGGCGGCCATGGGAATGT-3′), which included 
an internal NcoI site already present in orfPP1Y RS05470, and an upstream primer, 
RHA-up (5’-GGGAATTCCATATGCCGCGCCTTTCGCT-3’), designed to add a NdeI 
restriction site at 5’ of orf PP1Y RS05470. The second half to the gene, named rha-dw 
(1625 bp), was amplified using the upstream primer RHA-Intup (5’-
ACATTCCCATGGCCGCCT-3’), complementary to RHA-Intdw, and the downstream 
primer RHA-dw (5’-AAAACCGAGCTCTCAATGCCCGCCCGTG-3’) that was intended 
to incorporate a SacI restriction site downstream of the amplified orf. The amplified 
fragments, rha-up and rha-dw, were purified from agarose gel, digested, respectively, 
with NdeI/NcoI and NcoI/SacI, and individually cloned in pET22b(+) vector previously 
cut with the same enzymes. Ligated vectors were used to transform E. coli, strain 
Top10 competent cells. The resulting recombinant plasmids, named pET22b(+)/rha-
up and pET22b(+)/rha-dw, were verified by DNA sequencing. Next, the construction of 
complete rha-p gene in pET22b(+) was performed. First, both pET22b(+)/rha-dw and 
pET22b(+)/rha-up were digested with NcoI/SacI restriction endonu- cleases to obtain, 
respectively, fragment rha-dw and linearized pET22b(+)/rha-up. Digestion products 
were purified from agarose gel electrophoresis, eluted and ligated. Ligation products 
were used to transform E. coli Top10 competent cells and the resulting recombinant 
plasmid, named pET22b(+)/rha-p was verified by DNA sequencing.  
 
2.3 Construction of the pET22b(+)/rha-his expression vector. 
 To obtain the pET22b(+)/rha-his expression vector, which expresses a recombinant 
RHA-P fused to a C-terminus His-tag, a single point mutagenesis (TGA to CGA) on 
the STOP codon of the coding sequence of RHA-P, previously cloned, was performed. 
In this way, an arginine residue was inserted and the coding sequence was extended 
on the pET22b(+) plasmid, thus including a linker sequence and the coding region for 
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a 6-His-tag domain at 3’of the gene. The plasmid pET22b(+)/rha-dw, bearing only the 
C-terminus 1,625 bp-long fragment of the gene and already present in our laboratory, 
was chosen to perform the mutagenesis, in order to use a smaller plasmid for the 
amplification procedure. The mutagenesis experiment was done using specific 
designed complementary primers named RHAmutUP 
(5’ACCACGGGCGGGCATCGAGCCGTCGACAAGC3’) and RHAmutDW 
(5’GCTTGTCGACGGCTCGATGCCCGCCCGTGGT3’) containing the desired 
mutated codon.  Quickchange II site directed mutagenesis kit (Agilent technologies) 
was used for this experiment, following the manufacturer protocol. Mutagenesis was 
then verified by DNA sequencing. A fragment containing the mutated codon was 
identified between the single restriction sites AatII - NotI. The cassette was excised 
from the pET22b(+)/rha-dw plasmid, purified from agarose gel and subcloned in a 
pET22b(+)/rha-p total vector, by digesting both mutagenized fragment and 
pET22b(+)/rha-p with AatII / NotI restriction endonucleases. Digestion products were 
separated by agarose gel electrophoresis, purified and ligated. Ligation products were 
used to transform E. coli Top10 competent cells and the resulting recombinant plasmid, 
named pET22b(+)/rha-his was verified by DNA sequencing. 
 
2.4 Mutagenesis of the pET22b(+)/rha-his expression vector and construction of 
rRHA-Phis single mutants.  
A mutagenesis cassette containing all the residues to modify was identified in 
pET22b(+)/rha-his sequence, between the single restriction sites AatII and KpnI. The 
mutagenesis cassette was excised from pET22b(+)/rha-his vector, purified from 
agarose gel and ligated into a pGEM-3Z vector digested using the same enzymes. 
Ligation products were used to transform E. coli Top10 competent cells and the 
resulting recombinant plasmid, named pGEM-3Z/rha, was verified by DNA 
sequencing. The plasmid pGEM-3Z/rha was then used in five different mutagenesis 
experiments where for the identified conserved aminoacids D503, E506, D552, E644, 
and D763 were mutated into alanine codons. For D503, D552 and D763 the codon 
GAT was converted in GTC, for E506 the codon GAG was converted in GCG and for 
E644 the codon GAA was converted in GCA. Therefore, five couple of specific 
mutagenic primers were designed and the QuikChange II Site-Directed Mutagenesis 
Kit (Agilent Technologies) was used on pGEM-3Z/rha in five separate reactions, 
following the manufacturer protocol. Mutagenized fragments in pGEM-3Z/rha vector 
were then individually subcloned into pET22b(+)/rha-his vector using AatII/KpnI 
restriction endonucleases. Mutagenized clones were verified by DNA sequencing and 
named: pET22b(+)/D503A, pET22b(+)/E506A, pET22b(+)/D552A, pET22b(+)/E644A, 
and pET22b(+)/D763A (pET22b(+)/D-EXXXA). 
 
2.5 rRHA-P recombinant expression. Protein expression was carried out in E. coli 
BL21(DE3) strain transformed with pET22b(+)/rha-p plasmid. All the media described 
in this paragraph contained 100 g/mL of ampicillin. 
-Analytical expression: 
E. coli BL21(DE3) competent cells transformed with plasmid pET22b (+)/rha-p were 
inoculated in a sterile 50mL Falcon tube containing 12.5 mL of either LB or LB 
containing a final concentration of 0.5 M NaCl (LB-N). Cells were grown under constant 
shaking at 37 ◦ C up to 0.6–0.7 OD600. This preinoculum was diluted 1:100 in 12.5 mL 
of either one of the four following media: LB, LB-N, LB supplemented with 1 mM of 
both betaine and sorbitol (LB-BS), or LB containing a final concentration of 0.5 M NaCl 
and 1 mM of both betaine and sorbitol (LB-NBS). Cells were grown under constant 
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shaking at 37◦C up to 0.7–0.8 OD600. rRHA-P recombinant expression was induced 
with 0.1 mM IPTG at either 23 °C or 37 °C; growth was continued in constant shaking 
for 3h. Cells were collected by centrifugation (5,524×g for 15min at 4◦C) and 
suspended in 25 mM MOPS pH 6.9 at a final concentration of 14 OD600. Cells were 
disrupted by sonication (12 times for a 1-min cycle, on ice) and an aliquot of each 
lysate was centrifuged at 22,100 × g for 10 min at 4 °C. Both soluble and insoluble 
fractions were analyzed by SDS- PAGE. The soluble fraction was assayed for the 
presence of α-RHA enzymatic activity. 
-Large scale expression:  
Fresh transformed cells were inoculated into 10 mL of LB-N and incubated in constant 
shaking at 37 °C O/N. The preinoculum was diluted 1:100 in four 2 L Erlenmeyer flasks 
containing each 500 mL of LB-NBS and incubated in constant shaking at 37 °C up to 
0.7–0.8 OD600. Expression of the recombinant protein, named rRHA-P, was induced 
with 0.1mM IPTG and growth was continued for 3h at 23 °C. Cells were collected by 
centrifugation (5,524×g for 15min at 4 °C) and stored at −80 °C until needed.  
2.6 rRHA-P purification.  
rRHA-P was purified following three chromatographic steps. Cell paste was suspended 
in 25 mM MOPS pH 6.9, 5% glycerol (buffer A), at a final concentration of 100 OD600 
and cells were disrupted by sonication (10 times for a 1- min cycle, on ice). Cell debris 
were removed by centrifugation at 22,100 × g for 60 min at 4 ◦ C and the supernatant 
was collected and filtered through a 0.45 m PVDF Millipore membrane.  Afterwards, 
cell extract was loaded onto a Q Sepharose FF col- umn (30 mL) equilibrated in buffer 
A. The column was washed with 50 mL of buffer A, after which bound proteins were 
eluted by using a 300-mL linear gradient of buffer A from 0 to 0.4 M NaCl at a flow rate 
of 15 mL/h. The chromatogram was obtained by analyzing fractions absorbance at λ= 
280 nm and the presence of the recombinant α-RHA activity was detected using the 
pNPR assay. Relevant fractions were analyzed by SDS-PAGE, pooled and 
concentrated at a final vol- ume of  0.5 mL using a 30 kDa Amicon ultra membrane, 
Millipore. The sample was then loaded onto a Sephacryl HR S200 equilibrated with 
buffer A containing 0.2 M NaCl (buffer B). Proteins were eluted from the gel filtration 
column with 250 mL of buffer B at a flow rate of 12 mL/h. Fractions were collected, 
analyzed and screened for the presence of α-RHA activity as previously described. At 
this stage, NaCl was removed from pooled fractions by repeated cycles of ultrafiltration 
and dilution with buffer A. The sample was then loaded on a Q Sepharose FF column 
(30 mL) equilibrated in buffer A. The column was washed with 50 mL of buffer A, after 
which bound proteins were eluted with 300 mL of a linear gradient of buffer A from 0 
to 0.25 M NaCl at a flow rate of 13 mL/h. Fractions were collected, analyzed by SDS-
PAGE and screened for the presence of α-RHA activity. Relevant fractions were 
pooled, concentrated, purged with nitrogen, and stored at −80 °C until use. 
 
2.7 rRHA-Phis and mutants recombinant expression.  
Protein expression was carried out in E. coli BL21(DE3) strain transformed with either 
pET22b(+)/rha-his or pET22b(+)/D-EXXXA plasmids. All the media described in this 
paragraph contained 100 µg/mL of ampicillin. 
-Analytical expression:  
E. coli BL21(DE3) competent cells were transformed with plasmid pET22b(+)/rha-his 
and inoculated in a sterile 50 mL Falcon tube containing 12.5 mL of either LB or LB 
containing a final concentration of 0.5 M NaCl (LB-N). Cells were grown under constant 
shaking at 37°C up to 0.6–0.7 OD600. These preinoculus were diluted 1:100 in 2 sterile 
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50 mL Falcon tubes containing 12.5 mL of LB, and 2 sterile 50 mL Falcon tubes 
containing 12.5 mL of LB-N. Cells were grown under constant shaking at 37°C up to 
0.7–0.8 OD600. Then, rRHA-Phis recombinant expression was induced with 0.1 mM 
IPTG and growth was continued in constant shaking for 3hrs, at either 23°C or 37°C 
for both LB or LB-N. Cells were collected by centrifugation (5,524 x g for 15 min at 4°C) 
and suspended in 25 mM MOPS pH 6.9 at a final concentration of 14 OD600/mL. Cells 
were disrupted by sonication (12 times for a 1-min cycle, on ice) and an aliquot of each 
lysate was centrifuged at 22,100 x g for 10 min at 4°C. Both soluble and insoluble 
fractions were analyzed by SDS-PAGE. The soluble fraction was assayed for the 
presence of α-RHA enzymatic activity. 
A second analytical expression experiment was performed by transforming E. coli 
BL21(DE3) competent cells with plasmid pET22b(+)/rha-his. Five colonies were 
inoculated from the transformation plate in a sterile 50 mL Falcon tube containing 12.5 
mL of LB, and were grown under constant shaking at 37°C up to 0.6–0.7 OD600. This 
preinoculum was diluted 1:100 in either one of the following media: LB, LB 
supplemented with 1 mM of both betaine and sorbitol (LB-BS), LB supplemented with 
5 mM of both betaine and sorbitol (LB-BS), LB supplemented with 10 mM of both 
betaine and sorbitol (LB-BS) and cells were grown under constant shaking at 37°C up 
to 0.7–0.8 OD600. Then, rRHA-Phis recombinant expression was induced by testing 
0.1 mM IPTG or 1 mM IPTG, for all condition mentioned above and, in all cases, growth 
was continued in constant shaking for 3hrs, at 23°C. Cells were collected by 
centrifugation (5,524 x g for 15 min at 4°C) and suspended in 25 mM MOPS pH 6.9, 
5% glycerol at a final concentration of 14 OD600/mL. Cells were disrupted by sonication 
(12 times for a 1-min cycle, on ice) and an aliquot of each lysate was centrifuged at 
22,100 x g for 10 min at 4°C. Both soluble and insoluble fractions were analyzed by 
SDS-PAGE. The soluble fraction was assayed for the presence of α-RHA enzymatic 
activity.  
-Large scale expression: 
E. coli BL21(DE3) cells fresh transformed with pET22b(+)/rha-his, pET22b(+)/D503A,  
pET22b(+)/E506A, pET22b(+)/D552A, pET22b(+)/E644A, or pET22b(+)/D763A, were 
inoculated from the transformation plate into 5 mL of LB and incubated in constant 
shaking at 37°C up to ~ 0.5 OD600. The first preinoculum was diluted 1:10 in 4 sterile 
50 mL Falcon tubes containing 12.5 mL of LB and incubated in constant shaking at 
37°C up to ~ 0.6 – 0.7 OD600. The second preinoculum was diluted 1:40 in four 2 L 
Erlenmeyer flasks containing each 500 mL of LB-BS and incubated in constant shaking 
at 37°C up to 0.7– 0.8 OD600. Expression of rRHA-Phis or rRHA-Phis mutants, was 
induced with 1 mM IPTG and growth was continued for 3 hrs in costant shaking at 
23°C. Cells were collected by centrifugation (5,524 x g for 15 min at 4°C) and periplasm 
extraction of the culture was performed. 
 
2.8 rRHA-Phis and rRHA-Phis mutants purification. 
 E. coli BL21(DE3) cells were collected by centrifugation (5,524 x g for 15 min at 4°C), 
after 3 hrs of induction of rRHA-Phis or rRHA-Phis mutants expression. To periplasmic 
extraction, cell paste was suspended in 100 mM Tris/HCl pH 7.4, 20% sucrose, 1 mM 
EDTA (Lysis buffer) at a final concentration of 84 OD600/mL. 48 µg of native Lysozyme 
from chicken egg white (L6876 Sigma-Aldrich) for each OD600 of cells were added to 
the suspension buffer, and cultures were incubated at RT for 15 min. Then, distilled 
water was added to the cultures in equal volume respect to the Lysis buffer, and 
cultures were incubated at RT for 15 min. Cells were centrifuged at 5,524 x g for 15 
min at 4°C. The supernatant was collected as the periplasmic fraction of the induced 
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cultures. Debris were removed by centrifugation at 22,100 x g for 60 min at 4°C and 
the supernatant was collected and filtered through a 0.45 μm PVDF Millipore 
membrane. Afterwards, the periplasmic fraction was loaded overnight in batch under 
constant shaking at 4°C, onto a Ni-Sepharose FF resin (using ~3.5 mg of total proteins 
for each mL of resin) equilibrated with 15 column volumes of 50 mM Tris/HCl pH 7, 5% 
glycerol (buffer A). Then, the unbound portion was removed by centrifugation at 3200 
xg for 10 min at 4°C. The resin was washed with 15 column volumes of buffer A, and 
protein elution was directly carried out in column using a 2 steps gradient at a flow rate 
of ~1mL/min. In the first step 5 column volumes of buffer A containing 30 mM Imidazole 
were used, in the second step protein was eluted using 5 column volumes of buffer A 
containing 250 mM Imidazole. 1 mL fractions were collected and the chromatogram 
was obtained by analyzing absorbance at λ = 280 nm and the presence of rRHA-Phis, 
or rRHA-Phis mutants activity was detected using the pNPR assay. Relevant fractions 
were analyzed by SDS-PAGE and pooled. At this stage, imidazole was removed from 
the pooled fractions by repeated cycles of ultrafiltration and dilution with buffer A, the 
protein sample was purged with nitrogen, and stored at -80°C until use. 
 
2.9 Enzyme activity assays.  
rRHA-P activity was determined using pNPR as substrate (pNPR assay). Otherwise 
stated, all activity assays were performed at RT. The reaction mixture contained, in a 
final volume of 0.5mL of 50mM MOPS pH 6.9, pNPR at a final concentration of 600 M 
and variable amounts of the sample tested. The reaction was blocked after 10 and 20 
min by adding 0.5 M Na2CO3; the product, p-nitrophenolate (pNP), was detected 
spectrophotometrically at λ= 405 nm. The extinction coefficient used was λ405 = 18.2 
mM−1 cm−1. One unit of enzyme activity was defined as the amount of the enzyme that 
releases one micromole of pNP per min.  
-Kinetic parameters determination: 
Kinetic parameters were obtained at pH 6.9 using a pNPR concentration in the range 
0.025–1 mM. All kinetic parameters were determined by a non-linear regression curve 
using GraphPad Prism (GraphPad Software; www.graphpad.com).  
-pH optimum: 
pH optimum for rRHA-P activity was determined in the range 4.7–8.8. Enzyme assays 
were performed as described above, using the following buffers: 50mM potassium 
acetate (pH 4.7–5.7), 50 mM MOPS/NaOH (pH 5.7–7.7) and 50 mM Tris/HCl (pH 7.7–
8.8). 
-Temperature optimum and stability: 
Optimum temperature was evaluated by performing the standard pNPR assay and 
incubating the reaction mixture at different temperatures, in the range 25–55 °C. The 
thermal stability of the enzyme was determined by incubating the enzyme for one and 
3 h at 30, 40, 50, 60 °C and measuring, after each incubation, the residual specific 
activity.  
-Organic solvents tolerance: 
 The tolerance of the enzymatic activity to the presence of organic solvents in the 
reaction mixture, such as DMSO, acetone or ethanol, was evaluated by performing the 
standard pNPR assay in 50 mM MOPS pH 6.9 to which either 10% or 50% of solvent 
was added. 
- Whole cells pNPR assay:  
Samples were assayed in a total volume of 0.5 mL. The reaction mixtures contained, 
50 mM MOPS pH 6.9, pNPR at a final concentration of 600 μM, and variable amounts 
of rRHA-Phis or rRHA-Phis mutants expressing cells preincubated in M9 minimal 
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medium containing 0.4% glucose, and at a cell density ranging from 0.05 to 0.2 OD/mL. 
Reactions were incubated at RT and after 6 and 12 min aliquots of 0.2 mL were 
collected and centrifuged at 5,524 x g for 3 min in order to remove bacterial cells. 
Supernatants were collected and added to 0.5 M Na2CO3 in cuvette. The product, p-
nitrophenolate (pNP), was detected spectrophotometrically at λ= 405 nm. The 
extinction coefficient used was ε 405nm = 18.2 mM-1 cm-1. One unit of enzyme activity 
was defined as the amount of the enzyme that releases one micromole of pNP per 
min. The Specific Activity was reported as mU/OD600. 
 
2.10 TLC Analysis for substrate specificity.  
Reactions were carried out in 0.6 mL of 50 mM Na-phosphate buffer pH 7.0 under 
magnetic stirring at 40◦C in the presence of 20 mM of either aryl glycoside and 0.25 U 
of rRHA-P. Reactions were monitored over time (0–24 h) by TLC analysis. Compounds 
on TLC plates were visualized under UV light or charring with naphthol reagent. 
Hydrolysis reactions of maltose, pullulan, starch, amylopectin, sucrose, raffinose, 
lactose, xylan from birchwood, xylan from oat spelt, hyaluronic acid, cellulose, 
cellobiose, chitosan, Glucan from barley, laminarin, curdlan, fucoidan from Fucus 
versiculosus, rhamnogalacturonan, rutinose were performed using 2.5 mg of each 
substrate, which was suspended in 0.5 mL of 50 mM Na- phosphate buffer pH 7.0. 
Reactions were checked over time by TLC analysis (t = 0, 15 , 30, 60, 90, 120, 150, 
180 min, 24 h) with the following solvent system: EtOAc:MeOH:H2 O 70:20:10. An 
additional hydrolysis reaction of naringin was performed in conditions similar to those 
reported above in the presence of 10% DMSO, and the reaction was monitored over 
time. In all experiments, TLC standard solutions of pure reagents and products were 
used for comparison.  
 
2.11 Growth of Novosphingobium sp. PP1Y  
N. sp. PP1Y cells were grown either in Potassium Phosphate Minimal Medium (PPMM) 
supplemented with 0.4% glutamic acid as sole carbon and energy source or in Luria 
Bertani (LB) medium at 30°C under orbital shaking at 220 rpm. A pre-inoculum in LB 
was prepared by transferring 50 μL from a glycerol stock stored at −80°C to a 50 mL 
Falcon tube containing 12.5 mL of sterile LB medium. The pre-inoculum was allowed 
to grow at 30°C for 10 hrs under orbital shaking and then used to inoculate 1 L of either 
PPMM or LB at an initial cell concentration of 0.02 OD600.  
 
2.12 OMVs isolation and purification 
OMVs naturally secreted into the medium were collected from the supernatant in 
exponential phase by centrifuging cells at 7,500 g for 20 min at 4°C. 
Supernatants (2L) were then filtered through a 0.45 µm PVDF (Millipore) membrane, 
concentrated up to a final volume of 25 mL by using ultrafiltration with an Amicon 
device equipped with a Millipore YM30 membrane (cut-off 30 kDa). The concentrated 
sample was first centrifuged at 25,930 g for 30 min at 4°C; supernatant was subjected 
to high-speed centrifugation at 180,000 g for 2.30 h at 4°C and pellets were stored at 
-80°C until use. 
OMV-containing pellets were suspended in 100 µL of sterile PBS (pH 7.0) and 
ultracentrifuged using a sucrose gradient density at 164,000 g for 6 h at 4°C. Sucrose 
gradient was obtained by slowly stratifying, starting from the bottom of an 
ultracentrifugation vial, 70%, 60% and 20% sucrose solutions prepared in sterile PBS 
(pH 7.0). Sucrose fractions were separately collected and sucrose was removed    
using several cycles (at least 10) of concentration/dilution with sterile PBS (pH 7.0). 
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Concentration cycles were performed by ultrafiltration using an Amicon Ultra 30 K 
(Millipore) centrifuge tube, at 1,880 g and 4°C.  Purified samples were stored at -80°C 
until needed. OMVs were quantified by evaluating the total amount of protein. 
 
2.13 AFM analysis  
OMV samples for AFM analysis were prepared by placing a 20µl droplet of a purified 
sample on plasma-cleaned microscope slides and letting it dry out O/N at RT. 
Measurements were performed by using the WiTec alpha300 system, endowed with a 
closed-loop scan stage with a resolution less than 1 nm. AFM tips (Nano World, Arrow-
FMR) were specified by the manufacturer with a resonance frequency at ca. 75 kHz 
and an elastic spring constant of 2.8 N/m. All AFM images were captured in AC mode, 
in which the tip is in intermittent contact with the surface, therefore assuring a delicate 
tip-sample interaction. Typically, images were acquired with a scan step of 15 nm and 
a scan rate of 200 points/s. The driving frequency was set in correspondence to 90% 
of the peak amplitude of the cantilever oscillation. 
 
2.14 DLS and Zeta-potential measurements 
OMVs size distribution was evaluated using Dynamic Light Scattering (DLS) technique. 
A commercial apparatus Zetasizer Mod. ZSP – Malvern was used, which measured 
size distribution and Zeta-potential values.  
DLS measurement was carried out by placing samples in an appropriate cuvette. A 
laser beam emitting a maximum power of 4 mW at 633 nm was focused in the middle 
part of the cuvette. The scattered light was collected at an angle of 135° and, through 
an optical fiber, detected with an avalanche photodiode. The fluctuation intensities, 
originated by the Brownian motion of the OMVs, were analysed by a digital 
autocorrelator. The correlation curve was fitted to obtain size distribution of the 
particles. The operating range of our apparatus discriminates particles size varying 
form 0.3 nm to 20 µm. The Z-potential measurement was performed using a Doppler 
anemometry function using the Zetasizer Nano ZS. 
 
2.15 Scanning electron microscopy (SEM) 
PP1Y cells were grown in either PPMM or LB medium as described above (par. 2.2). 
Cell pellets were fixed in 2.5 % glutaraldehyde in phosphate buffer (65 mM, pH 7.2–
7.4) for 2 hrs at room temperature and washed three times in PBS for 10 min. Samples 
were then post-fixed with 1% osmium tetroxide in the same phosphate buffer for 1.5 
hrs at room temperature, and dehydrated with through consecutive steps of a graded 
series of ethanol (30%, 50%, 70%, 95% and 100%); in each step the sample was 
incubated for 15 min at RT. Samples were then mounted on aluminium stubs, coated 
with a thin gold film using an Edward E306 Evaporator, and observed with a FEI 
(Hillsboro, OR, USA) Quanta 200 ESEM in high vacuum mode at 30 kV voltage. 
 
2.16 Proteome Analysis 
1 mg of total proteins-containing OMVs was used for proteome analysis. Protein 
extracts from PP1Y cells and OMVs underwent LC-MS/MS-based proteomic analyses. 
Briefly, 30 μg of proteins were resolved on a 12 % 1D SDS-PAGE. Each resulting gel 
line was divided in 10 bands that were reduced to smaller pieces, washed with water 
and dehydrated in acetonitrile, reduced with dithiothreitol and alkylated with 
iodoacetamide. All bands underwent over-night in-gel digestion using trypsin. 
Resulting peptide were analyzed by LC/MS/MS using an Orbitrap XL instrument 
(Thermo Fisher, Waltham, MA, USA) equipped with a nano-ESI source coupled with a 
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nano-ACQUITY capillary UPLC (Waters): peptide separation was performed on a 
capillary BEH C18 column (0.075 mm × 100 mm, 1.7 μm, Waters) using aqueous 0.1% 
formic acid (A) and CH3CN containing 0.1% formic acid (B) as mobile phases. 
Peptides were eluted by means of a linear gradient from 5% to 50% of B in 90 minutes 
and a 300 nL min−1 flow rate. Mass spectra were acquired over an m/z range from 400 
to 1800. To achieve protein identification, MS and MS/MS data underwent MxQuant 
software (version 1.4.1.2) analysis: Andromeda search engine was used on NCBi 
protein database. Parameters sets were: trypsin cleavage; carbamidomethylation of 
cysteine as a fixed modification and methionine oxidation as a variable modification; a 
maximum of two missed cleavages; false discovery rate (FDR), calculated by 
searching the decoy database, 0.05. Only proteins from Ns. sp. PP1Y were considered 
as acceptable. Proteomic analyses were performed in triplicate on two different OMVs 
preparations and on two PP1Y cells samples. 
 
2.17 Fatty acids analysis 
1 mg of total proteins-containing OMVs was used for fatty acid analysis. To obtain fatty 
acid composition of isolated OMVs, each sample was dried for 90 min over P2O5 and 
then treated for 30 min at 60 °C with a solution of boron trifluoride/methanol 10% (1.3 
M, 1.5 mL) and 50 µL of dimethoxypropane. Afterwards, each solution was extracted 
twice with hexane and the organic phase was filtered on a Millex filter 0,45µm and 
dried. The fatty acid methyl esters were re-dissolved in hexane (100 µL) and injected 
into a gas chromatograph. Gas chromatography analyses were obtained on a 
Shimadzu model GC2010 instrument equipped with a SP52–60 capillary column 
(Sigma-Aldrich, St Louis, MO, USA; 100 m x 0.25 inside diameter x 0.20 film 
thickness); flow rate 1.0 mL/min; injector temperature: 275 °C; splitting ratio: 1:20; 
detector temperature: 275 °C; carrier gas: helium for chromatography at a pressure of 
1.8 psi; auxiliary gas: hydrogen for chromatography, under a pressure of 18 psi; air 
chromatography at a pressure of 22 psi; sensitivity of instrument: 4 to 16 times the 
minimum attenuation; amount of sample injected: 1.0 µL. Analyses were performed 
with the following temperature program: 170 °C for 7 min, 170–225 °C at 2.0 °C min-
1, and 225 °C for 20 min. Fatty acid methyl esters were identified by comparing their 
retention times with those of 22 commercial fatty acid standards purchased from 
Supelco (Sigma-Aldrich Group, St. Louis, MO, USA), with the limit of quantitation of 14 
ppb.  
 
2.18 Carbohydrates analysis 
1 mg of total proteins-containing OMVs was used for carbohydrates analysis. The 
determination of the sugar residues by GC–MS analysis was carried out as described 
in De Castro C et al. [43-44]. Briefly, monosaccharides were identified as acetylated 
O-methyl glycoside derivatives. After methanolysis (1.25 M HCl/MeOH, 85°C, 24 h) 
and acetylation with acetic anhydride in pyridine (85°C, 30 min), the sample was 
analyzed by GC–MS.  
 
2.19 Cell viability MTT assay  
HaCaT cells were seeded on 96-well plates at a density of 4×103 cells/well in 0.1 mL 
of complete DMEM 24 h prior to the treatment.  
Cells were incubated in the presence of OMVs sample at a final concentration of 10 
and 25 μg/mL, for 1,5 and 4 hours. As control, cells were incubated with PBS 1X buffer 
diluted in medium. Cell viability was evaluated by MTT assay, adding tetrazolium MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) diluted at 0.5 mg/mL in 
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DMEM without red phenol (0.1 mL/well). After 4 h of incubation at 37°C, the resulting 
insolu- ble formazan salts were solubilized in 0.04 M HCl in anhydrous isopropanol, 
and quantified by measuring the absorbance at λ = 570nm, using an automatic plate 
reader spectrophotometer (Synergy HTX Multi- Mode Reader-BIOTEK). Cell survival 
was expressed as means of the percentage values compared to control. Standard 
deviations were always < 5% for each repeat (values in quadruplicate of at least three 
independent experiments). 
 
2.20 Cell culture 
HaCaT ketatinocytes cell line were were coltured in high-glucose Dulbecco’s modified 
Eagle’s medium (DMEM) with 10% FBS, 1% Pen/strep at 37°C and 5% carbon dioxide 
(CO2). 
Murine macrophage Raw 264,7 cells were coltured in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% FBS, 1% Pen/strep at 37°C and 5% 
carbon dioxide (CO2). EVs were isolated from 24 h serum-free conditioned media of 
600,000 cells fort a T75 flask. 
Treatment for EVs isolation was performed for 24 h (with the following agents: Palmitic 
Acid (PA) 400 μM, Oleic Acid (OA) 400 μM, LPS 5 μg/mL and non-stimulated. 
Murine vascular smooth muscle cells (VSMC) were isolated from murine adult Aorta 
and coltured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 4mM L-glutamine, 1% v/v penicillin/streptomycin solution 
(100 U/ml) and 1mM sodium pyruvate  (Euroclone, Milano, Italy) at 37°C in 5% CO2 
incubator. 
 
2.21 Production and isolation of EVs 
Serum-free conditioned media were collected to isolate total EVs. The conditioned 
medium was first centrifuged at 1,500 x g for 15 min in order to eliminate cells and 
cellular debris. Supernatants containing total EVs were pelleted two times at 15,000 g 
for 50 min in order to isolate Microparticles (MPs). Pellets (MPs) were finally 
suspended in 200 µL of 0.9% NaCl and and stored at 4 °C. Supernatants, containing 
exosomes, were ultracentrifuged at 200,000 x g for 2hrs at 4°C (rotor MLA-50, 
Beckman Coulter Optima MAX-XP Ultracentrifuge). After two washing steps in NaCl 
0.9%, exosomes pellets were suspended  
into 200 µL of  PBS 1X and stored at 4 °C. 
The protein amount in the EV preparations was estimated by a DC protein assay 
(BioRad, Marnes la Coquette, France) using BSA as a standard.  
 
2.22 Western Blot analysis  
VSMC were resuspended in lysis buffer [50 mM Tris pH 7.4, 0.27 M sucrose, 1 mM 
Na-orthovanadate pH 10, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM 
ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraa- cetic acid (EGTA), 10 mM Na 
β-glycerophosphate, 50 mM NaF, 5 mM Na pyrophosphate, 1% (w/v) Triton X-100, 
0.1% (v/v) 2-mercaptoethanol and cOmpleteTM Protease Inhibitor Cocktail, (Roche 
Diagnostics, Meylan, France)] and left on ice for 30 min. Whole cell lysates were 
centrifuged at 15,000 × g for 10 min at 4°C and stored at −80°C. 
Cell lysates (8 μg), MPs and exosomes preparations (15 μg) were diluted with Laemmli 
Buffer 6X (in reducing conditions), subjected to SDS- PAGE on 4–12% bis-acrylamide 
resolving gels (Novex® NuPAGE® precast gels; Life Technologies, Saint Aubin, 
France) and transferred on to nitrocellulose membranes (GE Healthcare, Pittsburgh, 
PA, USA). The membrane was blocked for 90 min at room temperature in 5% (w/v) 
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BSA/ Tris-buffered saline (TBS) (50 mM Tris-HCl pH 7.6, 150 mM NaCl) supplemented 
with 0.1% (v/v) Tween-20.  
Antibodies for Western blot were: Alix (#611620; BD Biosciences, Le Pont de Claix, 
France), β-actin (#4970, clone 13E5; Cell Signaling), CD9 (#553758; BD Biosciences), 
CD63 (#D263-3, MBL International, Woburn, Massachusets, USA), CD81 (#sc- 18877; 
Santa Cruz Biotechnology), and Nlrp3 (NLRP3 (D4D8T) Rabbit mAb #15101 Cell 
Signaling). Nitrocellulose membranes were washed three times in TBS 0.1% Tween-
20 (v/v) for 5 min and visualization was performedwith horseradish peroxidase (HRP)-
coupled second- ary antibodies (Jackson Immuno-Research, West Grove, 
Pennsylvania, USA). Protein signals were visualized using enhanced 
chemiluminescence (Immunocruz, Santa Cruz Biotechnology) with a Chemi-smart 
5000 imager system (Vilber-Lourmat, Marne La Vallée, France). 
 
2.23 Nanoparticle tracking analysis 
EV samples were diluted in sterile NaCl 0.9% before nanoparticle tracking analysis 
(NTA). NTA was undertaken using the NanoSight NS300 (Malvern Instruments, 
Malvern, UK) equipped with a 405-nm laser. Ninetysecond videos were recorded in 
five replicates per sample with optimised set parameters (the detection threshold was 
set to 7 and 5, respectively, for lEVs and sEVs). Temperature was automatically 
monitored and ranged from 20°C to 21° C. Videos were analysed when a sufficient 
number of valid trajectories was measured. Data capture and further analysis were 
performed using the NTA software version 3.1. At least three independent biological 
samples of each EV subtype were analysed, and the presented results corre- spond 
to the mean of the five videos taken for a given biological sample. 
 
2.24 Cytofluorimetric Annexin V binding analysis 
Annexin V binding properties was measured by flow cytometry using the kit Annexin 
V-FITC (Miltenyi Biotec). Five microlitres of MPs (corresponding to 0.5 μg of MPs 
content) were washed with annexin V 1X binding buffer, centrifuged at 13,000 × g for 
15 min, then incubated with 5 μL of annexin V-FITC in annexin V 1X buffer in the dark 
for 45 min. Following staining, MPs were washed twice in 1X buffer, pelleted and 
resuspended in 200 μL 1X buffer for flow cytometry analysis. Annexin V positivity was 
determined on a MACSQuant flow cytometer. Data were further analysed using 
MACSQuant analysis software. 
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CHAPTER III- RESULTS SECTION I 
 
3.1.1 Cloning, recombinant expression and purification of recombinant RHA-P 
α-RHA activity was previously detected and isolated, in the laboratory in which this 
PhD project was developed, in the crude extract of N. sp. PP1Y grown in minimal 
medium and in the presence of 0.3 mM naringin [132]. In order to express, purify and 
characterize this novel enzymatic activity, PP1Y genomic DNA was cloned in a 
pET22b(+) recombinant plasmid as described in Materials and Methods [135]. 
Recombinant plasmid pET22b(+)/rha-p was used to transform E. coli BL21(DE3) 
strain, and first attempts to express the recombinant protein (rRHA-P) at 37°C showed 
the presence of a protein band with the expected molecular weight of 120 kDa almost 
exclusively in the insoluble fraction of the induced culture. At this stage, the induction 
temperature was lowered to 23°C and a SDS-PAGE analysis highlighted the presence 
of an analogous protein band also in the soluble portion of the induced culture (Fig. 8), 
thus suggesting a possible further improvement of the yield of soluble rRHA-P by 
modifying the experimental conditions of the recombinant expression. Neither the use 
of different IPTG concentrations nor the variation of the induction time seemed to 
further influence the presence of rRHA-P in the soluble fractions. However, it has been 
shown that the addition of osmolytes such as betaine and sorbitol, which behave as 
“chemical chaperones”, to the culture medium of induced recombinant cells of E.coli 
helps in assisting protein folding and might increase protein solubility. This effect can 
be improved by the presence in the growth medium of a high salt concentration that is 
responsible for increasing the uptake rate of betaine and sorbitol from the extracellular 
environment. It has been shown, in fact, that in the presence of an osmotic shock, 
caused for example by the presence of a high salt concentration, some bacteria 
equilibrate the osmotic pressure by accumulating both intracellular metabolites such 
as aspartate, glutamate, and proline and osmolytes present in the medium such as 
betaine and sorbitol [136]. 
 
 
Figure 8: SDS-PAGE of analytical expression of rRHA-P in E.coli, strain BL21(DE3). Lane 1: MW 
standard. Lane 2: insoluble fraction of induced cultures after 3 hrs of induction at 37°C. Lane 3: soluble 
fraction of induced cultures after 3 hrs of induction at 37°C. Lane 4: insoluble fraction of induced cultures 
after 3 hrs of induction at 23°C. Lane 5: soluble fraction of induced cultures after 3 hrs of induction at 
23°C. 
Therefore, analytical expression experiments were performed to optimize the yield of 
active rRHA-P in the soluble fraction of the induced culture. To this purpose, cell growth 
was performed in media of different composition that included a) LB, b) LB  
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supplemented with 0.5 M NaCl (LB-N), c) LB supplemented with 1 mM of both betaine 
and sorbitol (LB-BS), and d) LB containing 0.5 M NaCl, and 1 mM of both betaine and 
sorbitol (LB-NBS). rRHA-P expression was induced with 0.1 mM IPTG at either 23 °C 
or 37°C. Data obtained showed that the best condition involved an induction at 23°C 
using LB-NBS as growth medium, with a 46-fold-increase of the specific activity in the 
soluble fraction after cell lysis when compared to cultures grown in LB and induced at 
37 °C.   
Large-scale recombinant expression was performed by using the optimized 
exprimental conditions suggested by the analytical experiments described above. 
rRHA-P purification was carried out following three different chromatographic steps. 
Cell extract obtained after lysis, was loaded onto a Q Sepharose FF column and protein 
separation was carried out using a linear gradient from 0 to 0.4 M NaCl at a flow rate 
of 15mL/h. The chromatogram was obtained by analysing fractions absorbance at λ= 
280 nm and the presence of the recombinant α-RHA activity was detected by using 
the pNPR assay. Relevant fractions were analysed by SDS-PAGE, pooled and 
concentrated and then loaded onto a Sephacryl HR S200 gel filtration column; proteins 
were eluted at a flow rate of 12 mL/h. Fractions were collected, analysed and screened 
for the presence of α-RHA activity as previously described. The last chromatographic 
step involved a second ion exchange chromatography; sample was loaded on a Q 
Sepharose FF column and eluted with a linear gradient from 0 to 0.25 M NaCl at a flow 
rate of 13mL/h. Relevant fractions were pooled, concentrated, purged with nitrogen, 
and stored at -80°C until use. 
The purification table (Table1) showed a final purification factor (PF) of 6.9.  
 
Table 1: Purification table of rRHA-P. #Total Units 
 
SDS-PAGE analysis of peak fractions representative of all purification steps showed 
in the final purified sample of rRHA-P the presence of a major contaminant with an 
approximate molecular weight of ~35 kDa. This protein band was excised, digested in 
situ and analysed by LC-MS/MS. The protein was identified by searching in the E. coli 
sequence database and resulted to be the subunit of Glyceraldehyde 3-phosphate 
dehydrogenase which is composed of four identical subunits, as identified by 17 
peptides matches for a global sequence coverage of 71%.  
Purified rRHA-P amino acidic sequence was verified up to a 94% coverage, by MS 
Mapping analysis carried out by MALDI-TOF and LC–MS/MS after both an in-situ and 
an in-solution digestion with either trypsin or chymotrypsin. However, it is worth noting 
that the protein N-terminus, detected by MS analysis, lacks the first 23 amino acids 
from the expected cloned sequence (data not shown). To confirm the lack of the 
putative N-terminal peptide, purified rRHA-P was subjected, after an N-terminus 
labelling, to both MALDI-TOF and LC–MS/MS analysis. Mass spectrometry analysis 
 
 Tot U.# Specific Activity (U/mg) P.F. Yield 
(%) 
Cell lysate 13,728.8 49.8   
I Q-Sepharose 5,939.6 54.7 1.1 43.3 
Gel filtration 1,370.6 66.1 1.3 9.9 
II Q-Sepharose 920.9 346.9 6.9 6.7 
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allowed the identification of peptides 23 ESRDDAAEVAPSTRPEPSLEQAF45 (MH+ 
2502.17 ppm) and 23 ESRDDAAEVAPSTR36 (MH+ 1503.70) when rRHA-P was 
digested with chymotrypsin or trypsin, respectively. This evidence was also confirmed 
by Edman degradation N-terminus sequencing, which showed that the first 5 amino 
acids of the recombinant protein are ESRDD. It should be noted that the same N-
terminal peptide was also found in native RHA-P.  
 
3.1.2 Biochemical characterization of rRHA-P 
The oligomeric state of rRHA-P was verified by analytical gel filtration using a Superdex 
200 analytical column, in collaboration with prof. Antonio Molinaro of the Department 
of Chemical Sciences (University Federico II of Naples). The protein was eluted as a 
single peak with an apparent molecular weight of 101,500 ± 5,000 Da, which indicates 
that rRHA-P is a monomer.  
To gain a deeper insight into the biotechnological potential of rRHA-P, the reaction 
mechanism, the kinetic parameters, the optimal reaction conditions in terms of pH and 
temperature and the solvent tolerance were investigated.  
In order to understand the mechanism of action of rRHA-P, 1H NMR spectroscopy was 
used to monitor the stereochemical course of pNPR cleavage in collaboration with 
Prof. Antonio Molinaro, of the Department of Chemical Sciences, University of Naples 
Federico II. The data obtained suggest that rRHA-P acts as an inverting enzyme. 
Moreover, to investigate rRHA-P substrate specificity in hydrolysis and self-
condensation processes, several pNP and pNP derivatives were used as substrates 
in enzymatic assays performed as described in Materials and Methods. Reactions 
were followed over time by TLC analysis and purified enzyme showed activity only on 
pNPR, confirming that rRHA-P is indeed an α-L-rhamnosidase (data not shown). 
Moreover, no activity on pNP-β-d-Glucose was detected. Furthermore, oligo- and 
polysaccharides such as rutinose, maltose, sucrose, lactose, pullulan, starch, 
amylopectin, raffinose, xylan from birchwood, xylan from oat spelt, hyaluronic acid, 
cellulose, cellobiose, chitosan, Glucan from barley, laminarin, curdlan, fucoidan from 
Fucus versiculosus, were also tested as substrates for rRHA-P. TLC analysis of all 
these reactions showed the lack of activity of this enzyme on any of these compounds. 
Kinetic parameters were estimated at pH 6.9 using a pNPR concentration ranging 
between 0.025-1 mM. All kinetic parameters were determined with a non-linear 
regression curve using GraphPad Prism (GraphPad Software; www.graphpad.com). 
The reaction rate (μM/min) plotted as a function of the substrate concentration (μM) 
showed a typical Michaelis-Menten trend (Fig. 9 and Table 2). KM constant of 160.2 (± 
17.3) μM, Vmax of 21.1(± 8.0) μM min-1, a kcat of 734.4 (± 212.9) sec-1 and a KS of 4.6 
(± 1.7) sec-1 μM-1 were obtained.  
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Figure 9. rRHA-P kinetic behavior using pNPR as substrate. Reaction rate expressed in μM/min is 
plotted as a function of pNPR µM concentration. 
 
 
 
Table 2. Kinetic parameters determimned for rRHA-P on pNPR substrate. 
 
To further characterize rRHA-P, pH optimum was determined by performing pNPR 
assay in buffers with different pH (range 4.7-8.8). The recombinant protein revealed 
an optimal activity in the range 6.0-7.5 with an optimum at pH 6.9, retaining 47% and 
36% of activity at pH 7.9 and 8.8, respectively (Fig. 10A). In addition, rRHA-P optimum 
temperature activity was evaluated by performing the standard pNPR assay in the 
temperature range 25°C-55°C. Data, reported in Figure 10B, showed an optimal 
activity temperature at 40.9 °C. Moreover, to verify the thermal stability of rRHA-P in 
the same range used to determine the optimal temperature, an incubation of the 
purified protein for 1h and 3h was performed at each different temperature. The results 
indicate that the enzymatic activity is stable between 25 and 40 °C, and retains 44% 
of its value up to 50°C. At 40° C, the temperature optimum, the activity is stable up to 
24h.  
In addition, rRHA-P tolerance to the presence of organic solvents was assessed by 
performing the standard pNPR assay in 50mM MOPS pH 6.9 to which 10% and 50% 
of either DMSO, acetone or ethanol (EtOH) were added. Results, reported in Figure 
11, pointed up a drastic decrease of the activity in the presence of either concentration 
of acetone and in 50% DMSO and EtOH, while ≈ 66% of residual activity was detected 
in the presence of 10% of DMSO and EtOH.  
 
 
 KM (μM) Vmax  
(μM min-1) 
Kcat (sec-1) KS (sec-1 μM) 
rRHA-P 160.2 (± 17.3) 21.1(± 8.0) 734.4 (± 212.9) 4.6 (± 1.7) 
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Figure 10. rRHA-P pH (A) and temperature (B) optimum curves. 
 
 
 Figure 11. Organic solvents resistance of rRHA-P. Specific activity is reported in terms of %, compared 
to control. Data are resulting of three independent experiments. Errors were always within 20%. 
 
 
In light of these encouraging outcomes, the ability of rRHA-P to hydrolyze natural 
flavonoids was investigated. Enzymatic assays using naringin, rutin and neohesperidin 
dihydrochalcone were performed and followed by TLC analysis, as described in 
Materials and Methods. To this purpose, a 6 mM solution of each compound was 
incubated with purified rRHA-P in 50 mM Na-phosphate buffer pH 7.0 at 40 °C, and 
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the reaction was monitored by TLC analyses over time. After 3 h of incubation, TLC 
analysis of the reaction mixtures showed a 40–60% hydrolysis of neohesperidin 
dihydrochalcone and rutin in the corresponding derhamnosylated neohesperidin 
dihydrochalcone and isoquercitrin. Besides, a total conversion of naringin was 
observed as the corresponding products, rhamnose and prunin, were the only 
compounds observed on the TLC plate. Reaction on naringin was also carried out in 
the presence of 10% DMSO. In this case, in our experimental conditions, the complete 
conversion of naringin in prunin and rhamnose occurred after 1h. 
 
3.1.3 Optimization of rRHA-P purification: his-tag cloning 
 
Considering the low purification yield of rRHA-P previously obtained for the untagged 
recombinant protein and the burden of the previous purification protocol, the 
recombinant expression of rRHA-P fused to a His-tag was implemented. To this 
purpose, the recombinant plasmid pET22b(+)/rha-his was obtained through a site 
directed mutagenesis on the STOP codon of the coding sequence (TGA to CGA). 
Gene coding sequence was thus extended on the pET22b(+) plasmid, to include a 6-
His-tag coding region at 3’of the gene, as described in Materials and Methods. In this 
way, a rRHA-P fused to a C-terminal His-tag was obtained (Fig. 12). 
 
Figure 12. rha-his Cloning strategy.  
 
 
In order to evaluate rRHA-P-his expression, the plasmid pET22b(+)/rha-his was used 
to transform E. coli BL21(DE3) cells and analytical expression experiments were 
performed. As previously underlined, recombinant expression of rRHA-P (untagged) 
significantly increased when BL21(DE3) cells where induced at a temperature of 23°C, 
and were grown in a high-salt concentration (0.5 M NaCl) LB medium, containing 
betaine and sorbitol [135]. Therefore, a first analytical expression experiment was set-
up to evaluate the recombinant expression of rRHA-Phis as described in Materials and 
Methods. 
The SDS-PAGE analysis of the soluble and insoluble fractions of the induced cultures 
showed the foremost presence of a protein band at the expected molecular weight for 
rRHA-Phis in the soluble fraction, only in cultures induced at 23°C (data not shown). 
The soluble fractions were assayed for the presence of α-RHA enzymatic activity and, 
differently from what observed for rRHA-P, the presence of 0.5 M NaCl in the culture 
medium had no effect in raising the levels of active rRHA-Phis in the soluble fraction 
(data not shown). Data showed that the best expression conditions involved an 
induction with 1 mM IPTG, at 23°C, using LB supplemented with 5 mM of both betaine 
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and sorbitol [51]. Once defined the recombinant expression conditions for rRHA-Phis, 
another optimization of the previous rRHA-P purification protocol was set-up. As 
described above, the protein N-terminus expected from genomic sequence had been 
detected neither in the native nor in the recombinant rRHA-P, suggesting the presence 
of a signal peptide that is presumably cleaved through post-translational proteolytic 
processing. In order to verify the presence of rRHA-Phis in the periplasmic fraction, an 
analytical expression experiment was performed (Material and Methods). Starting from 
the same cell growth, an 8 OD600 aliquot was collected and sonicated, while another 8 
OD600 aliquot was used to perform periplasmic extraction as described in Materials and 
Methods section. Fractions containing the total cell extract, periplasm and cytoplasm 
were analyzed by SDS-PAGE and the α-RHA activity was evaluated. As evident from 
SDS PAGE (Fig. 13), the amount of rRHA-P his is comparable in both periplasmic 
fraction (lane3) and total cell extract (lane 2), whereas only a slight amount of protein 
was observed in cytoplasm. Moreover, enzymatic assays showed that the specific 
activity expressed in the periplasmic space (9,38U/mg) was more than 400 times 
higher than that detected in the cytoplasmic fraction (0,02 U/mg).  
Therefore, large-scale recombinant expression of rRHA-Phis was performed using the 
optimized condition described above and, in order to implement the yield of the purified 
rRHA-Phis, a large-scale extraction of the periplasm fraction was set-up as described 
in Materials and Methods. rRHA-Phis purification was then carried out in a single step 
affinity chromatography using a Ni-sepharose 6 fast flow column. SDS-PAGE analysis 
of purified rRHA-Phis showed a quite pure protein (Fig.14) and the purification table 
(Table 3) showed a final purification factor (PF) of 5.6 and a total yield of 24.8%, 
corresponding to a 1.6 total mg of rRHA-Phis recovered for liter of colture  
 
 
 
Figure 13. SDS PAGE gel analysis of analytical espression of rRHAP-his. Lane 1: standard molecular 
weight, lane 2: total cell extract, lane 3. Periplasmic fraction, lane 4: cytoplasmic fraction. 
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Figure 14. SDS PAGE analysis of purified rRHA-Phis.  Lane 1: standard molecular weight, lane 2-4: 
1,2,4 µg of purified rRHA-Phis 
 
 
 
 
 
 
Table 3. Purification table of rRHA-Phis. S.A: specific activity. U tot: total units  
  
Sample Total 
Units  
Specific 
Activity (U/mg) 
P.F. Yield (%) 
 
Periplasm  
 
3212.5 
 
41.2 
 
 
 
 
 
RHA-Phis 
 
798.40 
 
230.4 
 
5.6 
 
24.8 
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To evaluate the potential effect of the his-tag on protein functionality, specific activity 
of the purified rRHA-Phis was compared to the specific activity of the native rRHA-P. 
Data showed a small decrease of the specific activity on pNPR, with rRHA-Phis 
displaying 87% of the native rhamnosidase activity (Fig. 15). Kinetic constants on 
pNPR for rRHAP-his were also evaluated. Results (Fig. 15) showed that KM and Ks 
values evaluated for RHA-Phis are comparable to those of the the untagged protein 
(160.2 µM-1 and 4.6 sec-1 µM-1 respectively).  
 
                 
Figure 15. Specific activity (A) and Kinetics parameters (B) of rRHA-P his compared with native rRHA-
P. Data are resulting of three independent experiments. Errors were always within 20%. 
 
 
 
3.1.4 Functional and structural characterization of rRHA-P: Alanine scanning 
mutagenesis 
In order to further characterize rRHA-P catalytic activity and specificity, an alanine 
scanning mutagenesis of putative catalytic residues was performed. Therefore, an 
alignment of the rRHA-P amminoacid sequence with other 130 GH106 protein 
sequences available from the online database, was performed using the BLAST 
alignment tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) in collaboration with Prof. Marco 
Moracci and Dr. Andrea Strazzulli, Department of Biology, Federico II of Naples. Five 
conserved residues with a consensus of > 90% were found: D503, E506, D552, E644, 
and D763. An “alanin scanning” strategy was set-up for all 5 residues. This approach 
would led to a loss of function of mutants, in which the catalytic residue is replaced 
with an alanine, through site-directed mutagenesis (Fig. 16). pET22b(+)/D-EXXXA 
mutated plasmids were obtained by the construction of a mutagenesis cassette, after 
digesting pET22b(+)/rhaPhis with AatII/KpnI endonucleases. This cassette contained 
all residues to mutagenize, as described in Materials and Methods. Mutagenesis 
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experiments were performed using QuikChange II Site-Directed Mutagenesis Kit 
(Agilent Technologies) and mutagenized fragments, cloned into pGEM-3Z vector, were 
then individually cloned back into pET22b(+)/rhahis vector using AatII/KpnI restriction 
endonucleases. Mutagenized clones were named: pET22b(+)/D504A,  
pET22b(+)/E506A, pET22b(+)/D552A, pET22b(+)/E644A, and pET22b(+)/D763A and 
were used, separately, to transform E. coli BL21(DE3) competent cells (Fig. 16). 
 
 
 
Figure 16: Mutagenesis strategy of rRHA-P gene. 
 
 
 
Preliminary analytical expressions confirmed the same experimental conditions used 
for wt rRHA-Phis. Therefore, large-scale expressions were performed in order to 
evaluate, for each clone, specific activity on pNPR of either recombinant whole cells or 
cell extracts. To this purpose, an initial screening for the α-RHA activity expressed by 
the recombinant cells was performed using E. coli BL21(DE3) whole cells, according 
to the procedures described in Materials and Methods. No activity was detected for 
mutants rRHA-Phis/D503A and rRHA-Phis/E644A, and a significant reduction in α-
RHA activity for mutants rRHA-Phis/E506A (0.57%), rRHA-Phis/D552A (11.3%) and 
rRHA-Phis/D763A (12.2%) was observed (Fig. 17A). Enzymatic activity was also 
assayed on the corresponding cell lysates. Results, shown in Figure 17B, confirmed 
the data obtained by using recombinant whole cells.  
rRHA-P-his mutants were purified from crude extracts following the same protocol 
used for rRHA-P-his, and the specific activity of the purified mutants was evaluated.  
As underlined in figure 18, mutation in residues D503, E506 and E644, led to an almost 
total inactivation of the enzyme; on the contrary, mutations in positions D552 and D763 
allowed maintaining a residual activity of 47.87% and 15.75% respectively (Fig. 18).  
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Figure 17. Residual specific activity of RHA-Phis mutants. A) pNPR assays on whole cells of E. coli 
BL21(DE3) transformed with pET22b(+)/D-EXXXA, compared to the control recombinant cells 
transformed with pET22b(+)/rha-his. Rhamnosidase specific activity is reported as the percentage of 
residual activity, expressed as mU/OD600, compared to the control. B) pNPR assays of lysates of E. coli 
BL21(DE3) transformed with pET22b(+)/D-EXXXA, compared to the control recombinant cells 
transformed with pET22b(+)/rha-his. Rhamnosidase specific activity is reported as percentage of 
residual activity, expressed as U/mg, compared to the wt protein. 
Data are resulting of three independent experiments. Errors were always within 20%. 
 
 
 
Figure 18. pNPR assays of purified RHA-Phis mutants, compared to wt RHA-Phis. Rhamnosidase 
specific activity is reported as percentage of residual activity, expressed as U/mg, compared to the wt 
protein. Data are resulting of three independent experiments. Errors were always within 20%. 
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In addition, Kinetics experiments were performed as described in Materials and 
Methods section. The reaction rate (µM/min) was plotted as a function of the substrate 
concentration (µM), showing the typical Michaelis-Menten trend. Table 4 summarizes 
the kinetic constants measured for rRHA-Phis and for the active mutants. Firstly, 
results showed that KM and Ks value found for rRHA-Phis are quite close to the ones 
measured for the untagged protein (160.2 µM-1 and 4.6 sec-1 µM-1 respectively). 
Moreover, Ks values obtained for rRHA-Phis/D552A and rRHA-Phis/D763A mutants 
were equivalent to the ~ 65% and ~ 21% of rRHA-Phis Ks, respectively.  
 
 
 
 
Table 4. RHA-Phis, RHA-Phis/D552A and RHA-Phis/D763A kinetic constants using pNPR as 
substrate. Errors were always within 20%. 
 
 
 
  
 
Protein KM  (µM) Vmax (µM min-1) Kcat (sec-1) KS  (sec-1 µM-1) 
RHA-Phis 156.30 26.76 691.47 4.42 
RHA-Phis 
D552A 
158.80 26.83 457.69 2.88 
RHA-Phis 
D763A 
138.20 25.57 126.08 0.94 
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CHAPTER III- RESULTS SECTION II 
EXTRACELLULAR VESICLES IN BIOTECHNOLOGICAL 
PROCESSES 
 
3.2.1 Outer Membrane Vesicles (OMVs) from Novosphingobium sp. 
PP1Y 
 
Outer membrane vesicles (OMVs) are bacterial extracellular vesicles, with a diameter 
range of 20-200 nm. Current research is focusing on the use of OMVs for their 
biotechnological potential as immobilization scaffolds and drug delivery systems. The 
second activity planned in my PhD project was to isolate, purify and characterize OMVs 
from the microorganism Novosphingobium sp. PP1Y. 
 
3.2.1.1 Identification of OMVs from PP1Y 
To verify N. sp. PP1Y vesiculation and identify the best growth conditions for OMVs 
production, cells were grown either in PPMM supplemented with 0.4% glutamic acid 
as the sole carbon and energy source (minimal medium) or in LB (rich medium) as 
described in Materials and Methods section. Cells were harvested during both 
exponential (16 hrs) and stationary phase (20 hrs) at 7,500 g for 20 min at 4°C. Cell 
pellets were processed for SEM visualization and each sample was spotted on 
aluminium stubs and analyzed. The images obtained (Figure 19), showed the 
presence of rod-shaped PP1Y cells embedded in an extracellular matrix rich of small 
globular nanostructures that appeared quite heterogenous in size. This occurred only 
when PP1Y was grown in PPMM (Fig 19 A) and mainly during the exponential growth 
phase; noteworthy, PP1Y grown in LB did not show the presence of extracellular 
vesicles (Fig 19 B).  
 
 
 
Figure 19. SEM images of PP1Y cells. SEM images of PP1Y cells grown either in PPMM (A) or LB 
(B).  Scale bars: 2 µm. 
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Further attempts to analyse by SEM cell-free exhausted growth media to obtain images 
of free-floating vesicles failed to give positive results. 
To overcome this problem, cell free supernatants of PP1Y cells grown under different 
conditions were collected and analysed using Atomic Force Microscopy (AFM) in 
collaboration with Dr. Giulia Rusciano and Prof. Antonio Sasso at the Department of 
Physics, University Federico II of Naples. N. sp. PP1Y was grown in the same 
experimental conditions described for SEM using either PPMM or LB. Two litres of 
exhausted growth medium were collected in both exponential and stationary phase, 
concentrated at a final volume of 15 mL using a 30 kDa Amicon ultra (Millipore) 
membrane and filtered through a 0.45 μm PVDF Millipore membrane. Samples were 
ultracentrifuged at 180,000 x g for 2.5 h at 4°C and were analyzed for the presence of 
OMVs as described in Materials and Methods. AFM data were processed in order to 
obtain 3D images, which confirmed the presence of globular nanostructures in the 
exhausted media collected during the exponential phase growth of N. sp. PP1Y in 
PPMM (Fig. 20). In addition, AFM analysis indicated an average size for these 
structures of  100-200 nm, in agreement with data reported in literature [78, 80, 90, 
93, 140]. It is worth noting that AFM highlighted, at this stage, the presence of a 
heterogeneous sample (Fig. 20), which confirmed what previously observed with SEM 
and prompted the need for a further purification of the sample.  
 
 
Figure 20. AFM analysis of N. sp PP1Y OMVs. AFM images of OMVs isolated in late exponential phase 
from N. sp. PP1Y grown in PPMM. Scale bar 1 µm.  
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3.2.1.2 OMVs purification  
PP1Y cells were grown in PPMM supplemented with 0.4% glutamic acid, in the same 
experimental conditions described above, and 2 L of exhausted growth media were 
processed as described above. Vesicles were puriﬁed through ultracentrifugation by 
stratifying the sample on a sucrose gradient density (Materials and Methods). The 
fractions obtained from this procedure, one for each sucrose concentration, were 
separately recovered and analysed using AFM analysis. The sample before the density 
gradient separation (Fig. 21A) resulted to be heterogeneous in terms of particles shape 
and morphology. Figure 21B and 21D show the 20% and the 70% sucrose fractions, 
respectively, where size and morphology heterogeneity is still evident. The 60% 
fraction (Fig. 21C), instead, showed the presence of a homogenous population of small 
circular particles with the expected size of 100-200 nm [78, 80, 90, 93, 140]. Therefore, 
we focused our attention exclusively on the vesicles isolated in the 60% sucrose 
fraction, from now on referred to as OMVs. The total protein concentration of purified 
OMVs was performed, and indicated that these latter had a total protein concentration 
of ca. 340 µg/mL. 
 
 
Figure 21. AFM images of OMVs total fraction (A), 20% sucrose fraction (B), 60% sucrose fraction (C) 
and 70% sucrose fraction (D). Scale bars 1 µm. Data are resulting of three independent experiments.  
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3.2.1.3 OMVs characterization 
- Size determination 
To better define their size and morphology, purified OMVs were analysed using 
dynamic light scattering (DLS) technique, which indicated the presence of a 
homogenous population owning a size of 130-150 nm (Fig. 22). The same sample was 
also analyzed through Nanotracking particles Analysis (NTA). This methodology allows 
knowing, as a function of particles movement in a fluid medium, the size of 
nanoparticles and their concentration (particles/mL). NTA analysis confirmed for these 
OMVs an average size of  130 nm (Figure 23) and a concentration of about 1.02*109 
particles/mL. Z-potential and electrophoretic mobility of these novel OMVs were 
measured using the Doppler anemometry function of the Zetasizer Nano ZS. Results 
showed a Z-potential of -11.0 mV (±0.757) with an electrophoretic mobility of -0.864 
(µm x cm)/Vs (±0.0616). The net negative charge of these nanostructures was 
consistent with a cell wall charge as other OMVs reported in literature [140]. 
 
 
Figure 22: DLS size distribution of purified OMVs. Figure is representative of 3 independent 
experiments. The average peak size resulted to be 199 nm. All mesuraments resulting of three 
independent experiments. 
 
 
 
Figure 23. NTA analysis of purified OMVs. All measurements derive from trhee independent 
experiments. 
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- Proteomic analysis 
To obtain protein composition of purified OMVs, an LC-MS/MS- based approach was 
used in collaboration with Dr. Fabrizio Dal Piaz (Department of Medicine, Surgery and 
Dentistry at the University of Salerno). Results were compared with those obtained on 
whole N. sp. PP1Y cells. At least six analyses for each sample type were performed: 
only those proteins that were detected in all measurements were taken into account. 
Using such a restrictive approach it was possible able to positively identify 17 proteins 
(Table 5). An high score was achieved for Protease IV; in addition, other hydrolytic 
enzymes were identified such as Amidase, 3-oxoacyl-(Acyl-carrier-protein) reductase, 
alpha-L-fucosidase, aldehyde dehydrogenase (Table 5 and figure 24D). A comparison 
between proteins identified in OMVs and in whole PP1Y cells showed that many 
proteins that resulted highly abundant in the bacterium were completely absent in 
OMVs proteome. In particular, as underlined in figure 24, PP1Y OMVs contained a 
higher percentage of hydrolytic enzymes and other enzymatic activity and a total 
absence of enzymes implicated in metabolic processes (Fig. 24D), compared to PP1Y 
whole cells (Fig. 24C). Moreover, PP1Y OMVs contained more membrane proteins 
(37%) (Fig. 24B) compared to whole cells (12%) (Fig. 24A), and only a little presence 
of intracellular proteins (19%) was detected (Fig 24B).  
 
 
 
 
Table 5. Proteins profile identified by LC-MS/MS-based proteomic analysis of OMVs.  
 
 
 
 
Score significant 
matches 
significant 
sequences 
Description Gene 
11820 499 18 Protease IV  PP1Y_AT18626  
577 6 5 Molecular chaperone GroEL  PP1Y_AT4091  
232 5 3 Peptidase M48, Ste24p PP1Y_AT37085 
209 5 3 Methylmalonyl-CoA epimerase  PP1Y_AT13590 
189 4 3 TonB-dependent siderophore receptor PP1Y_Mpl5927 
176 4 3 Amidase PP1Y_Mpl2820 
161 3 3 Outer membrane protein PP1Y_Mpl9648  
159 4 3 Two-component system, NtrC family, 
response regulator 
PP1Y_AT21969 
143 4 3 3-oxoacyl-(Acyl-carrier-protein) 
reductase 
PP1Y_AT18239 
138 3 3 Carboxypeptidase-related protein PP1Y_AT34079  
124 3 2 Alpha-L-fucosidase PP1Y_Mpl858  
114 3 2 Acetyl-CoA hydrolase/transferase PP1Y_AT33599  
105 3 3 Methylitaconate delta2-delta3-
isomerase 
PP1Y_Mpl10392  
97 2 2 Aldehyde dehydrogenase PP1Y_AT13240  
93 2 2 Dimethylmenaquinone 
methyltransferase 
PP1Y_AT31205 
89 2 2 Adenosylmethionine-8-amino-7-
oxononanoate aminotransferase 
PP1Y_AT5612 
75 2 2 Major facilitator transporter  PP1Y_AT12732  
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Figure 24. Proteomic profile analysis. Subcellular localization (A-B) and biological function (C-D) of 
PP1Y whole cell (A, C) and OMVs (B, D) proteins. 
 
 
 
- Fatty acids and carbohydrate analysis 
OMVs fatty acid profile was also evaluated [141-143]. A gas chromatography analysis 
was performed in collaboration with Dr. Armando Zarrelli (Department of Chemical 
Sciences, University of Naples Federico II) on purified OMVs and fatty acid methyl 
esters were identified by comparing their retention times with those of 22 commercial 
fatty acid standards, with the limit of quantitation of 14 parts per billion (ppb). Results 
(Table 7 and Fig. 25) underlined differences between PP1Y whole cells and OMVs. 
More in detail, OMVs membrane showed a greater abundance of Saturated Fatty Acids 
(SFAs) compared to PP1Y cell membranes. A more significative evidence could be 
obtained by grouping fatty acids into four different groups (Figure 25): Unsaturated 
Fatty Acids (UFAs), Poly-Unsaturated Fatty Acids (PUFAs), Mono-Unsaturated Fatty 
Acids (MUFAs) and Saturated Fatty Acids (SFAs) [143].  
Comparison between OMVs and PP1Y cells composition, reported in Figure 6, 
revealed that OMVs membrane had a great abundance of SFAs, corresponding to 71% 
of total fatty acids, and about 9% of MUFAs, whereas PP1Y cell membrane contained 
only 4% of SFAs, almost the same percentage of MUFAs (8.8%) and 87.2% of PUFAs.  
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Figure 25. Fatty acid composition of PP1Y membranes (raw black) and OMVs (raw grey) are reported 
in terms of percentage of total amount. Data are resulting of three independent experiments. Errors were 
always within 20%. 
 
 
 
Table 7. Fatty acids composition of N. sp PP1Y OMVs and whole cells. 
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As for carbohydrate analysis, OMVs showed as main component glucose, likely 
deriving from the sucrose contamination used for the gradient. Beside this 
monosaccharide, vesicles contained (in low amounts) galacturonic acid and galactose 
(data not shown). The heavy contamination of sucrose unfortunately hampered a 
quantitative evaluation of these and other sugars present in the vesicles. 
 
3.2.1.4 Biocompatibility 
 
In order to use these isolated OMVs as drug delivery systems, their biocompatibility 
was preliminary evaluated using, as a model, human normal keratinocytes (HaCaT) 
cells. Biocompatibility of purified OMVs was assessed by performing an MTT assay. 
Cells were seeded on 96-well plates and treated with 10 and 25 μg/mL of purified 
OMVs. After 1,5 and 4 hours of incubation, a MTT stock solution in 1X PBS was added 
to the cells to a final concentration of 0.5 mg/mL and, after a 4h incubation, MTT 
formazan salts were dissolved in 100 µL of 0.1 N HCl in anhydrous isopropanol. Cell 
survival was expressed as the ABS of blue formazan measured at 570 nm with an 
automatic plate reader. Three independent experiments were performed and, for each 
experiment, standard deviations were always <5%. Results shown in Figure 26, 
underlined that cell viability was not affected at any of the concentration and incubation 
time tested, indicating that OMVs does not affect human keratinocytes viability.  
 
 
 
Figure 26. MTT assay on HaCaT cell line. Cell survival is expressed as percentage compared to control. 
Data are resulting of three independent experiments. Standard deviations were always <5% for each 
experiment. 
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3.2.2 Extracellular Vesicles (EVs) from macrophages 
 
Extracellular vesicles (EVs) are membrane-derived particles of 30-2,000 nm 
diameter, released by cells in the human body [108]. EVs are classified, based on 
their cellular origin, biological function or biogenesis, in exosomes and microparticles 
(MPs) [71]. Within the past decade, EVs have gained much attention as 
biotechnological tools for enzyme immobilization and drug delivery systems. 
However, to evaluate their effective use, their inflammatory properties need to be 
better investigated. Among others, we decided to focus our attention on monocyte-
derived EVs, a system well described in literature, that are characterized by pro-
inflammatory effects, mostly through interaction with endothelial cells, but also with 
other cells, including monocytes themselves, fibroblasts, and smooth muscle cells 
[124]. Main aim of this part of my PhD project, which was performed at the laboratory 
of Professor Ramaroson Andriantsitohaina of the University of Angers (INSERM), 
France, has been to better characterize monocytes/macrophages-derived EVs.  
 
3.2.2.1 Isolation of extracellular vesicles (EVs) from murine macrophages RAW 
264.7 cell lines 
 
In order to isolate and characterize EVs (Both MPs and Exosomes) from 
macrophages, a murine cell line (RAW 264.7) was selected and different types of 
stimualtions were choosen, such LPS, Oleic Acid (OA) and Palmitic Acid (PA) [146].  
Different concentrations were tested for each type of stimulation, and optimal 
vesiculation conditions were set-up. Two million RAW 264.7 cells were plated in T75 
flaks and cultured in DMEM high glucose at 37°C, 5%CO2, as described in Materials 
and Methods. To get rid of serum-contaminating EVs, cells were pre-incubated in a 
medium deprived of FBS for 24 hrs and stimulated for additional 24 hrs either by using 
LPS (5 µg/mL), or oleic acid (400 µM), or palmitic acid (400 µM).  
It is important to underline that EVs are classified in two principal groups: exosomes 
and microparticles (MPs) [71] and their purification is carried out following a 
combination of centrifugation steps at different g values [147]. Supernatants recovered 
from the three different stimulation conditions were first centrifuged at 1,500 g for 15 
min to eliminate cellular debris. Cell supernatants were then centrifuged twice at 
15,000 g for 50 min to isolate Microparticles (MPs) first. Pellets containing MPs were 
suspended in 200 µL of 0.9% NaCl in sterile water and stored at 4 °C. Supernatants 
were ultracentrifuged twice at 200,000 g for 2 h and pellets, which contain exosomes, 
were suspended in 200 µL of PBS 1X and stored at 4 °C. 
A first protein quantification, performed using Biorad quantification kit, indicated that 
LPS stimulation increased both the MPs and exosomes amount; oleic acid stimulation 
increased mostly MPs secretion, whereas palmitic acid treatment increased exosomes 
vesiculation (Fig. 27)  
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Figure 27. Vesicular protein quantification. Data are resulting of three independent experiments. Errors 
were always within 20%. 
 
 
3.2.2.2 Characterization of EVs 
 
- Size determination 
Exosomes were analysed by Nanoparticle Tracking Analysis (NTA) technique, using 
Malvern NanoSight instrument. Exosomes samples were diluted at a final 
concentration of 0.02 µg/mL and loaded on Malvern NanoSight instrument. Three 
independent experiments were performed and results are shown in Figure 28 A-B. It 
is evident that all exosomes are characterized by an average diameter of ≈ 100 nm 
(Fig 28A) and no significant variation between vesicles derived from different growth 
conditions were evidenced. Conversely, particles concentration (Fig. 28B) underlined 
important differences among all conditions tested. In particular, stimulation with LPS 
and Palmitic Acid increased the amount of exosomes isolated compared to both control 
(non-stimulated cells) and macrophages stimulated with Oleic Acid (Fig 28B).  
 
 
Figure 28. NTA exosomes analysis. Comparison of size distribution (A) and exosomes concentration 
(B). Data are resulting of three independent experiments. Standard errors were always within 20%. 
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MPs were instead analysed using flow cytometry (FC) analysis [148-149] and using 
annexin V as a marker for MPs [147,150]. 5 µL of each MPs sample were incubated 
with Annexin V for 30’ at RT, and charged on FC500 Beckman coulter, France 
cytometer. Results, obtained from three independent experiments (Fig 29), revealed 
that all MPs were Annexin V-positive with a diameter of ≈ 400 nm. Interestingly, MPs 
amount mainly increased when RAW 264,7 cells were treadet with LPS and Oleic Acid 
(Fig. 29).  
 
 
Figure 29. Microparticles cytometric analysis. Data shown, derived from 3 independent experiments 
and p value is always under 0,005. 
 
 
- Protein content analysis  
To investigate the presence of some exosomes and MPs target proteins, such as 
CD63, CD81, CD9, Alix and β-Actin [107,152], in the isolated nanostructures, a 
western blot analysis was performed. To this purpose, 20 µg of total proteins was 
loaded on SDS-PAGE precast gel and western-blot analysis was performed as 
described in Materials and Methods. From the results obtained, β-Actin was exclusively 
recovered in the MPs fraction and was instead undetectable in the Exosome fraction 
(Fig. 30), in agreement with data reported in literature [153]. In contrast, exosomes 
were significantly enriched with Alix (Fig. 31 C), the endosomal sorting complex 
required for transport I (ESCRT-I) component and the tetraspanins CD9 and CD81 
(Fig. 31 A-B). No significative difference was observed between EVs isolated under 
the different conditions tested.  
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Figure 30: β-actin expression in exosomes and MPs. Lane1: exosomes isolated from macrophages 
stimulated with palmitic acid; lane 2: exosomes isolated from macrophages stimulated with oleic acid; 
lane 3: exosomes isolated from macrophages stimulated with LPS; lane 4: exosomes isolated from 
unstimulated macrophages; lane 5: MPs isolated from macrophages stimulated with palmitic acid; lane 
6: MPs isolated from macrophages stimulated with oleic acid; lane 7: MPs isolated from macrophages 
stimulated with LPS; lane 8: MPs isolated from unstimulated macrophages. The figure shows a 
representative example of three independent Western blot analysis. 
 
 
 
Figure 31: CD9 (A) CD81 (B) and Alix (C) expression in exosomes. Lane1: molecular weight standard; 
lane 2 exosomes isolated from macrophages stimulated with LPS; lane 3: exosome isolated from 
macrophages stimulated with oleic acid; lane 4: exosome isolated from macrophages stimulated with 
palmitic acid; lane 5: exosomes isolated from unstimulated macrophages. The figure shows a 
representative example of three independent Western blot analysis. 
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3.2.2.3 The role of isolated EVs in inflammatory processes 
 
- Nlrp3 presence on isolated EVs 
EVs appear to be a suitable alternative to traditional delivery systems currently in 
development, limiting inflammation processes and enhancing specific delivery. For this 
reason, studying the effect of macrophages-derived EVs in the inflammatory process 
could be particularly beneficial for the of development of a future drug delivery strategy. 
In recent years a strict correlation between EVs derived from macrophages and the 
presence of inflammatory states was demonstrated [154]. In particular, these 
pathologies are caused by the action of a specific complex, named “inflammasome”, 
and Nlrp3 (Nucleotide-binding domain and leucine rich repeat containing family pyrin 
domain containing) remains the best-studied model of inflammasome [154].  
In this context, the presence of Nlrp3 was evaluated on both exosomes and MPs 
isolated from murine macrophages. 
All EVs isolated from macrophages cultured in all conditions previously described (i.e. 
LPS, OA, PA) were quantified as described in paragraph 4.1; 20 µg of total proteins 
were loaded on a SDS-PAGE, transferred on a nitrocellulose membrane and WB 
analysis were performed as described in Materials and Methods. Results, showed in 
Figure 32, underlined a marked increase of Nlrp3 expression on both exosomes and 
MPs isolated from macrophages stimulated with PA and LPS, in according with wich 
described in literature [155-156]. Conversely, oleic acid does not seem to modify Nlrp3 
expression in EVs (both MPs and exosomes), as already described in literature [157] 
 
  
 
 
Figure 32. Western blot analysis of Nlrp3 in MPs and exosomes isolated from macrophages. Lane 1: 
exosomes isolated from unstimulated macrophages; lane1: exosomes isolated from unstimulated 
macrophages; lane 2: MPs isolated from unstimulated macrophages; lane 3: exosome isolated from 
macrophages stimulated with oleic acid; lane 4:  MPs isolated from macrophages stimulated with oleic 
acid; lane 5: exosome isolated from macrophages stimulated with palmitic acid; lane 6: MPs isolated 
from macrophages stimulated with palmitic acid; lane 7: exosomes isolated from macrophages 
stimulated with LPS; lane 8: MPs isolated from macrophages stimulated with LPS. The figure shows a 
representative example of three independent Western blot analysis. 
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-Effects of EVs on vascular smooth muscle cells. 
To evaluate possible different effects of EVs on inflammatory processes, 
cardiovascular cells, and in particular murine vascular smooth muscle cells (VSMC), 
were used as a model [158]. The induction of inflammation via inflammasome 
activation occur once the protein complexes have formed and the inflammasome 
activate caspase-1, which proteolytically activates the pro-inflammatory cytokines 
interleukin-1β (IL-1β) and IL-18 [160] causing a rapid, pro-inflammatory form of cell 
death called pyroptosis [161]. In addition, inflammasome activation could stimulate cell 
apoptosis mechanism through the activation of caspase 8 [162] (Fig.33). 
 
 
 
 
 
Figure 33. Framework of Nlrp3 inflammosome activation. Pyroptosis activation is indicated in the blue 
square, while in the green one induction of apoptosis is depicted. 
 
 
In order to understand EVs inflammation mechanism induction, VSMC were isolated 
from a murine Aorta as described in Materials and Methods, and cultured in DMEM 
supplemented with 10% FBS, 4mM L-glutamine, 1% v/v penicillin/streptomycin 
solution (100 U/ml) and 1mM sodium pyruvate (Euroclone, Milano, Italy) at 37°C in 5% 
CO2 incubator. VSMC cells were treated with 40 μg/mL of all EVs samples and, after 
4 hrs of incubation, cells were detached, collected and lysed. In all experiments 10 
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μg/mL LPS was used as positive control; moreover, to confirm Nlrp3 involvement in 
this mechanism, all conditions were also tested by pre-treating VSMC cells with a Nlrp3 
inhibitor (MCC95 at a final concentration of 0,5 μM) [163]. Cell lysates were used to 
perform western-blot analysis, where 20 μg of total proteins were loaded on SDS-
PAGE precast gel and western-blot experiments were performed as already described 
(Materials and Methods). 
Figure 34 showed EVs (both MPs and exosomes) effect on caspase-1 activation.  
It is evident that MPs and exosomes isolated from macrophages stimulated with LPS 
increased the concentration of activated caspase-1 in VSMC cells; in this case, control 
performed with cells pre-treated Nlrp3 inhibitor (MCC95) does not shown the same 
effect (Fig 34A). The same outcome occurs for both exosomes and MPs isolated from 
macrophages stimulated with palmitic acid (Fig 34B). For what concerns oleic acid 
stimulation, only exosomes showed a caspase-1 activation Nlrp3-dependent (Fig 34B). 
Figure 35 shows EVs (both MPs and exosomes) effect on caspase-8 activation. It is 
evident that caspase-8 levels increased only when VSMC cells were treated with 
exosomes isolated from macrophages stimulated with LPS (fig 35A). When 
considering palmitic acid stimulation, only exosomes isolated showed a caspase-8 
activation, whereas control with Nlrp3 inibithor does not influence caspase-8 activation 
(Fig. 35B). Exosomes isolated from macrophages stimulated with oleic acid increased 
caspase-8 amount, also in presence of MCC95 (Fig. 35B). EVs isolated from 
unstimulated macrophages did not increase either caspase-1, nor caspase-8 
activation. 
 
 
Figure 34. Western blot analysis of Caspase-1 expression in VSMC cells treated with EVs isolated. NT: 
Non-treated VSMC; positive control: VSMC treated with LPS 5 µg/mL; control: VSMC treated with EVs 
isolated from unstimulated macrophages; LPS: VSMC treated with macrophages stimulated with LPS; 
Oleic acid: VSMC treated with macrophages stimulated with oleic acid; Palmitic acid: VSMC treated with 
macrophages stimulated with palmitic acid. Data reported are representative of Three independent 
experiments.  
* : pvalue ≤ 0,05 
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Figure 35. Western blot analysis of Caspase-8 expression in VSMC cells treated with EVs isolated. NT: 
Non-treated VSMC; positive control: VSMC treated with LPS 5 µg/mL; control: VSMC treated with EVs 
isolated from unstimulated macrophages; LPS: VSMC treated with macrophages stimulated with LPS; 
Oleic acid: VSMC treated with macrophages stimulated with oleic acid; Palmitic acid: VSMC treated with 
macrophages stimulated with palmitic acid. Data reported are representative of Three independent 
experiments. 
 
 
 
  
* : pvalue ≤ 0,05 
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CHAPTER 4 
DISCUSSION 
Nowadays, biocatalysis represents a versatile and valuable tool for the development 
of industrial biotechnologies and can be performed with either whole cells or purified 
enzymes. Whereas whole cells generally offer a simple and effective option for cofactor 
regeneration and enhanced enzyme stability, protein engineering and the use of single 
enzymes continues to be considered more economic and practical. Nevertheless, the 
use of enzymes in industrial applications is still limited by several factors, mainly the 
high cost of enzymes, their instability, and their availability in small amounts. To 
overcome these problems, the quest for new catalytic activities from one side, and the 
development of new technical approaches to improve their stability and practical 
applications from the other, remain a central focus of current biotechnological 
research. Among these, technological developments in the field of immobilized 
biocatalysts resulted to be a very powerful tool to improve almost all enzyme 
properties, such as stability, activity, specificity selectivity, and enzyme inhibition [58, 
59]. In this framework, nanobiotechnology is gaining much attention from the 
scientific community, and “nanobiocatalysis” is one direct application of this growing 
field [66] in which artificial or natural lipid bilayers of biological membranes from 
bacteria (Outer Membrane Vesicles) and eukaryotic cells (Extracellular Vesicles) might 
be used as versatile immobilization systems. 
In this PhD thesis, the quest for new enzymatic activities and the need to explore new 
biological systems for the immobilization of biotechnologically relevant enzymes were 
investigated by i) expressing and characterizing a recently identified bacterial 
rhamnosidase, and ii) isolating and characterizing both bacterial OMVs and eukaryotic 
vesicles (EVs) to be used as innovative scaffolds for the immobilization of enzymes or 
as delivery systems.  
For what it concerns the first aim, a novel α-RHA (rRHA-P) was successfully isolated 
and characterized from Novosphingobium sp. PP1Y, a gram-negative bacterium 
isolated from surface waters of a small dock bay in the harbor of Pozzuoli. α-RHAs are 
a group of glycosyl hydrolases (GHs) that have attracted a great deal of attention due 
to their potential application as biocatalysts in a variety of industrial processes. These 
enzymes are of particular interest for the biotransformation of several natural 
compounds that are used in pharmaceutical and food industry, as the removal of the 
terminal rhamnose residues might improve their bioavailability in the small intestine.  
The recombinant expression in E.coli was optimized and the purification protocol was 
implemented to obtain a protein suitable for a further biochemical and structural 
characterization. More in detail, first attempts of expression of the recombinant protein, 
rRHA-P, resulted in the foremost presence of the protein in the insoluble portion of the 
induced cultures. A lower induction temperature, shifted from 37 °C to 23 °C, along 
with the use of a high-salt LB formulation containing both betaine and sorbitol, which 
presumably act as “chemical chaperones”, efficiently concurred in improving the yield 
of soluble, active rRHA-P. It is well known that the induction temperature is considered 
as one of the main determinants responsible for protein misfolding in recombinant 
expression and consequent formation of inclusion bodies. In addition, several 
evidences in literature have shown that the addition of osmolytes such as betaine and 
sorbitol to the culture medium of induced recombinant cells of E. coli helps in assisting 
protein folding and might increase protein solubility [135-136]. This effect can be 
improved by the presence in the growth medium of a high salt concentration that might 
be responsible for both increasing the uptake rate in the cytoplasm of betaine and 
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sorbitol from the extracellular environment and adjuvating the effect of the osmolytes 
themselves by inducing the expression of additional heat-shock proteins that help in 
assisting protein folding [136]. Indeed, by combining a lower temperature with the 
presence of osmolytes and a 2.9% final concentration of NaCl in the growth medium, 
we succeeded in obtaining a reasonable amount of active protein, which was purified 
following a three-step purification protocol, but with a relatively poor yield. 
A preliminary structural characterization showed that rRHA-P is a monomeric protein 
with an approximate molecular weight of 101,500 ± 5,000 Da. Mechanism of action, 
kinetic parameters and optimum reaction conditions were determined using a synthetic 
substrate, pNPR. As for the reaction mechanism, GHs are generally grouped in two 
main classes, inverting and retaining. These different hydrolysis mechanisms lead to 
a retention or an inversion of the anomeric oxygen configuration of the substrate [137]. 
NMR experiments showed that rRHA-P acts as an inverting GH, although further 
investigation is needed to better investigate the details of the catalytic mechanism. 
rRHA-P catalytic efﬁciency, deﬁned by a Ks value of 4.6 s−1 M−1  , underlined an 
activity comparable or even higher than that of other bacterial α-RHAs described in 
literature. When clearly reported, such as in lactic acid bacteria Lactobacillus 
plantarum, and Pediococcus acidilactici, Ks values on pNPR range from 0.01 s−1 M−1  
to 0.019 s−1 M−1  [42-43]. In addition, rRHA-P Ks resulted to be approximately 3 times 
higher than the one reported for the α-RHA isolated from S. paucimobilis FP2001 [51] 
and the comparison among the KM values present in literature, ranging from 1.18 mM 
for S. paucimobilis FP 2001 to 16.2 mM for the α-RHA isolated from P. acidilactici , 
showed a higher apparent afﬁnity of rRHA-P for pNPR (KM of 160 µM). In addition, 
rRHA-P appeared to be a valuable biocatalyst in the biotransformation of flavonoids, 
due to its optimal reaction conditions in terms of pH, temperature and presence of 
organic solvents. More in detail, rRHA-P, in line with other bacterial α-RHAs, has an 
optimal activity at pH 6.9, but retains a significative percentage of its enzymatic activity 
at pH 8.0, which is suitable for the conversion of flavonoids that are scarcely soluble 
at lower values of pH. rRHA-P shows also an optimal activity at 40.9◦C and a significant 
overall thermal stability, retaining 66% of the activity up to 45◦C, a temperature range 
mainly used in most industrial processes. A great majority of other fungal and bacterial 
enzymes exhibit also similar values of temperature stability and optimal activity 
[35,37,42-44], whereas only a limited number of α-RHAs is more thermophilic and has 
an optimum of temperature at ca. 60 ◦C [42,47]. In addition, rRHA-P has a moderate 
tolerance to organic solvents, which are usually employed for the biotransformation of 
flavonoids that are poorly soluble in water, retaining the 66% of activity in solutions 
containing 10% of either DMSO or ethanol. These data suggest a higher tolerance of 
rRHA-P to the presence of solvents compared to α-RHAs described in literature for 
which a residual 20 − 30% activity in 12% ethanol and a 24% activity in 25% DMSO 
has been reported [35]. It is worth mentioning that rRHA-P residual activity in ethanol-
containing buffers might be of additional importance as many biologically relevant 
rhamnosylated flavonoids are found in wine and possibly citrus derived alcoholic 
beverages.  
In this framework, experiments to verify the hydrolytic properties of rRHA-P on few 
natural ﬂavonoids containing either α-1,2 or α-1,6 glycosidic linkages were performed. 
TLC analysis showed a total conversion of naringin (α-1,2 linkage) in the 
corresponding prunin and rhamnose, while a partial hydrolysis of rutin and 
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neohesperidin  (α-1,6 linkage) was observed, thus conﬁrming the ability of this enzyme 
to hydrolyze both α-1,2 and α-1,6 linkages. Likewise, the majority of other bacterial 
and fungal α-RHAs exhibit similar substrate speciﬁcity, even though these enzymes 
often show a slight preference for the hydrolysis of α-1,6 linkages [42-43,47,138]. 
rRHA-P specificity on natural flavonoids resulted to be peculiar when compared to 
fungal counterparts, thus paving the way to the use of this enzyme for a new array of 
bioconversion applications. 
However, despite all the interesting biotechnological aspects described so far, the poor 
yield of purification of rRHA-P was a major drawback to its use in large scale 
processes. We approached this problem with a dual strategy, i.e. by better 
investigating the initial sorting of the recombinant protein in the bacterial cell (periplasm 
vs. cytoplasm), and by fusing a His-tag to rRHA-P, thus reducing the purification steps 
to be used.  
rRHA-P amino acid sequence, verified by MS mapping, showed the lack of the N-
terminal peptide, suggesting the presence of a signal peptide presumably cleaved 
through a post-translational proteolytic processing. A similar evidence has been 
described for the α-RHA isolated from S. paucimobilis FP2001, recombinantly 
expressed in E. coli [51]. The analysis of the amino acid sequence of the putative signal 
peptide revealed several features owned by bacterial signal peptides. These features 
encompass the presence of a charged region (2 – 5 residues) followed by a 
hydrophobic stretch of ~ 12 aa and, 1-3 aa upstream the cleavage site, the occurrence 
of small and hydrophobic residues. The functional role of this cleavage sequence, also 
in the native bacterium, is possibly due to the sorting of these proteins in the 
periplasmic space to accomplish their function. The presence of rRHA-P in the 
periplasmic space was confirmed by comparing specific activities separately measured 
in the cytoplasmic and the periplasmic fractions of the recombinant cells.   
The use of the periplasmic fraction as starting material and the presence of a unique 
purification step concurred in improving the purification yield from 6.7% (untagged 
rRHA-P from the crude extract) to 25.3%,(His-tagged rRHAP from periplasm).  
The analysis of the kinetic constants evaluated on pNPR suggested that the His-tag 
did not significantly affect the activity of the recombinant protein on this synthetic 
substrate. 
Once improved the purification yield, we focused our attention on gathering more 
insights into the catalytic mechanism of rRHA-P, by identifying the residues involved 
in catalysis for a future fine-tuning of its activity, an important aspect in view of the 
biotechnological application of this enzyme. 
Alignment of the RHA-Phis amino acid sequence with other 130 protein sequences 
belonging to the GH106 family was performed. Five highly conserved residues of 
glutamic and aspartic acid were identified, i.e. D503, E506, D552, E644 and D763, 
which were subjected to a “alanine scanning” mutagenesis.  
RHA-Phis single mutants were successfully expressed and purified. Activity assays 
performed again on pNPR, both using recombinant whole cells and purified proteins, 
highlighted that mutations at positions D503, E506 and E644 led to an almost total 
inactivation of the enzyme, thus suggesting that these amino acids might be part of the 
catalytic residues present in the active site. On the other hand, mutations at positions 
D552 and D763 allowed maintaining a residual activity of 47.9% and 15.7% 
respectively, thus suggesting that residues D552 and D763 are not directly implicated 
in the functionality of the enzyme active site. After the initial screening procedure using 
whole recombinant cells, the evaluation of residual specific activity was performed on 
purified proteins. The hypotheses on the role of mutated residues were also supported 
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by the analysis of the kinetic constants measured on pNPR for these two partially active 
mutants. In fact, the decrease in the efficiency of catalysis, expressed by the Ks, is 
almost exclusively dependent on the kcat value and not on a difference in the apparent 
affinity of the enzyme for the substrate, thus suggesting that the mutagenized residues 
might not be directly involved in the binding or positioning of the substrate in the active 
site.  
The data collected would indicate the presence of better  properties in comparison with 
similar enzymes and suggest a possible use of the enzyme for a large number of 
biotechnological purposes, in particular in the food industry. The possibility to fine-tune 
the activity of this enzyme can be foreseen, but undoubtedly more residues need to be 
mutagenized to gain a larger picture of the molecular determinants responsible for 
rRHA-P substrate specificity.  
In this context, the determination of the 3D structure of the enzyme, either by homology 
modelling or by solving the crystal structure of the protein, is an important task to fulfil 
in the near future for better exploring the biotechnological potential of this bacterial 
rhamnosidase. 
 
As underlined in the first part of the Discussion, the use of enzymes in industry is 
generally limited by their instability and availability in small amounts. Over the last few 
decades, intense research in the area of enzyme technology has provided many 
approaches that facilitate their practical applications. Among these, technological 
developments in the field of immobilized biocatalysts resulted to be a very powerful 
tool to improve almost all enzyme properties, such as stability, activity, specificity and 
selectivity. 
Besides their application in industrial processes, immobilization techniques could pave 
the way to the development of a large number of biotechnological devices with 
applications in diagnostics and biosensors.  
During the second part of my PhD project, two different potential immobilization 
scaffolds from bacteria (Outer Membrane Vesicles: OMVs) and from eukaryotic cell 
lines (Extracellular Vesicles: EVs) were isolated and partially characterized.  
OMVs are spherical buds of the outer membrane (OM) filled with periplasmic content 
commonly produced by Gram-negative bacteria which can be foreseen as platforms 
for the immobilization of proteins and enzymatic complexes and could be employed as 
carriers for drugs. The possibility to use these structures for different biotechnological 
purposes has prompted a recent attention towards the isolation and characterization 
of OMVs from non-pathogenic bacteria [84,90]. During my PhD, OMVs were isolated 
from a non-pathogen Gram-negative microorganism lacking LPS, Novosphingobium 
sp. PP1Y. SEM analyses on PP1Y cells grown in minimal medium and collected during 
exponential phase showed the presence of rod-shaped cells in a matrix of globular 
nanostructures that resembled “canonical” OMVs described in literature.  
Further attempts to analyze by SEM cell-free exhausted growth media to obtain images 
of free-floating vesicles failed to give positive results. To overcome this problem, cell 
free supernatants of PP1Y cells grown under different conditions were collected and 
analyzed using Atomic Force Microscopy (AFM). This technique is currently 
considered a gold standard for biological imaging compared to conventional 
microscopes such as SEM and TEM, because AFM does not require, among others, 
conducting materials for imaging, staining, labelling or coating of samples. By far, the 
greatest advantage of AFM is that cells and biomolecules can be imaged in 
physiological environments, in solution and under controlled  temperatures [139]. 
Indeed, AFM analysis allowed us to identify OMVs in cell-free supernatants, before 
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and after an ultracentrifugation purification procedure on a sucrose gradient. AFM 
images confirmed OMVs production in N. sp. PP1Y grown in minimal medium during 
the late exponential phase, which could be explained as a physiological strategy of this 
microorganism to overcome a possible nutrients depletion in these conditions 
[84,88,92]. AFM, DLS and Nanosizer (NTA) data showed that purified OMVs from 
strain PP1Y are predominantly spherical in shape, with an average size of ≈ 130-150 
nm, which is in agreement with the description of other OMVs from different Gram-
negative bacteria [85,90,95]. These vesicles were normally distributed, resulted to be 
homogeneous and owned a negative zeta potential of -11.0 mV (± 0.757). The net 
negative charge of these nanostructures was consistent with a cell wall charge and 
with the values reported in literature for similar nanostructures [140]. Several studies 
described for OMVs a peculiar protein pattern characterized by a marked presence of 
OM proteins (e.g. OmpW) and some proteolytic enzymes for nutrient acquisition 
[80,91-92]. Proteins from these OMVs belong to different functional categories, 
including OM structural proteins, porins, ion channels, transporters, periplasmic and 
cytoplasmic enzymes, and proteins related to stress response [89,92]. Proteomic 
analysis of purified OMVs from PP1Y showed the presence of at least 17 proteins of 
N. sp. PP1Y among which the expression of Protease IV was predominant. This might 
be the direct consequence of the presence in the minimal medium of glutamic acid as 
sole carbon and energy source. In addition, other hydrolytic enzymes were identified, 
such as Amidase, 3-oxoacyl-(Acyl-carrier-protein) reductase, alpha-L-fucosidase, 
aldehyde dehydrogenase, which are in accordance with a physiological role of PP1Y 
vesiculation for environmental adaptation and nutrient acquisition. Interestingly, a 
comparison between proteins identified in OMVs and in whole PP1Y cells showed that 
many proteins that resulted highly abundant in the bacterium were completely absent 
in OMVs proteome, thus suggesting that proteins internalization in these vesicles might 
be finely regulated. Noteworthy, OMVs displayed a marked presence of membrane 
proteins when compared to PP1Y whole cells, thus confirming their peculiar 
composition and their origin from the outer membrane of this microorganism.  
In OMVs secretion, a finely controlled fatty acids distribution in the outer membrane 
has been already described, which is probably related to a complex relationship 
between membrane fluidity and vesicles biosynthesis [141-143]. In fact, fatty acids 
analysis underlined differences between PP1Y whole cells and OMVs. More in detail, 
OMVs membrane showed a greater abundance of Saturated Fatty Acids (SFA) 
compared to PP1Y cell membranes. This aspect has been already described for P. 
aeruginosa, where OMVs isolated from this bacterium contained a 71% of SFA vs. a 
49% of these fatty acids present in the cell membrane [143]. It is worth to note that 
phospholipids that contain UFAs are more flexible than those richer in SFA [141-142]. 
Hence, it can be argued that OMVs show a more rigid membrane compared to 
“parental” cells. The decrease in membrane fluidity of PP1Y OMVs could confirm that 
these structures are released from membrane sites where the outer membrane is 
relatively rigid, as already suggested in literature [144]. Intriguingly, as a rigid 
membrane does not appear to easily adapt to changes in environment, it was also 
hypothesized that the release of OMVs could be an additional strategy to increase OM 
fluidity and thus bacterial survival in harsh environments [141,143-144]. However, the 
detailed mechanism of OMVs biosynthesis is still under investigation, both in 
pathogenic and non-pathogenic bacteria. Among the diverse applications, a great deal 
of attention was also devoted to the potential use of OMVs in drug delivery, enzyme 
immobilization and construction of innovative biosensors [78,96-97].  
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In this context, a preliminary evaluation of the biocompatibility of these structures for a 
possible use with eukaryotic cells was performed, by using human normal 
keratinocytes (HaCaT). In recent years, skin has been shown to contain a broad 
spectrum of enzymes capable to metabolize a wide range of topically applied drugs. 
This metabolic capacity may have consequences for the topical, as well as the 
transdermal delivery of drugs. For this reasons, there is growing interest in studying 
biocompatibility of drugs on skin cells lines. The spontaneously immortalized human 
keratinocyte cell line HaCaT represent a readily available in vitro model and has 
already been used as model for skin toxicity studies [164]. Biocompatibility of purified 
OMVs was assessed by performing an MTT assay, which suggested that OMVs do 
not affect human keratinocytes viability. However, the effect of OMVs on other cell lines 
such epithelial intestinal cells, endothelial cells and vascular smooth muscle cells 
should be also evaluated in the near future, to better investigate the biotechnological 
potential of OMVs as novel drug delivery systems.   
 
EVs from eukaryotic cells, as well as bacterial OMVs, are ideal target for 
biotechnological purposes. The interest in using eukaryotic EVs rather than OMVs lies 
in their specific drug delivery application. Indeed, their specific cell-targeting might help 
in improving target-specific delivery [120,126-129]. Moreover, the fact that EVs derive 
from eukaryotic cells, could make these latter less immunogenic than OMVs, even if 
the presence of histocompatibility factors on EVs surface need to be further 
investigated. 
Main aim of this part of my PhD project has been to better characterize macrophages-
derived EVs, a system already well described in literature, which are characterized 
by pro-inflammatory effects, mostly through the interaction with endothelial cells, 
fibroblasts, and smooth muscle cells [14]. 
EVs are classified in two principal groups: exosomes and microparticles (MPs) [71]. 
MPs are small bioactive vesicles with a diameter between 0.1 to 1μm, whereas 
Exosomes have a diameter of 30-100 nm [126]. EVs, both exosomes and MPs, were 
isolated from murine macrophages and their release resulted to be stimulated by 
specific types of stress such as LPS, oleic acid and palmitic acid [145]. More in detail, 
LPS induces macrophage activation and stimulates immune responses by inducing 
the generation of cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-
1, and IL-6 [145]. Fatty acids such as oleic acid (OA) and palmitic acid (PA) seem to 
directly influence inflammatory gene expression [146]; in particular, palmitic acid 
increases pro-inflammatory gene expression like TNF-α, whereas oleic acid increases 
anti-inflammatory gene expression in macrophages [146].  
In order to purify EVs (Exosomes and MPs), a combination of centrifugation steps at 
different g values was performed [147]. A differential production was observed for 
either exosome, where macrophages were stimulated with LPS and PA, or MPs, 
whose secretion was incremented by LPS and oleic acid stimulation. This differential 
effect could be explained by the fact that MPs and exosomes have different secretion 
mechanisms, which might be triggered by different molecular signals and cellular 
stress [126,145-146].  
Exosomes were analyzed by Nanoparticle Tracking Analysis (NTA) technique, 
whereas MPs were analyzed by flow cytometry (FC) analysis [148-149] and using 
annexin V as a marker for MPs [147,150].  
NTA is an advantageous technique to study nanoparticles from 10-1000 nm in solution, 
which are individually but simultaneously analyzed by direct observation and 
measurement of diffusion events. This particle-by-particle methodology produces high 
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resolution results for particle size distribution and concentration and allows to measure 
both particle size and concentration. Conversely, FC is a widely used method for MPs 
detection and recently, there have been improvements in the standardization of 
membrane vesicles FC measurements [148-149]. With this technique, it is possible to 
specifically identify particles of ≈ 300-500 nm diameter, using microbeads of the 
desired diameter, as standards, and evaluate their concentration in terms of 
particles/mL. 
Results obtained for exosomes and MPs, underlined that the different vesiculation 
conditions did not affect EVs size. On the contrary, different cell stimulations influenced 
EVs amount. In particular, LPS cell stimulation caused an increase of both exosome 
and MPs number, whereas Palmitic Acid and Oleic Acid seemed to have different 
effects. More specifically, palmitic acid is responsible for the increase of exosomes 
production, whereas oleic acid increases MPs secretion. This differential effect could 
be explained by the fact that MPs and exosomes have different secretion mechanisms, 
which might be stimulated by different molecular signals [126]. 
Both exosomes and MPs have a well-defined protein profile. In particular, exosomes 
feature phosphatidylserine markers of tetraspanin family proteins including CD63, 
CD81, CD9, [107,152] and the endosomal protein Alix. Conversely, β-Actin was 
generally described in literature in the MPs fraction, in agreement with the critical role 
of cytoskeleton remodeling in the process of microvesicle shedding. Western Blot 
experiments performed on purified exosomes and MPs, showed a typical protein 
expression for each [152] and no contamination between MPs and exosomes was 
found. 
In the overall goal to use EVs as novel drug delivery systems, it is important to better 
detail the effect of macrophages-derived EVs on the inflammatory process. In recent 
years, in fact, a strict correlation between EVs derived from macrophages and the 
presence of inflammatory states, such as type 2 diabetes and atherosclerosis, was 
demonstrated [154]. In particular, these pathologies seem to be caused by the action 
of a specific complex, named “inflammasome”, a large, multiprotein complex that 
oligomerizes in the cytoplasm of innate immune cells to cleave and activate pro–IL-1β. 
Nlrp3 (Nucleotide-binding domain and leucine rich repeat containing family pyrin 
domain containing) is a component of the inflammatory complex and remains the best-
studied model of inflammasome [154]. In the light of this evidence, it was hypothesized 
that there could be an association between Nlrp3, Extracellular Vesicles and 
inflammatory diseases. In particular, it would be of interest to understand whether 
Nlrp3 could be conveyed by EVs from activated macrophages thus contributing to the 
induction of the inflammation process. 
In this context, the presence of Nlrp3 was evaluated on both exosomes and MPs 
isolated from murine macrophages. Western Blot analysis underlined a marked 
increase of Nlrp3, in exosomes and MPs isolated after macrophages stimulation with 
LPS and PA, in accordance with what reported in literature [155-156]. It is already well 
known, in fact, that LPS chronic stimulation activates the NLRP3 inflammasome in 
macrophages [155-156]; moreover, fatty acids, in particular PA have recently been 
proposed as triggers of the NLRP3 inflammasome [157]. Conversely, OA does not 
seem to modify Nlrp3 expression in EVs (both MPs and exosomes), thus confirming 
what is already reported in literature [157]. 
Vascular smooth muscle cells (VSMCs) [158] were used in this part of my PhD project 
as a model to study the effect of macrophages-derived EVs in the inflammatory 
process. These cells undergo a unique, coordinated morphological and functional 
transition between contractile and synthetic states in injury and disease [158]. VSMC 
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inflammatory activation contributes to vessel pathophysiology, vascular disease 
progression and ultimately, adverse clinical outcome [159].  
The inflammation induction that occurs via inflammasome activation begins once the 
protein complexes have formed and the inflammasome activate caspase-1 
proteolitically activates the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18 
[160], thus pyroptosis [161]. In addition, inflammasome activation could stimulate cell 
apoptosis mechanism through the activation of caspase 8 [162] (Fig.31). VSMC were 
isolated from a murine Aorta and treated with 40 μg/mL of all EVs for 4 hrs. In all 
experiments 10 μg/mL LPS was used as positive control; moreover, to confirm Nlrp3 
involvement in this mechanism, all conditions were also tested by pre-treating VSMC 
cells with a Nlrp3 inhibitor [163].  
Results obtained suggest a different effect among EVs on inflammation and vascular 
dysfunction. In fact, MPs and exosomes isolated from macrophages stimulated with 
LPS and PA increased active caspase-1 levels, in a Nlrp3 dependent manner, causing 
a canonical pyroptosis pathway. Conversely, only exosomes isolated from 
macrophages stimulated with both LPS and palmitic acid activated caspase-8, and 
subsequently apoptosis pathway. These results underlined a complex mechanism for 
inflammasome activation. Because of the great number and diversity of NLRP3 stimuli 
known to activate the NLRP3 inflammasome, it seems unlikely that they all bind to the 
NLRP3 structure to activate the inflammasome. Thus, a major question in the field 
relates to the exact molecular activation mechanism of the NLRP3 inflammasome.  
Noteworthy, EVs naturally derived from macrophages (unstimulated), do not stimulate 
either inflammation or apoptosis pathways, suggesting these latter to be the real valid 
alternative to bacterial OMVs. However their large-scale production is still a major 
problem, therefore it is still useful to focus at the moment our attention on the EVs 
derived from stimulated macrophages to evaluate in the near future their potential as 
drug delivery systems. The know-how acquired will be then transferred for the 
biotechnological use of naturally derived EVs.    
 
 
 
  
  
 
93 
 
  
  
 
94 
 
 
  
  
 
95 
REFERENCES 
 
 
1. Kötzler, M. P., Hancock, S. M., and Withers, S. G. Glycosidases: Functions, Families 
and Folds. eLS 2014.  
2. Cantarel B. L., et al. The Carbohydrate-Active EnZymes database (CAZy): an expert 
resource for Glycogenomics. Nucleic Acids Research. 2009. 37(1):D233–D238. 
3. Bojarova P., and Kren V. Biotechnol. Glycosidases: a key to tailored carbohydrates. 
Trends in Biotechnol. 2009. 27(4):199-209. 
4. Ito S., Kobayashi T., Ara K., Ozaki K., Kawai S., Hatada Y. Alkaline detergent 
enzymes from alkaliphiles: enzymatic properties, genetics, and 
structures.  Extremophiles. 1998. 2(3):185-90 
5. Kulkarni N., Shendye A., Rao M. Molecular and biotechnological aspects of 
xylanases. FEMS Microbiol Rev. 1999. 23(4):411-56 
6. Bayer E.A., Lamed R., Himmel M.E. The potential of cellulases and cellulosomes for 
cellulosic waste management. Curr Opin Biotechnol. 2007. 18(3):237-45.  
7. James, J.A.; Lee, B.H. Glucoamylases: Microbial sources, industrial applications 
and molecular biology. Journal of Food Biochemistry.  1997 21(1):1-52 
8. Kashyap, D.R.; Vohra, P.K.; Chopra, S. et al. Applications of pectinases in the 
commercial sector: a review. Bioresource.Technology. 2001. 77(3):215-227 
9.  Brás N.F., et al. Glycosidases: A Mechanistic Overview. Intech. 2012.  
10. Bras N. F., Fernandes P. A., Ramos M. J. Docking and molecular dynamics studies 
on the stereoselectivity in the enzymatic synthesis of carbohydrates. Theoretical 
Chem. Acc. 2009. 122(5-6):283. 
11. Plou, F. J., Segura, A. G. D., and Ballesteros, A. Application of glycosidases and 
transglycosidases in the synthesis of oligosaccharides. Ind. Enz. 2007. 141-157.  
12. Cobucci-Ponzano B., Moracci M. Glycosynthases as tools for the production of 
glycan analogs of natural products. Nat Prod Rep. 2012. 29(6):697-709 
13. Planas, A., and Faijes, M. Glycosidases and glycosynthases in enzymatic 
synthesis of oligosaccharides. An overview. Afinidad. 2002. 59(500):295-313.  
14. Manzanares P., Vallés S., Ramón D., Orejas M. α-L-Rhamnosidases: Old and New 
Insights. Industrial Enzymes. 2007. 117–140. 
15. Mutter M., Beldman G., Schols H.A., Voragen A.G.J.  Rhamnogalacturonan α-L-
Rhamnopyranohydrolase' a novel enzyme specific for the terminal nonreducing 
rhamnosyl unit in rhamnogalacturonan regions of pectin. Plant Physiol. 1994. 
106(1) 241-250. 
16. Hashimoto R.W., Miyake O., Nankai H., Murata K. Molecular identification of an α-
l-rhamnosidase from Bacillus sp. strain GL1 as an enzyme involved in complete 
metabolism of gellan. Arch. Biochem. Biophys. 2003. 415(2):235-44. 
17. Rahim R., Ochsner U.A., Olvera C., Graninger M., Messner P.,. Lam J.S, Soberón-
Chávez G. Cloning and functional characterization of the Pseudomonas 
aeruginosa rhlC gene that encodes rhamnosyltransferase 2, an enzyme 
responsible for di-rhamnolipid biosynthesis. Mol. Microbiol. 2001. 40(3):708–718. 
18. Maxwell E.G., Colquhoun I.J., Chau H.K., Hotchkiss A.T., Waldron K.W, Morris 
V.J., Belshaw N.J., Rhamnogalacturonan I containing homogalacturonan inhibits 
colon cancer cell proliferation by decreasing ICAM1 expression. Carbohydr. 
Polym. 2015. 132:546–553 
19. Nguema-Ona E., Vicré-Gibouin M., Gotté M., Plancot B., Lerouge P., Bardor M., 
Driouich A. Cell wall O-glycoproteins and N-glycoproteins: aspects of 
  
 
96 
biosynthesis and function. Front. Plant. Sci. 2014. 5-499. 
20. Nereus W., Gunther I.V., Nun˜ez A., Fett W., Solaiman D.K.Y. Production of 
Rhamnolipids by Pseudomonas chlororaphis, a Nonpathogenic Bacterium. Appl. 
Env. Microb. 2005. 71(5):2288–2293. 
21. Champion E., Andre I., Mulard L.A., Monsan P., Remaud-Simeon M., Morel S., 
Synthesis of L-Rhamnose and N-Acetyl-D-Glucosamine Derivatives Entering in 
the Composition of Bacterial Polysaccharides by Use of Glucansucrases. J. 
Carbohydr. Chem.  2009. 28:142–160. 
22. Seifert, G. J. Nucleotide sugar interconversions and cell wall biosynthesis: how to 
bring the inside to the outside. Curr. Op. in plan. Biol. 2004. 7(3):277-284. 
23. Panche A.N., Diwan A.D, Chandra S.R. Flavonoids: an overview. J Nutr Sci. 2016 
5-47. 
24. Benavente-García O., Castillo J. Update on uses and properties of citrus 
flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory 
activity. J Agric Food Chem. 2008. 56(15):6185-205. 
25.  Middleton E.Jr., Kandaswami C., Theoharides T.C., The Effects of Plant 
Flavonoids on Mammalian Cells: Implications for Inflammation, Heart Disease, 
and Cancer. Pharmacol. Rev. 2000. 4(52):673-751. 
26. Perez-Vizcaino F.L., Duarte J. Flavonols and cardiovascular disease, Mol. Aspects 
Med. 2010. 31(6):478-94. 
27. Fresco P., Borges F., Marques M.P.M., Diniz C. The Anticancer Properties of 
Dietary Polyphenols and its Relation with Apoptosis. Curr. Pharm. Des. 
2010.16:114-134. 
28. Ce´liz G., Audisio M.C., Daz M. Antimicrobial properties of prunin, a citric flavanone 
glucoside, and its prunin 6”-O-lauroyl ester. J. Appl. Microbiol. 2010. 
109(4):1450–1457. 
29. Németh K., Plumb G.W., Berrin J.G., Juge N., Hassan R.J., Naim H.Y., Williamson 
G., Swallow D.M., Kroon P.A. Deglycosylation by small intestinal epithelial cell β-
glucosidases is a critical step in the absorption and metabolism of dietary 
flavonoid glycosides in humans.  Eur. J. Nutr. 2003. 42:29–42. 
30. Bokkenheuser V. D., Shackleton C. H., Winter J. Hydrolysis of dietary flavonoid 
glycosides by strains of intestinal Bacteroides from humans. Biochem J.  1987. 
248(3):953–956. 
31. Hollman P.C., Bijsman M.N., van Gameren Y., Cnossen E.P., de Vries J.H., Katan 
M.B. The sugar moiety is a major determinant of the absorption of dietary 
flavonoid glycosides in man, Free Radic. Res. 1999. 31(6):569-73. 
32. Day A.J., Gee J.M., DuPont M.S., Johnson I.T., Williamson G. Absorption of 
quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: the 
role of lactase phlorizin hydrolase and the sodium-dependent glucose 
transporter. Biochem. Pharmacol. 2003. 65(7):1199-2006. 
33. Puri M., Marwaha S.S., Kothari R.M., Kennedy J.F. Biochemical basis of bitterness 
in citrus fruit juices and biotech approaches for debittering. Crit. Rev. Biotechnol. 
1996. 16:145–155. 
34. González-Barrio R., Trindade L. M., Manzanares P., de Graaff L. H.,. Tomás-
Barberán F. A., Espín J. C., Production of bioavailable flavonoid glucosides in 
fruit juices and green tea by use of fungal alpha-L-rhamnosidases. J. Agric. Food 
Chem. 2004. 52(20):6136-42.  
35. M.V. Gallego, F. Piñaga, D. Ramón, S. Vallés, Purification and Characterization of 
an α‐L‐Rhamnosidase from Aspergillus terreus of Interest in Winemaking, J. 
Food Sci. 66(2) (2001) 204 - 209. 
  
 
97 
36. Gunata Z., Bitteur S., Brillouet J. M., Bayonove C., Cordonnier R. Sequential 
enzymatic hydrolysis of potentially aromatic glycosides from grape. Carbohydr. 
Res. 1988. 184:139–149. 
37. Manzanares P., Orejas M., Gil J. Vde Graaff L. H. , Visser J., Ramón D., 
Construction of a Genetically Modified Wine Yeast Strain Expressing the 
Aspergillus aculeatus rhaA Gene, Encoding an α-l-Rhamnosidase of Enological 
Interest. Appl. Environ. Microbiol. 2003. 69(12):7558–7562. 
38. Gantt R. W., Peltier-Pain P., Thorson J.S. Enzymatic methods for 
glyco(diversification/randomization) of drugs and small molecules. Natural 
Product Reports.  2011. 28(11):1811-1853. 
39. Xu L., Liu X., Yin Z., Liu Q., Lu L., Xiao M. Site-directed mutagenesis of α-L-
rhamnosidase from Alternaria sp. L1 to enhance synthesis yield of reverse 
hydrolysis based on rational design. Appl Microbiol Biotechnol. 2016. 
100(24):10385-10394. 
40. Hashimoto W., Nankai H., Sato N., Kawai S., Murata K. Characterization of α-L-
rhamnosidase of Bacillus sp. GL1 responsible for the complete depolymerization 
of gellan, Arch. Biochem. Biophys. 1999. 415(2):56–60. 
41. Zverev V.V., Hertel C., Bronnenmeier K., Hroch A., Kellermann J., Schwarz W.H. 
The thermostable α-L-rhamnosidase RamA of Clostridium stercorarium: 
biochemical characterization and primary structure of a bacterial α-L-rhamnoside 
hydrolase, a new type of inverting glycoside hydrolase Mol. Microbiol. 2000. 
35:173–179. 
42. Avila M., Jaquet M., Moine D., Requena T., Peláez C., Arigoni F., Jankovic I., 
Physiological and biochemical characterization of the two alpha-L-
rhamnosidases of Lactobacillus plantarum NCC245. Microbiol. 2009. 155:2739–
2749. 
43. Beekwilder J., Marcozzi D., Vecchi S., de Vos R., Janssen P., Francke C., van 
Hylckama Vlieg J., Hall R.D. Characterization of rhamnosidases from 
Lactobacillus plantarum and Lactobacillus acidophilus. Appl. Environ. Microbiol. 
2009. 75:3447–3454. 
44. Miake F., Satho T., Takesue H., Yanagida F., Kashige N., Watanabe K. Purification 
and characterization of intracellular alpha-L-rhamnosidase from Pseudomonas 
paucimobilis FP2001. Arch. Microbiol. 2000. 173(1):65-70. 
45. Li L., Yu Y., Zhang X., Jiang Z., Zhu Y., Xiao A., Ni H., Chen F., Expression and 
biochemical characterization of recombinant α-l-rhamnosidase r-Rha1 from 
Aspergillus niger JMU-TS528. Int J Biol Macromol. 2016. 85:391-9. 
46. Young N.M., Johnston R.A.Z., Richards J.C. Puriﬁcation of the α-L-rhamnosidase 
of Penicillium decumbens and characteristics of two glycopeptide components. 
Carbohydr. Res. 1989. 191:53–62. 
47. Koseki T., Mese Y., Nishibori N., Masaki K., Fujii T., Handa T., Yamane Y., Shiono 
Y., Murayama T., Iefuji H. Characterization of an alpha-L-rhamnosidase from 
Aspergillus kawachii and its gene. Appl. Microbiol. Biotechnol. 2008. 80(6):1007-
13. 
48. Puri M. Updates on naringinase: structural and biotechnological aspects. Applied 
Microbiology and Biotechnology. 2012. 93(1):49-60 
49. Elíades, L. A., et al. α-L-Rhamnosidase and β-D-glucosidase activities in fungal 
strains isolated from alkaline soils and their potential in naringin hydrolysis. J. of 
basic microbiol. 2011. 51(6):659-665. 
50. Yadav V., Yadav P., Yadav S., Yadav K.D.S. α-L-Rhamnosidase: A review. 
Process Biochemistry. 2010. 45:1226-1235. 
  
 
98 
51. Miyata T., Kashige N., Satho T., Yamaguchi T., Aso Y., Miake F. Cloning, sequence 
analysis, and expression of the gene encoding Sphingomonas paucimobilis 
FP2001 alpha-l-rhamnosidase. Curr Microbiol. 2005. 51:105–109. 
52. Ndeh D., Rogowski A., Cartmell A., Luis A.S., Baslé A., Gray J., Venditto I., Briggs 
J., Zhang X., Labourel A., Terrapon N., et al. Complex pectin metabolism by gut 
bacteria reveals novel catalytic functions. Nature. 2017. 544(7648):65-70. 
53. Bonanno J.B., et al. New York-Structural GenomiX Research Consortium 
(NYSGXRC): a large scale center for the protein structure initiative. J. Struct. 
Funct. Genomics. 2005. 6(2):225-32. 
54. Cui Z., Maruyama Y., Mikami B., Hashimoto W., Murata K. Crystal structure of 
glycoside hydrolase family 78 α-l-rhamnosidase from Bacillus sp. GL1. J. Mol. 
Biol. 2007. 374(2):384–398. 
55. Fujimoto Z., Jackson A., Michikawa M., Maehara T., Momma M., et al. The 
structure of a Streptomyces avermitilis α-L-rhamnosidase reveals a novel 
carbohydrate-binding module CBM67 within the six-domain arrangement. J. Biol. 
Chem. 2013. 288(17):12376-85. 
56. O'Neill E.C., Stevenson C.E., Paterson M.J., Rejzek M., et al. Crystal structure of 
a novel two domain GH78 family α-rhamnosidase from Klebsiella oxytoca with 
rhamnose bound. Proteins. 2015. 83(9):1742-9. 
57. D’Souza S. F. Immobilized enzymes in bioprocess. Curr. Sci. 1999. 69-79. 
58. Mateo C., Palomo J.M., Fernandez-Lorente G., Guisan J.M, et al. Improvement of 
enzyme activity, stability and selectivity via immobilization techniques. Enz. and 
Microb. Technol. 2007. 40:1451–1463 
59. Brena B.M., and Batista-Viera F. Immobilization of Enzymes. A Literature Survey. 
Immob. Enz. and cells. 2006. 15-30. 
60. Wubbolts M.G., Bucke C., Bielecki S. How to get the biocatalyst. Appl. Biocat. 2000. 
153. 
61. Massolini G., Calleri E. Immobilized trypsin systems coupled on-line to separation 
methods: recent developments and analytical applications. J. Sep. Sci. 2005. 
28:7–21 
62. Trevan M.D. Immobilized Enzymes: an Introduction and applications in 
biotechnology. Wiley. 1980. 1–9. 
63. Brodelius, P., Mosbach, K. Immobilization Techniques for Cells/Or ganelles. 
Methods in Enzymol. 1987. 135:173–454. 
64. Buchholz K., Klein J. Characterization of Immobilized Biocatalysts. Methods in 
Enzymol. 1987. 135:3–30. 
65. Cabral J.M.S., Kennedy, J. F. Covalent and coordination immobilization of proteins. 
Protein immobilization. 1991. 73–138. 
66. Girelli A.M., Mattei E. Application of immobilized enzyme reactor in on-line high-
performance liquid chromatography: a review. J. Chromatogr. B. 2005.  819:3–
16. 
67. Chow D.C., Johannes M-S., Lee W.K. et al. Nanofabrication with biomolecules. 
Mater. Today 2005. 8:30–39. 
68. Aniel M.C., Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, 
quantum-size-related properties, and applica- tions toward biology, catalysis, and 
nanotechnology. Chem. Rev. 2004. 104:293–346. 
69. Heeremans, J. L. M., et al. Long-term stability of liposomes containing both tissue-
type plasminogen activator and glu-plasminogen. Int. J. of pharm. 1996. 129(1-
2):191-202. 
70. Mashburn-Warren L., McLean R. J., Whiteley M. Gram negative outer membrane 
  
 
99 
vesicles: beyond the cell surface. Geobiol. 2008. 6(3):214–219. 
71. Yáñez-Mó M., et al. Biological properties of extracellular vesicles and their 
physiological functions. 2015. J Extracell. Vesicles. 2015. 4(1):27066. 
72. Roier, S., et al. A novel mechanism for the biogenesis of outer membrane vesicles 
in gram negative bacteria. Nature Commun. 2016. 7:10515. 
73. Sullivan C., et al. Envelope control of outer membrane vesicle production in Gram-
negative bacteria. Biochem. 2013. 52:3031–3040. 
74. Kulp A., and Kuehn M. J. Biological functions and biogenesis of secreted bacterial 
outer membrane vesicles. Annu. Rev. Microbiol. 2010. 64:163–184. 
75. Zhou, L., et al. On the origin of membrane vesicles in Gram-negative bacteria. 
FEMS Microbiol. Lett.1998. 163:223–228. 
76. Biller, S. J. et al. Bacterial vesicles in marine ecosystems. Science 343, 183–186 
(2014). 
77. Hellman, J. et al. Release of gram-negative outer-membrane proteins into human 
serum and septic rat blood and their interactions with immunoglobulin in 
antiserum to Escherichia coli J5. J. Infect. Dis. 2000. 181:1034–1043.  
78. Kim G. H., et al. Isolation and proteomic characterization of bacterial extracellular 
membrane vesicles. Curr. Protein Pept. Sci. 2014. 15:719–731. 
79. Lee, E. Y. et al. Global proteomic profiling of native outer membrane vesicles 
derived from Escherichia coli. Proteomics. 2007. 7(17):3143–3153. 
80. Yonezawa, H., et al. Outer membrane vesicles of Helicobacter pylori TK1402 are 
involved in biofilm formation. BMC Microbiol. 2009. 9:197. 
81. Bauman, S. J., and Kuehn, M. J. Purification of outer membrane vesicles 
from Pseudomonas aeruginosa and their activation of an IL-8 response. Microbes 
Infect. 2006. 8:2400–2408. 
82. Wai, S. N. et al. Vesicle-mediated export and assembly of pore-forming oligomers 
of the enterobacterial ClyA cytotoxin. Cell. 2003. 115:25–35. 
83. Schooling, S. R., Hubley, A. and Beveridge, T. J. Interactions of DNA with biofilm-
derived membrane vesicles. J. Bacteriol. 2009. 13:4097–4102. 
84. Schwechheimer, C., and Kuehn, M. J. Outer-membrane vesicles from Gram-
negative bacteria: biogenesis and functions. Nat. Rev. Microbiol. 2015. 
13(10):605–619. 
85. Manning, S. J., and Kuehn, M. J. Contribution of bacterial outer membrane vesicles 
to innate bacterial defense. BMC Microbiol. 2011. 11:258. 
86. Li, Z., Clarke, A. J., and Beveridge, T. J. Gram-negative bacteria produce 
membrane vesicles which are capable of killing other bacteria. J. Bacteriol. 
1998.20:5478–5483. 
87. Mashburn-Warren, L. M. and Whiteley M. Special delivery: vesicle trafficking in 
prokaryotes. Mol. Microbiol. 2006. 61(4):839–846. 
88. Heramb, M. K. and Medicharla, V. J. Biogenesis and multifaceted roles of outer 
membrane vesicles from Gram-negative bacteria. Microbiol. 2014. 
160(10):2109–2121. 
89. McBroom, A. J. and Kuehn, M. J. Release of outer membrane vesicles by Gram-
negative bacteria is a novel envelope stress response. Mol. Microbiol. 
2007. 63:545–558. 
90. Yun, S. H. et al. Proteomic characterization of the outer membrane vesicle of the 
halophilic marine bacterium Novosphingobium pentaromativorans. J. Microbiol. 
2014. 55(1):56–62. 
91. Choi, C. W. et al. Proteomic characterization of the outer membrane vesicle of 
Pseudomonas putida KT2440. J. Proteome Res. 2014. 13:4298–4309. 
  
 
100 
92. Frias, A., et al. Membrane vesicles: a common feature in the extracellular matter 
of cold-adapted antarctic bacteria. Microb. Ecol. 2010. 59:476–486. 
93. Mashburn-Warren, L. et al. Interaction of quorum signals with outer membrane 
lipids: insights into prokaryotic membrane vesicle formation. Mol. Microbiol. 2008. 
69:491–502. 
94. Kesty, N. C. and Kuehn M. J. Incorporation of heterologous outer membrane and 
periplasmic proteins into Escherichia coli outer membrane vesicles. J. Biol. 
Chem. 2004. 279:2069–2076. 
95. Kim, J. Y. et al. Engineered bacterial outer membrane vesicles with enhanced 
functionality. J. Mol. Biol. 2008. 380(1):51–66. 
96.  Gujrati, V. et al. Bioengineered bacterial outer membrane vesicles as cell-specific 
drug-delivery vehicles for cancer therapy. ACS Nano. 2014. 8(2):1525–1537. 
97. Ellis, T. N. and Khuen, M .J. Virulence and Immunomodulatory Roles of Bacterial 
Outer Membrane Vesicles. Microbiol. Mol. Biol. Rev. 2010. 1:81–94. 
98. Park M., et al. Positional assembly of enzymes on bacterial outer membrane 
vesicles for cascade reactions. PLoS One. 2014. 9(5):e97103 
99. Notomista, E. et al. The Marine Isolate Novosphingobium sp. PP1Y Shows Specific 
Adaptation to Use the Aromatic Fraction of Fuels as the Sole Carbon and Energy 
Source. Microb. Ecol. 2011. 61(3):582–594.  
100.  van der Meel R., et al. Extracellular vesicles as drug delivery systems: Lessons 
from             the liposome field. J Control Release. 2014. 195:72-85.  
101. Baglio S.R., Pegtel D.M., and Baldini N. Mesenchymal stem cell secreted vesicles 
provide novel opportunities in (stem) cell-free therapy. Front Physiol. 2012. 
3:359. 
102. Heijnen H.F., Schiel A.E., Fijnheer R., Geuze H.J., Sixma J.J. Activated platelets 
release two types of membrane vesicles: microvesicles by surface shedding 
and exosomes derived from exocytosis of multivesicular bodies and alpha-
granules. Blood 1999. 94:3791–3799. 
103. Lai R.C., et al. Exosomes for drug delivery - a novel application for the 
mesenchymal stem cell. Biotechnol. Adv. 2013. 31:543–551. 
104. Rozmyslowicz T., et al. Platelet- and megakaryocyte-derived microparticles 
transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to 
infection by X4-HIV. AIDS. 2003. 17:33–42. 
105.  Boulanger C.M. Microparticles, vascular function and hypertension. Curr. Opin. 
Nephrol. Hypertens. 2010. 19:177–180. 
106. Cocucci E., Racchetti G., and Meldolesi J. Shedding microvesicles: artefacts no 
more. Trends. Cell. Biol. 2009. 19:43–51. 
107. Dignat-George F., and Boulanger C.M. The many faces of endothelial 
microparticles. Arterioscler. Thromb. Vasc. Biol. 2011. 31:27–33.  
108. György B., et al. Membrane vesicles, current state-of-the-art: emerging role of 
extracellular vesicles. Cell. Mol. Life Sci. 2011. 68:2667–2688. 
109.  EL Andaloussi S., et al. Extracellular vesicles: biology and emerging therapeutic 
opportunities. Nat. Rev. Drug. Discov. 2013. 12(5):347-57. 
110.  Barry O.P., and FitzGerald G.A. Mechanisms of cellular activation by platelet 
microparticles. Thromb. Haemost. 1999. 82:794–800. 
111.  Horstman L.L., et al. New horizons in the analysis of circulating cell-derived 
microparticles. Keio J. Med. 2004. 53:210–230. 
112.  VanWijk M.J., et al. Microparticles in cardiovascular diseases. Cardiovasc. Res. 
2003. 59:277–287. 
113. Raposo G. and Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, 
  
 
101 
and friends. J. Cell. Biol. 2013. 200(4):373-83. 
114. Del Conde I., et al. Tissue-factor-bearing microvesicles arise from lipid rafts and 
fuse with activated platelets to initiate coagulation. Blood. 2005. 106(5):1604-11. 
115.  Martinez M.C. and Andriantsitohaina R. Microparticles in angiogenesis: 
therapeutic potential. Circ. Res. 2011. 109(1):110-9. 
116. De Toro J., et al. Emerging roles of exosomes in normal and pathological 
conditions: new insights for diagnosis and therapeutic applications. Front. 
Immunol. 2015. 6:203. 
117. Iraci, N., et al. Focus on Extracellular Vesicles: Physiological Role and Signalling 
Properties of Extracellular Membrane Vesicles. International J. of Mol. Sci. 2016. 
17(2):171. 
118.  Cocucci E., et al. Enlargeosome traffic: exocytosis triggered by various signals is 
followed by endocytosis, membrane shedding or both. Traffic. 2007. 8:742–757. 
119. Moskovich O., and Fishelson Z. Live cell imaging of outward and inward 
vesiculation induced by the complement c5b-9 complex. J. Biol. Chem. 2007. 
282:29977–29986. 
120.  Lösche W., et al. Platelet-derived microvesicles transfer tissue factor to 
monocytes but not to neutrophils. Platelets. 2004. 15:109–115. 
121. Eken C., et al. Polymorphonuclear neutrophil-derived ectosomes interfere with the 
maturation of monocyte-derived dendritic cells. J. Immunol. 2008. 180:817–824.  
122.  Pluskota E., et al. Expression, activation, and function of integrin alphaMbeta2 
(Mac-1) on neutrophil-derived microparticles. Blood. 2008. 112:2327–2335. 
123. Fais S., et al. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in 
Nanomedicine. ACS Nano. 2016. 10(4):3886–3899. 
124. Schneider D. J., et al. Signed, Sealed, Delivered: Microenvironmental Modulation 
of Extracellular Vesicle-Dependent Immunoregulation in the Lung. Front. Cell 
Dev. Biol. 2016. 4.  
125. Bruno S., et al. Mesenchymal stem cell-derived microvesicles protect against 
acute tubular injury. J. Am. Soc. Nephrol. 2009. 20(5):1053-67. 
126. Milbank E., et al. Extracellular vesicles: pharmacological modulators of the 
peripheral and central signals governing obesity. Pharmacol Ther. 2016.157:65-
83. 
127.  Andriantsitohaina R., et al. Microparticles as regulators of cardiovascular 
inflammation. Trends in cardiovasc. med. 2012. 22(4):88-92. 
128.  Gaceb A., et al. Extracellular vesicles: new players in cardiovascular diseases. 
The int. J. Biochem. & cell biol. 2014. 50:24-28. 
129. Martinez, M. C., et al. Microparticles: targets and tools in cardiovascular disease. 
Trends pharm. Sci. 2011. 32(11):659-665. 
130. D'Argenio V., et al. De Novo Sequencing and Assembly of the Whole Genome of 
Novosphingobium sp. Strain PP1Y. J. Bacteriol. 2011. 193(16):4296.  
131. Hashimoto K. et al. alpha-L-rhamnosidase of Sphingomonas sp. R1 producing an 
unusual exopolysaccharide of sphingan. Biosci. Biotechnol. Biochem. 1998. 
62(6):1068-74. 
132. Izzo V., et al. Rhamnosidase activity in the marine isolate Novosphingobium sp. 
PP1Y and its use in the bioconversion of flavonoids, J. Mol. Catal. B: Enzym. 
2014. 105:95–103. 
133. Baraniecki C.A., Aislabie J., and Foght J.M. Characterization of Sphingomonas 
sp.  Ant 17, an aromatic hydrocarbon-degrading bacterium isolated from Antarctic 
soil. Microb. Ecol. 2002. 43:44–54. 
134. Leahy, J.G. and Colwell R.R., Microbial degradation of hydrocarbons in the 
  
 
102 
environment. Microbiol. Rev. 1990. 54(3):305-15. 
135. De Lise F., et al. RHA-P: isolation, expression and characterization of a novel -L-
rhamnosidase from Novosphingobium sp. PP1Y. J. Mol. Cat.: Enzymatic. 2016. 
134:136-147. 
136.  Oganesyan N., et al. Effect of Osmotic Stress and Heat Shock in Recombinant 
Protein Overexpression and Crystallization. Prot. Express. and purif. 2007. 
52(2):280-285.  
137.  Vuong T.V., and Wilson D.B. Glycoside Hydrolases: Catalytic Base/Nucleophile 
Diversity. Biotechnol. Bioeng. 2010. 107:195–205. 
138. Manzanares P., et al. Purification and characterization of two different alpha-L-
rhamnosidases, RhaA and RhaB, from Aspergillus aculeatus. Appl. Environ. 
Microbiol. 2001. 67(5):2230-4. 
139.  Allison, D. P., et al. Atomic force microscopy of biological samples.  Wiley 
Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010. 2(6):618–634. 
140.  Eddy, J. L., et al. Production of Outer Membrane Vesicles by the plague pathogen 
Yersinia pestis. PLOS One. 2014. 9(9): e107002. 
141. Mansilla, M. C., et al. Control of membrane lipid fluidity by molecular 
thermosensors. J. Bacteriol. 2004. 186:6681–6688.  
142.  Crescenzo, R., et al. Fat quality influences the obesogenic effect of high fat diets. 
Nutrients. 2015. 7(11):9475-9491. 
143. Bacia, K., Schwille, P., and Kurzchalia, T. Sterol structure determines the 
separation of phases and the curvature of the liquid-ordered phase in model 
membranes. PNAS 2005. 102(9):3272-3277.  
144.  Denich, T. J., et al. Effect of selected environmental and physicochemical factors 
on bacterial cytoplasmic membranes. J. Microbiol. Meth. 2003. 52:149–182.  
145.  Meng F., and Lowell C.A. Lipopolysaccharide (LPS)-induced macrophage 
activation and signal transduction in the absence of Src-family kinases Hck, Fgr, 
and Lyn. J. Exp. Med. 1997. 185(9):1661-1670. 
146. Reyes A.D, et al. The Effects of Palmitic Acid and Oleic Acid on Macrophage 
Gene Expression. 2013. FASEB J. 27(1 Supplement):1192-6. 
147. Durcin M., et al. Characterisation of adipocyte-derived extracellular vesicle 
subtypes identifies distinct protein and lipid signatures for large and small 
extracellular vesicles. J. of Extracell. Vesicles. 2017 6(1):1305677. 
148. Opal, S. M. The host response to endotoxin, antilipopolysaccharide strategies, 
and the management of severe sepsis. Int. J. Med. Microbiol. 2007. 297(5):365–
377. 
149.  Robert S., et al. Standardization of platelet-derived microparticle counting using 
calibrated beads and a Cytomics FC500 routine flow cytometer: a first step 
towards multicenter studies? J. Thromb. Haemost. 2009.  7(1):190–197. 
150. Lacroix R., et al. Standardization of platelet-derived microparticle enumeration by 
flow cytometry with calibrated beads: Results of the International Society on 
Thrombosis and Haemostasis SSC Collaborative workshop. J. Thromb. and 
Haemost. 2010. 8(11):2571-2574. 
151. Dachary-Prigent J., et al. Annexin V as a probe of aminophospholipid exposure 
and platelet membrane vesiculation: a flow cytometry study showing a role for 
free sulfhydryl groups. Nurden. Blood. 1993. 81:2554-2565. 
152.  Chaput N., Thery C. Exosomes: immune properties and potential clinical 
implementations. Semin. Immunopathol. 2010. 33(5):419.440. 
153.  Fox J.E., Austin C.D., and Boyles J.K. Role of the membrane skeleton in 
preventing the shedding of procoagulant-rich microvesicles from the platelet 
  
 
103 
plasma membrane. J Cell Biol. 1990. 111(2):483–493. 
154.  Vanaja S.K., et al. Mechanisms of inflammasome activation: recent advances and 
novel insights. Trends Cell Biol. 2015. 25(5):308-15. 
155. Gurung P., et al. Chronic TLR Stimulation Controls NLRP3 Inflammasome 
Activation through IL-10 Mediated Regulation of NLRP3 Expression and 
Caspase-8 Activation. Scientific Reports. 2015. 5:14488. 
156. Martinon F., Burns K., and Tschopp J. The Inflammasome: A Molecular Platform 
Triggering Activation of Inflammatory Caspases and Processing of proIL- beta. 
Mol. Cell. 2001. 10:417–426. 
157.  Legrand-Poels S., et al. Free fatty acids as modulators of the NLRP3 
inflammasome in obesity/type 2 diabetes. Biochem. Pharmacol. 2014. 92(1):131-
41. 
158. Owens G.K., Kumar M.S., and Wamhoff B.R. Molecular regulation of vascular 
smooth muscle cell differentiation in development and disease. Physiol. Rev. 
2004. 84:767–801. 
159.  Sprague A.H., and Khalil R.A. Inflammatory cytokines in vascular dysfunction and 
vascular disease. Biochem Pharmacol. 2009. 78:539–552. 
160.  Latz E.T., Xiao S., and Stutz A. Activation and regulation of the inflammasomes. 
Nat. Rev. Immunol. 2013. 13(6). 
161. Miao E.A., Rajan J.V., and Aderem A. Caspase-1-induced pyroptotic cell death. 
Immunol. Rev. 2011. 243:206–214 
162. Sagulenko V., et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and 
pyroptotic death pathways via ASC. Cell Death Differ. 2013.  20(9):1149-60. 
163.  Coll R.C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the 
treatment of inflammatory diseases. Nat. Med. 2015. 21(3):248-55. 
164. Altenburger, R. and Kissel, T. The human Keratinocytes cell Line HaCaT: An In 
Vitro Cell Culture Model for Keratinocyte Testosterone Metabolism. Pharm. Res. 
1999. 16:766.  
165. Van der Meel R., et al. Extracellular vesicles as drug delivery systems: Lessons 
from the liposome field. Journal of contr. Real. 2014. 195:72-85. 
   
  
  
 
104 
 
  
  
 
105 
 
 
 
APPENDICES 
 
 
 
  
  
 
106 
 
  
  
 
107 
APPENDIX I  
SCIENFITIC PUBBLICATIONS. 
 
P1)    Donadio G, Sarcinelli C, Pizzo E, Notomista E, Pezzella A, Di Cristo C, De Lise 
F, Di Donato A, Izzo V. The Toluene o-Xylene Monooxygenase Enzymatic 
Activity for the Biosynthesis of Aromatic Antioxidants. PLoS One. (2015) 10(4), 
e0124427. doi: 10.1371/journal.pone.0124427.  
 
P2)    Conti V., Izzo V., Corbi G., Russomanno G., Manzo V., De Lise F., Di Donato 
A., Filippelli A. Antioxidant supplementation in the treatment of aging-associated 
diseases. Front Pharmacol. 2016 Feb 12;7:24. doi: 10.3389/fphar.2016.00024. 
eCollection 2016. Review.v. 
 
P3)    De Lise F., Mensitieri F., Tarallo V., Ventimiglia N., Vinciguerra R., Tramice A., 
MarchettiR., Pizzo E., Notomista E., Cafaro V., Molinaro A., Birolo L., Di Donato 
A. and Izzo V. RHA-P: isolation, expression and characterization of a novel α-
L-rhamnosidase from Novosphingobium sp. PP1Y. Journal of Molecular 
Catalysis B: Enzymatic 134 (2016) 136–147. 
 
P4)    Pingeon M., Charlier B., De Lise F., Mensitieri F . , Dal Piaz
 
F., Izzo V. Novel    
Drug Targets for the Treatment of Cardiac Diseases. Current 
Pharmacogenomics and Personalized Medicine, 2017, 15, 1-13. 
 
P5)     De Lise F., Mensitieri F.,Rusciano G., Dal Piaz F., Di Lorenzo F., Molinaro A., 
Zarrelli A., Romanucci V., Valeria Cafaro1, Sasso A., Filippelli A., Di Donato A., 
Izzo V. Isolation and Purification of Extracellular Nanostructures from 
Novosphingobium sp. PP1Y: a Novel Example of Outer Membrane Vesicles. 
Scient. Rep. 2017. Under Review 
 
 
 
  
  
 
108 
APPENDIX II 
COMMUNICATIONS. 
 
A1) Manzo V., Donadio G., Notomista E., Russomanno G., Sarcinelli C., De Lise 
F., Mensitieri F., Ventimiglia N., Di Cristo C., Pizzo E., Pezzella A., Di Donato 
A., Izzo V. Microbial Oxygenase Activities for the Biosynthesis of Novel 
Aromatic Antioxidant Compounds. Giornate della Facoltà di Farmacia e 
Medicina a Salerno. 22-23 maggio 2014, Università degli Studi di Salerno. 
Translational Medicine @ UniSa (2014) - ISSN 2239-9747 2014, Special Issue 
(1): 9 
. 
A2) Di Donato A., De Lise F., Mensitieri F., Donadio G., Tramice A., Trincone A., 
Cafaro V., Notomista E., Izzo V. From Bioremediation to Biocatalysis: 
biotecnologically relevant enzymes from microorganisms adapted to polluted 
environments. Japan-Italy Symposium on New Trends in Science and 
Engineering of Enzyme and Microbiology for Sustainable Society, Lecture T3, 
Nara, Japan (2014). (This abstract was selected for an oral presentation). 
 
A3)     De Lise F., Mensitieri F., Rusciano G., Molinaro A., dal Piaz F., Di Cosmo A., 
Sasso A., Di Donato A., Izzo V. Isolation and purification of extracellular 
nanostructures from N. sp. PP1Y: a novel exa mple of Outer Membrane 
Vesicles?  “ISEV 2016”. Rotterdam, The Netherlands. May 2016. 
 
A4)   Mensitieri F., De Lise F., Strazzulli A., Del sorbo M., Tramice A., Molinaro A.,     
Birolo L., Moracci M., Di Donato A., Izzo V. RHA-P: insight into a Novel Bacterial 
α-L-Rhamnosidase from Novosphingobium sp. PP1Y. CBM12, Wien. April 
2017. 
 
A5)   Mensitieri F., De Lise F., Cafaro V., Lumacone M., Strazzulli A., Notomista E., 
Moracci M., Di Donato A., Izzo V. RHA-P: a novel bacterial α-L-rhamnosidase 
of biotechnological relevance from Novosphingobium sp. PP1Y. SIB 2017. 
Caserta. September 2017. 
 
A6)    De Lise F., Mensitieri F., Castaldi S., Rusciano G., Dal Piaz F., Sasso A., Zarrelli 
A., Di Donato A., Izzo V. Purification and characterization of extracellular 
nanostructures from N.sp. PP1Y: a novel example of Outer Membrane Vesicles. 
SIB 2017. Caserta. September 2017. (This abstract was selected for an oral 
presentation). 
 
A6)    Mensitieri F., De Lise F., Siepi M., Cafaro V., Notomista E., Izzo V., Di Donato 
A., Oliva R., Del Vecchio P., Petraccone R., Isticato R., Ricca E., Donadio G. 
BIOBLUE BIOSENSOR – a new biosensor for the detection of environmental 
pollutants. SIB 2017. Sao Paoulo School of Advanced Science on Biophysical 
Methods to study Biomolecular Interactions. 10/2017. 
 
 
 
  
 
109 
APPENDIX III 
EXPERIENCES IN FOREIGN LABORATORIES. 
 
From September 21st 2016 to March 21st 2017, the research activity of Dr. Siepi has 
been carried out at the INSERM institute (University of Angers, France) in the 
laboratories of the “Stress oxidant et patologies mètaboliques U1063”. The work was 
supervised by Prof. Ramaroson Andriantsitohaina. 
 
   
  
 
110 
APPENDIX IV  
PUBLISHED PAPERS. 
 
 
 
Isolation and purification of extracellular nanostructures from 
Novosphingobium sp. PP1Y: a novel example of Outer Membrane Vesicles? 
 
Federica De Lise1, Francesca Mensitieri1, Giulia Rusciano2, Fabrizio Dal Piaz3, Flaviana Di 
Lorenzo4, Antonio Molinaro4, Armando Zarrelli4, Giovanni Di Fabio4, Valeria Cafaro1, 
Antonio Sasso2, Alberto Di Donato1, Viviana Izzo3. 
 
1 Department of Biology, University of Federico II Naples, Italy. 
2 Department of Physics, University of Federico II Naples, Italy.  
3 Department of Medicine, Surgery and Dentistry, University of Salerno, Italy. 
4 Department of Chemical Sciences, University of Federico II Naples, Italy. 
 
 
 
Corresponding author: 
Dr. Viviana Izzo, PhD     
Tel/Fax. +39(0)89965225/5116   email: vizzo@unisa.it 
 
 
 
Under Revision 2017. 
 
RESEARCH ARTICLE
The Toluene o-Xylene Monooxygenase
Enzymatic Activity for the Biosynthesis of
Aromatic Antioxidants
Giuliana Donadio1☯, Carmen Sarcinelli1☯, Elio Pizzo1, Eugenio Notomista1,
Alessandro Pezzella2, Carlo Di Cristo3, Federica De Lise1, Alberto Di Donato1,
Viviana Izzo1,4*
1 Department of Biology, University of Naples Federico II, Via Cinthia I, 80126, Napoli, Italy, 2 Department of
Chemical Sciences, University of Naples Federico II, via Cinthia I, 80126, Napoli, Italy, 3 Department of
Sciences and Technologies, University of Sannio, Via Port'Arsa, 11, Benevento, Italy, 4 Department of
Medicine and Surgery, University of Salerno, via S. Allende, 84081, Baronissi (SA), Italy
☯ These authors contributed equally to this work.
* vizzo@unisa.it
Abstract
Monocyclic phenols and catechols are important antioxidant compounds for the food and
pharmaceutic industries; their production through biotransformation of low-added value
starting compounds is of major biotechnological interest. The toluene o-xylene monooxy-
genase (ToMO) from Pseudomonas sp. OX1 is a bacterial multicomponent monooxygen-
ase (BMM) that is able to hydroxylate a wide array of aromatic compounds and has already
proven to be a versatile biochemical tool to produce mono- and dihydroxylated derivatives
of aromatic compounds. The molecular determinants of its regioselectivity and substrate
specificity have been thoroughly investigated, and a computational strategy has been de-
veloped which allows designing mutants able to hydroxylate non-natural substrates of this
enzyme to obtain high-added value compounds of commercial interest. In this work, we
have investigated the use of recombinant ToMO, expressed in cells of Escherichia coli
strain JM109, for the biotransformation of non-natural substrates of this enzyme such as 2-
phenoxyethanol, phthalan and 2-indanol to produce six hydroxylated derivatives. The hy-
droxylated products obtained were identified, isolated and their antioxidant potential was
assessed both in vitro, using the DPPH assay, and on the rat cardiomyoblast cell line H9c2.
Incubation of H9c2 cells with the hydroxylated compounds obtained from ToMO-catalyzed
biotransformation induced a differential protective effect towards a mild oxidative stress in-
duced by the presence of sodium arsenite. The results obtained confirm once again the ver-
satility of the ToMO system for oxyfunctionalization reactions of biotechnological
importance. Moreover, the hydroxylated derivatives obtained possess an interesting antiox-
idant potential that encourages the use of the enzyme for further functionalization reactions
and their possible use as scaffolds to design novel bioactive molecules.
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Introduction
In living organisms, aerobic metabolic processes such as respiration and photosynthesis cause
the generation of reactive species of either oxygen (ROS) or nitrogen (RNS) in specific organ-
elles such as mitochondria, chloroplasts, and peroxisomes. Both ROS and RNS share a well-
documented role in stimulating physiological events such as signaling and cell differentiation.
However, these molecules are also highly unstable and tend to acquire electrons from nucleic
acids, lipids, proteins, carbohydrates causing a sequence of chain reactions that are responsible
for cellular damage [1,2]. The correct balance inside the cell between the prooxidant action of
both ROS and RNS and the antioxidant activity of either enzymatic (such as superoxide dis-
mutase, catalase, glutathione peroxidase and glutathione reductase) or non-enzymatic (such as
vitamin C, vitamin E, selenium, zinc, taurine, hypotaurine, glutathione, β-carotene) systems is
indeed a very delicate equilibrium which is maintained through the activity of a complex array
of molecular mechanisms [1,3].
Evidence has been accumulating which shows that oxidative stress, the condition deriving
from an imbalance between prooxidants and antioxidants in the cell, might represent a com-
mon element for the onset of several pathologies such as cancer, neurodegenerative and cardio-
vascular diseases, and the occurrence of complications in diabetes [4,5].
The quest for novel natural and synthetic antioxidants has undoubtedly drawn the attention
of the scientific community in recent years. In this context, several antioxidant pharmaco-
phores have been identified, among which phenols and catechols have been given much atten-
tion as they are very susceptible to oxidation by acting as electron donors [6, 7].
Phenols are endowed with the property of suppressing or delaying spontaneous autoxida-
tion of organic molecules and might be useful to prevent in vivo the consequences of the autox-
idation of biomolecules [6,8]. Thus, it is not surprising that fruits and vegetables, which are
characterized by a high content of phenolic compounds such as phenolic acids and flavonoids,
have been so far the main suppliers of molecules analyzed as potential antioxidant drugs, and
their consumption in a healthy and varied diet has been demonstrated to significantly reduce
the risk of cancer [9,10–13]. In addition, synthetic phenolic antioxidants such as butylated hy-
droxyanisole (BHA), butylated hydroxytoluene (BHT), tert-butylhydroquinone (TBHQ) and
propyl gallate (PG) have been also studied and used, although the use of BHA and BHT has
been restricted by legislative rules due to uncertainties concerning their toxic and carcinogenic
effects [6].
Despite all the interest towards phenolic antioxidants, there are still many issues to unravel
concerning their biological activity. The analysis of kinetic and thermodynamic data available
so far in the literature indicates that the efficiency of phenols as inhibitors of the autoxidation
of organic matter depends on a variety of factors, and this becomes undoubtedly challenging in
complex systems such as living organisms [6].
Other antioxidant pharmacophores have been identified, among which catechols, 1,2-dihy-
droxybenzenes, have been given much attention [7]. It should be noted that the Comprehen-
sive Medicinal Chemistry (CMC) database shows the presence of many drugs containing the
catechol moiety for which several pharmacological effects have been described [14,7]. For these
molecules, it is commonly accepted that their antioxidant effect depends on the fact that the
semiquinone radical derived from H-atom donation of catechol can be stabilized by both an in-
tramolecular hydrogen bond and by the electron-donating properties of the ortho-OH [15–16].
Thus, the chemical versatility of both phenols and catechols and the numerous pharmacologi-
cal effects described for some of their derivatives, encourage their use as scaffolds to design
novel bioactive molecules where the different nature of the substituents bound to the aromatic
Monooxygenase Mediated Biosynthesis of Aromatic Antioxidants
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ring may influence the reactivity of these molecules towards oxidizing agents, their pharmaco-
kinetics, and their tissue and cellular distribution [14,7].
However, the synthesis of substituted phenols and catechols by chemical methods is often
complex and may involve severe reaction conditions, resulting in low yields and the formation
of racemic mixtures [17,18]. These complications have boosted the research for the develop-
ment of biotransformations, also known as bioconversions, which make use of the metabolic
versatility of either purified enzymes or whole microorganisms, for the selective hydroxylation
of commercially available, low-added-value, aromatic precursors [19].
The toluene o-xylene monooxygenase (ToMO) from Pseudomonas sp. OX1 is a bacterial
multicomponent monooxygenase (BMM) [19–23] that has been extensively characterized in
the last decade from both a biochemical and a biotechnological point of view [24–26]. The mo-
lecular determinants of its regioselectivity and substrate specificity have been thoroughly inves-
tigated, and a computational strategy has been developed which analyzes the interactions
between the active-site residues of its hydroxylase component ToMOA and the substrates [26–
31]. Recently, mutants of the ToMOmulticomponent system were used to produce tyrosol
(4-hydroxyphenylethanol, bearing a phenol moiety) and hydroxytyrosol (3,4-dihydroxypheny-
lethanol, bearing a catechol moiety), strong antioxidants commonly found in extra virgin olive
oil [32–36,13], using a cheap and commercially available aromatic precursor such as 2-pheny-
lethanol (S1 Fig) [18]. The results obtained showed the great versatility of ToMO and suggested
the potential use of this enzyme for the hydroxylation of other non-natural aromatic substrates
to produce antioxidant phenols and catechols of interest for both the food and pharmaceutical
industries.
In the present study we have used the recombinant ToMO system, expressed in strain
JM109 of E.coli, to hydroxylate three commercially available aromatic monocyclic molecules
that are non-natural substrates of the enzyme, to obtain mono- and dihydroxylated derivatives
analogous to natural antioxidants tyrosol and hydroxytyrosol, but with some structural differ-
ences that might influence their antioxidant potential.
The three aromatic molecules used in this study as starting compounds are benzene deriva-
tives bearing one or two substituents in ortho (Fig 1B):
- 2-phenoxyethanol, is a benzene derivative with a-O-(CH2)2-OH substituent bound to the
aromatic ring. This compound differs from 2-phenylethanol (Fig 1A), the starting sub-
strate used for the biosynthesis of tyrosol and hydroxytyrosol [18] (S1 Fig), for the pres-
ence of an additional oxygen atom directly linked to the aromatic ring;
Fig 1. Starting substrates. (A) Structures of 2-phenylethanol and o-xylene. (B) Substrates used for the
ToMO-catalyzed biotransformations presented in this study.
doi:10.1371/journal.pone.0124427.g001
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- 2-indanol, is similar to 2-phenylethanol but with an additional methylene group, linking
the ethanol moiety to the ring, which makes the structure more rigid;
- phthalan, which differs from o-xylene, a natural substrate of ToMO (Fig 1A), for the pres-
ence of an oxygen atom bridging the two methyl substituents.
Phenols and catechols obtained from the hydroxylation of these compounds were isolated,
purified and identified by NMR and mass spectrometry analysis. Their antioxidant potential
was first assessed in vitro using the DPPH chemical assay [37–38], and then on the rat cardio-
myoblast cell line H9c2 [39–40] to evaluate their effect during a mild oxidative stress induced
by sodium arsenite (SA). Exposure to SA inhibits protein synthesis in eukaryotic cells and acti-
vates multiple stress signaling pathways such as the generation of what is usually referred to as
“stress granules” [4,41–43]. Confocal microscopy analysis suggested that in stressed H9c2 cells,
pretreatment with optimal concentrations of the hydroxylated compounds resulted in a lower
percentage of cells containing stress granules, thus highlighting a potential antioxidant activity
of these molecules in the cellularmilieu, and paving the way to their future functionalization to
increase and diversify their biological activities.
Materials and Methods
Generals
Bacterial cultures, plasmid purifications, and transformations were performed according to
Sambrook et al [44]. E. coli strain JM109 was from Novagen. Plasmid pGEM3Z/Tou wt and
mutant E103G/F176A were prepared as already described [18]. 2-phenoxyethanol, phthalan,
and 2-indanol were purchased from Sigma-Aldrich. Water and methanol used for HPLC ex-
periments were from Romil. Formic acid was from Carlo Erba.
Docking of substrates in ToMOA active site
Reaction intermediates were docked into the active site of ToMO by using the Monte Carlo en-
ergy minimization strategy as previously described [18], except that the 2010 version of the
ZMM software was used, and the dielectric constant was calculated using the default option of
this version. The PDB files for the initial manually generated complexes and the ZMM instruc-
tion files containing the lists of mobile residues, constraints, and parameters used during calcu-
lations are available upon request.
ToMO-catalyzed bioconversion of 2-phenoxyethanol, phthalan and
2-indanol: isolation and purification of the reaction products
Cells of E. coli strain JM109 transformed with either plasmid pBZ1260 or variant E103G/F176A,
were routinely grown in LB to which ampicillin was added to a final concentration of 100 μg/mL
(LB/amp). Several well-isolated colonies were picked from LB/amp agar plates, inoculated into
12.5 mL of LB/amp in a sterile 50 mL Falcon Tube and incubated in constant shaking at 37°C up
to 0.6 OD600. The preinoculum was diluted 50-fold in two 500 mL Erlenmeyer flasks containing
each 250 mL of LB/amp, and incubated under constant shaking at 37°C up to 0.7–0.8 OD600. Ex-
pression of the recombinant ToMO proteins was induced with 0.2 mM IPTG at 37°C and in the
presence of 0.2 mM Fe(NH4)2(SO4)2; this latter was necessary for the assembly of the iron-con-
taining catalytic center of the recombinant ToMO. After 1 hour of induction, cells were collected
by centrifugation (1,880 x g for 15’ at 4°C), resuspended in M9medium containing 0.4% glucose
(M9-G) at a final concentration of 6 OD600 and incubated with 2 mM of either 2-phenoxyetha-
nol, phthalan, or 2-indanol dissolved in methanol (final methanol concentration was 2%). After
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a 16h incubation at 28°C under constant shaking at 230 rpm, cells were collected by centrifuga-
tion at 1,880 x g for 15’ at 4°C; an aliquot of the cell-free supernatants was loaded on HPLC to
check for the presence of hydroxylated products before their purification (S2 Fig). To this pur-
pose, an HPLC system equipped with a Waters 1525 binary pump coupled to a Waters photodi-
ode array detector was used. Substrates and hydroxylated derivatives were separated using a
Ultrasphere C18 reverse-phase column (4.6 x 250 mm; particle size 10 μm, pore size 100 Å). Sep-
aration was carried out at a flow rate of 1 mL/min by using a two-solvent system consisting of a
0.1% formic acid solution in water (solvent A) and a 0.1% formic acid solution in methanol
(solvent B). Compounds were separated using a 3-min isocratic elution with 10% solvent B, fol-
lowed by a 20-min linear gradient from 10 to 75% solvent B and an isocratic 5-min step at 98%
solvent B.
For the purification of the hydroxylated products identified by analytical HPLC, cell-free su-
pernatants, prepared as described above, were extracted twice with ethyl acetate added in a 1:2
ratio with respect to the aqueous phase. The organic phase was recovered, dried with a Rotava-
por apparatus, and the pellet was dissolved in 100% methanol and stored at -20°C. The sample
was then diluted to a final 10% concentration of methanol and loaded on HPLC using an Econ-
osil C18 reverse-phase semi-preparative column (10 x 250 mm, particle size 10 μm, pore size
100 Å). Separation was carried out at a flow rate of 2 mL/min by using a two-solvent system
consisting of a 0.1% formic acid solution in water (solvent A) and a 0.1% formic acid solution
in methanol (solvent B). Compounds were separated using a 10-min isocratic elution with 10%
solvent B, followed by a first 10-min linear gradient from 10 to 40%, a second 10-min linear
gradient from 40% to 75%, a third 5-min gradient from 75% to 90%, an isocratic 10-min step
at 90% of solvent B and a final 15-min step at 10% of solvent B. Each peak of interest was indi-
vidually collected, concentrated, and stored at -20°C.
Identification by NMR and mass spectrometry analysis
For NMR analysis, aliquots of the purified cell-free supernatants, prepared as described in the
previous paragraph and fractionated by HPLC, were lyophilized, and directly used for NMR
analysis in deuterated methanol. 1H NMR spectra were recorded at 600, 400, or 300 MHz, and
13C NMR spectra were recorded at 75 MHz. 1H and 13C distortionless enhancement by polari-
zation transfer heteronuclear single-quantum correlation and 1H and 13C heteronuclear mul-
tiple-quantum correlation (HMBC) experiments were run at 600 and 400 MHz, respectively,
on instruments equipped with a 5 mm 1H/broadband gradient probe with inverse geometry
using standard pulse programs. The HMBC experiments used a 100-ms long-range coupling
delay. Chemical shifts are reported in δ values (ppm) downfield from tetramethylsilane. Regioi-
somers were distinguished according to the spin-coupling pattern in the aromatic region of the
1H NMR spectra (S3 Fig). Compound eluting in peak 1 (S2 Fig), indicated from now on as
compound 1, showed only two signals featuring a doublet shape as a consequence of the ortho-
type coupling. On this basis, the direct attribution of the symmetric para-substituted structure
to compound 4HEP, recognized as the 4-(2-hydroxyethoxy)phenol, was allowed. In the case of
compounds eluting in peaks 2 and 3 (compounds 2 and 3) a more complex pattern in the aro-
matic region of the 1H NMR spectra was present, suggesting, respectively, a meta and an ortho
substitution of the aromatic rings (S3 Fig). The characterization of compounds 2 and 3 as 3-
(2-hydroxyethoxy)phenol (3HEP) and 2-(2-hydroxyethoxy)phenol (2HEP), respectively, re-
sulted from the ratios of shielded and unshielded signals. Indeed, the 1H integration for com-
pound 3HEP is accounted with the two H atoms in ortho (Ho) and the one H atom in para
(Hp) to the OH group. For compound 2HEP, the ratio Ho/Hp is 1 which is coherent with the
presence of only two shielded H atoms, the one in ortho and one in para to the OH group.
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HR ESI+/MS spectra (S4 Fig) were obtained in 0.5% Formic Acid/methanol 1:1 v/v and
were recorded on a Agilent 1100 LC/MSD/ESI apparatus.
Evaluation of the concentration of the hydroxylated derivatives of
2-phenoxyethanol, phthalan and 2-indanol
To evaluate the concentration of the compounds obtained from the ToMO-catalyzed hydroxyl-
ation reaction we selected, for each of them, a similar compound whose UV-vis spectrum and
corresponding extinction coefficient was available in the literature (S5 Fig). All the spectro-
scopic data used for calculations were obtained from the “Organic Electronic Spectral Data”
book series (Analitical chemistry. 58. 1886. G. Norwitz et al Wiley eds).
DPPH assay
2,2-diphenyl-1-picrylhydrazyl (DPPH) is a stable free radical with λmax at 515 nm (purple, ε515
in methanol = 12 mM-1cm-1). The neutralization of the DPPH radical is responsible for the dis-
appearance of the absorbance at 515 nm and is commonly used as a readout of radical scaveng-
ing of an antioxidant compound [37–38]. The reaction mixture contained, in a final volume of
1 mL of methanol, different concentrations of our hydroxylated compounds and 0.1 mM of a
freshly prepared DPPH solution in methanol. It is important to note that, as recommended by
Kedare and coauthors [38] the initial DPPH concentration should give an absorbance! 1.0.
The reaction was allowed to proceed at RT until completion, and was followed at λ = 515nm.
Cell cultures and treatments
H9c2 cells (Rat Embryonic Myocardium Cells, CRL-1446) were purchased from American
Type Culture Collection (ATCC) and grown in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 4 mM L-glutamine, 1% v/v penicillin/strep-
tomycin solution (100 U/mL) and 1mM sodium pyruvate (Euroclone, Milano, Italy) at 37°C in
5% CO2 incubator. Oxidative stress was induced by adding sodium arsenite (Sigma Aldrich),
freshly prepared in stock aqueous solutions and added to the conditioned medium at a final
concentration of 0.25 mM.
MTT assay
H9c2 cells were seeded on 96-well plates at a density of 2.5×103 cells/well in 0.1 mL of DMEM
24 h prior to the treatment with the different compounds. As control, cells were incubated with
buffer diluted in medium.
After 72 h of incubation, cell viability was evaluated by MTT assay, adding tetrazolium
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) diluted at 0.5 mg/mL in
DMEM without red phenol (0.1 mL/well). After 4 h of incubation at 37°C, the resulting insolu-
ble formazan salts were solubilized in 0.04 M HCl in anhydrous isopropanol, and quantified by
measuring the absorbance at λ = 570nm, using an automatic plate reader spectrophotometer
(VICTOR3 Multilabel Counter; Perkin Elmer, Shelton, CA, USA). Cell survival was expressed
as means of the percentage values compared to control. Standard deviations were always< 5%
for each repeat (values in quadruplicate of at least three experiments).
The hydroxylated derivatives of 2-phenoxyethanol, phthalan and 2-indanol were used at a
concentration close to their EC50 value (5 to 10 μM higher) obtained from the DPPH assay.
When the EC50 was not available, as in the case of tyrosol, 3HEP,DHI, andDHiBF (S4 Fig),
two arbitrary concentrations were initially tested, 40 and 80 μM. As results obtained with these
two concentrations were comparable, the lower concentration (40 μM) was used to test the
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potential antioxidant activity of these compounds in the following experiments such as the ap-
optosis assay and the analysis of stress granules.
The non-hydroxylated precursors, when assayed, were used at a concentration equal to the
higher concentration used for any of their hydroxylated derivatives. In conclusion, the concen-
trations used in the experiments with H9c2 cells presented in the “Results and Discussion” sec-
tion of this manuscript were: 25 μM for hydroxytyrosol, 40 μM for phenylethanol, tyrosol,
4HEP, 3HEP, phthalan, DHiBF, 2-indanol, DHI, THI, and 90 μM for 2-phenoxyethanol and
2HEP (S4 Fig).
EB and AO staining assay
Apoptotis was evaluated by ethidium bromide (EB) and acridine orange (AO) staining of nu-
clei [45]. AO is a fluorescent DNA binding dye that permeates all the cells staining the nuclei
green, whereas EB is only taken up by the cells when cytoplasmic membrane integrity is com-
promised, staining apoptotic nuclei red. H9c2 cells were seeded in 6-well plates at a density of
1.5 ×105 cells/well in 2 mL of DMEM and grown up to nearly 60% confluence. The cells were
then incubated at 37°C for 3 h in the presence of the tested compounds. Afterwards, the SA-in-
duced oxidative stress (0.25 mM for 90 min) was performed. Cells were trypsinized, collected
by centrifugation, and washed with ice-cold PBS. Cells were re-suspended in 50 μL of PBS con-
taining the EB/AO dye mixture (5 μg/mL) and incubated at 37°C for 20 min. Stained cells were
placed on a microscope slide and covered with coverslips. Images were taken at a 100 X magni-
fication. Both apoptotic (red) and live (green) cells were counted in five microscopic fields for
each sample, to estimate the percentage of apoptotic cells.
Immunofluorescence analysis and confocal microscopy
H9c2 cells were seeded onto coverslips in 24-well plates at a density of 2.5×104 cells/well in
0.5 mL of DMEM and grown for 48 h, up to nearly 60% confluence. Cells were incubated at
37°C for 3 h with either the starting aromatic compounds or their hydroxylated derivatives. Af-
terwards, an incubation with 0.25 mM SA for 90 min was performed. As negative and positive
controls of the stress effect, cells were treated with either buffer or 0.25 mM SA, respectively, in
the absence of any exogenous compound. Cells were then fixed in 4% paraformaldehyde in
PBS 1X at room temperature for 15 min and rinsed three times with PBS 1X. Quenching of
free aldehydic sites of the fixative was performed by adding 50 mMNH4Cl in PBS 1X, at room
temperature for 15 min. After washing with PBS 1X, cells were permeabilized using 0.1% Tri-
ton X-100 in PBS 1X at room temperature for 30 min, then rinsed in PBS 1X for three times.
After incubating the cells in a blocking solution consisting of 5% bovine serum albumin (BSA)
in PBS 1X at room temperature for 1 hour under constant shaking, PABP monoclonal antibody
(Sigma Aldrich), a specific marker used to evidence the presence of stress granules in the cell,
was used at 2 μg/mL in blocking buffer at 4°C overnight. After washing in PBS 1X, cells were
incubated with secondary antibody Cy3 conjugated goat anti-mouse F(ab’)2 (1:1,000 dilution
in blocking buffer) (Jackson Immuno Research Laboratories, UK), at room temperature for 1
hour. For nuclear counterstaining, cells were incubated with DAPI, diluted at 0.1μg/mL in PBS
1X, at room temperature for 10 min. After washing, coverslips were mounted in 50% glycerol
in PBS 1X. Images were captured using a Zeiss confocal laser-scanning microscope LSM 510
using suitable lasers. Image analyses on stress granules was performed using “Stress granule
counter” and “Analyze particles” ImageJ (http://rsbweb.nih.gov/ij/index.html) plugins. Nuclear
counterstaining was used to count the total number of cells. Statistical analyses were performed
using GraphPad (Prism) software ver. 5.0.
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Results and Discussion
ToMO-catalyzed hydroxylation of 2-phenoxyethanol, phthalan and
2-indanol
The aromatic substrates used in this study (Fig 1B) were used without any further purification.
For each compound the corresponding UV-vis spectrum was recorded after dilution in metha-
nol; λmax of 2-phenoxyethanol, phthalan and 2-indanol were respectively 269.7, 270.9 and
272.1 nm. ToMO-catalyzed biotransformation of these aromatic substrates, used at a final con-
centration of 2 mM in the incubation mediumM9-G, was performed by using recombinant
cells of E.coli, strain JM109, transformed with the plasmid coding for the complete ToMO wt
enzymatic system, as described in detail in Materials and Methods.
After incubation for different time intervals (0, 30 min, 1 h, and 16 h) at 30°C under con-
stant shaking (220 rpm), samples were withdrawn, cells were collected by centrifugation, and
an aliquot of the exhausted medium was loaded on HPLC to check for the presence of hydrox-
ylated products (Materials and Methods, and S2 Fig). As evident from the chromatographic
profiles obtained, ToMO wt was able to hydroxylate 2-phenoxyethanol and phthalan. Three
different peaks eluting respectively at 10.4 min (compound 1, λmax = 287.5 nm), at 12.6 min
(compound 2, λmax = 273.5nm) and 15.2 min (compound 3, λmax = 275.3nm) were evident
when using 2-phenoxyethanol as the substrate (Panel A in S2 Fig). Formation rates of com-
pounds 1, 2 and 3 were of 0.89(±0.04), 1.15(±0.20) and 0.510(±0.001) μMmin-1, respectively.
Compounds 1, 2 and 3 accounted respectively for the 37.8(± 3.1), the 43.8(±1.3) and the 18.3
(±1.8)% of the total yield of product which was of 15.3(±1.3)% (total μM products/μM sub-
strate) and was calculated after 2h of incubation, the maximum time at which the products
yield was still proportional to the time of incubation (data not shown). When using phthalan
as substrate a single peak of product was eluted at 14.3 min (compound 4, λmax = 279.2 nm)
(Panel B in S2 Fig) with a formation rate of 1.79(±0.03) μMmin-1 and a yield of 10.8(±0.2)%
after 2h of incubation. No evident hydroxylation product was instead observed when the sub-
strate used for the ToMO-catalyzed bioconversion was 2-indanol (data not shown).
The exhausted media obtained from the ToMO wt-catalyzed bioconversion of 2-phenox-
yethanol and phthalan were further purified through organic extraction, as described in detail
in Materials and Methods. Samples were then loaded on a semi-preparative HPLC C-18 col-
umn. Each peak was manually collected, lyophilized and analyzed by NMR and mass spec-
trometry analysis (Materials and Methods, and S3 and S4 Figs). Fig 2A and 2B show the
starting compounds 2-phenoxyethanol and phthalan and the corresponding products identi-
fied through these analyses.
Selection of an efficient catalyst for the hydroxylation of 2-indanol
The conversion of 2-phenoxyethanol to a mixture of the three mono-hydroxylated products is
not surprising as this result is very similar to what previously observed in the case of 2-pheny-
lethanol [18]. As for phthalan, the most similar substrate we have previously tested, o-xylene is
converted to a mixture of 3,4-dimethylphenol (80%) and 2,3-dimethylphenol (20%) [27]. We
have previously suggested that this result is due to the fact that the site for the ortho substitu-
ents is more hindered than the site for the para substituents [26]. Likely, in the case of phthalan
the steric hindrance caused by the additional oxygen atom (Fig 1B) further disfavors the proxi-
mal hydroxylation of this compound, thus providing exclusively the hydroxylation product
corresponding to 3,4-dimethylphenol i.e. 1,3-dihydro-5-hydroxyisobenzofuran (DHiBF),
(Fig 2B and S4 Fig).
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In order to identify a ToMO variant able to hydroxylate 2-indanol, we have analyzed the in-
teraction of 2-indanol and phthalan (this latter considered as our positive control) with the ac-
tive site of ToMO using a Monte Carlo modelling strategy previously applied to ToMO natural
substrates and to 2-phenylethanol [26, 18]. Briefly, this strategy is based on the docking of a
crucial intermediate of the hydroxylation reaction i.e. the “arenium intermediate”. By compar-
ing the geometrical parameters for any desired complex ToMO (ToMO-variant)/intermediate
to those found for the complex ToMO wt/arenium intermediate for para-hydroxylation of the
optimal substrate toluene (the “reference complex”), it is possible to predict if an aromatic
compound will be a good substrate and which product(s) will be produced. As described previ-
ously [26,18], two geometrical parameters defining the orientation of the arenium ring with re-
spect to the diiron cluster were used for the comparison: (i) the distance between the carbon
atom of the substrate that accepts the oxygen atom from the diiron cluster during the hydroxyl-
ation reaction (herein called Cn) and the C4 atom of the reference complex, and (ii) Δθ, a pa-
rameter that measures the angle deviation of the plane of the arenium ring in a ToMOmutant/
intermediate complex with respect to the plane of the arenium ring in the reference structure. θ
is the torsion angle Fe2-O-Cn-Cm where Cm is the carbon atom of the substrate adjacent to Cn
closer to the substituent bound to the benzene ring (Fig 3). In the reference structure, θ angle
(Fe2-O-C4-C3) is 103.6°. Previously [26, 18] we have demonstrated that Cn-C4 distances lower
than about 0.2 Å, and Δθ values in the range -10°/+5° are predictive of high kcat values (similar
to or even higher than those measured for ToMO wt on its natural substrate toluene).
Fig 2. Hydroxylated products. Starting substrates and corresponding hydroxylated products obtained
through ToMO-catalyzed biotransformation of (A) 2-phenoxyethanol and (B) phthalan.
doi:10.1371/journal.pone.0124427.g002
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Data in Table 1 show that in the case of phthalan only the arenium intermediate leading to
1,3-dihydro-5-hydroxyisobenzofuran (DHiBF) docks in an orientation very similar to that of
the reference structure suggesting that this isomer can be efficiently produced by ToMO. On
the contrary, the arenium intermediate leading to 1,3-dihydro-4-hydroxyisobenzofuran adopts
an orientation very different from that of the reference intermediate described above. Accord-
ing to our model this would indicate poor or none production of the 4-hydroxy isomer in spite
of a non-covalent binding energy value (ncBE in Table 1) more negative than that of the 5-hy-
droxy isomer. Overall, data in Table 1 allow to predict that ToMO can convert phthalan only
to 1,3-dihydro-5-hydroxyisobenzofuran in agreement with the experimental finding. In the
case of 2-indanol both arenium intermediates 24I and 25I leading to the two possible products,
Fig 3. Docking of intermediates in ToMO active site. Docking of the two possible arenium intermediates
(4PT and 5PT) deriving from phthalan in the active site of ToMOA. In the case of 4PT, θ is the torsion angle
Fe(2)-O-C4-C9, whereas, in the case of 5PT, θ is the torsion angle Fe(2)-O-C4-C5. Similar arenium
intermediates can be hypothesized for the hydroxylation of 2-indanol.
doi:10.1371/journal.pone.0124427.g003
Table 1. Geometrical parameters and non covalent binding energies (ncBE) of the complexes between ToMO or E103G/F176A-ToMO and the are-
nium intermediates for the phthalan/1,3-dihydro-4-hydroxyisobenzofuran (4PT), the phthalan/1,3-dihydro-5-hydroxyisobenzofuran (5PT), the
2-indanol/2,4-dihydroxyindan (24I) and the 2-indanol/2,5-dihydroxyindan (25I) reactions.
Arenium intermediate Geometrical parameters ToMO
wild type E103G/F176A
C4-C4 (Å) 0.42 - a
4PT Δθ (°) +36.7 -
ncBE (kcal mol-1) -42.4 -
C4-C5 (Å) 0.25 -
5PT Δθ (°) -6.7 -
ncBE (kcal mol-1) -33.5 -
C4-C4 (Å) 0.49 0.45
24I Δθ (°) +28.8 +35.6
ncBE (kcal mol-1) -40.0 -39.6
C4-C5 (Å) 0.43b 0.25
25I Δθ (°) +36.1c -7.6
ncBE (kcal mol-1) -23.6 -35.3
a not determined.
b in the case of phenylethanol we previously found C4-C4 distances of 0.3 and 0.23 Å for the para- and meta-hydroxylation, respectively.
c in the case of phenylethanol we previously found Δθ values of +41° and +22° for the para- and meta-hydroxylation, respectively.
doi:10.1371/journal.pone.0124427.t001
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2,4-dihydroxyindan and 2,5-dihydroxyindan respectively, dock into the active site with orien-
tations very different from that adopted by the natural substrate toluene. An accurate examina-
tion of the complex ToMO/25I showed that the steric hindrance of phenylalanine 176 prevents
the correct accommodation of the intermediate in a manner similar to that previously de-
scribed for themeta- and para-hydroxylation of phenylethanol [18]. However, in the case of
2-indanol the presence of the additional methylene group and the rigidity caused by the ring
structure markedly increase the deviation from the ideal geometry (Table 1) in agreement with
the fact that ToMO slowly converts phenylethanol to tyrosol isomers but seems to be almost
completely inactive on 2-indanol.
Since we have previously demonstrated that mutations F176A and E103G, removing the
hindrance at the “para site”, allow the accommodation of large substituents in para, we have
modeled the complexes between the double mutant and the arenium intermediates 24I and
25I. Data in Table 1 and the models in S6 Fig show that the two mutations selectively improve
the geometrical parameters calculated for the intermediate 25I. The two mutations also in-
crease the non-covalent binding energy of 25I indicating that this intermediate not only could
dock with a better geometry but could bind more tightly to the active site.
According to the analysis described above, the ToMO variant E103G/F176A was used for
the bioconversion of 2-indanol under the same experimental conditions used for the recombi-
nant ToMO wt system (Materials and Methods). The HPLC chromatogram in Fig 4 shows in
this case the presence of two peaks of products eluting respectively at 13 min (compound 5,
λmax = 280.3 nm) and 10 min (compound 6, λmax = 288 nm). It is worth noting that the pres-
ence of compound 6 was evident only after at least 16h of incubation (Panel C in S2 Fig). Due
to a partial loss of viability of E.coli cells strain JM109 after this time, neither the formation rate
nor the yield of this compound were calculated. Rate of formation of compound 5 was of 5.77
(±1.35) μMmin-1; the yield after 2h of incubation was of 28.9(±0.4)%. By NMR and mass spec-
trometry analysis (Materials and Methods, and S3 and S4 Figs) compound 5 was identified as
2,5-dihydroxyindan (DHI) in agreement with the docking analysis. Moreover, compound 6
was identified as 2,5,6-trihydroxyindan (THI, Fig 4 and S4 Fig), thus indicating that in the
ToMO variant E103G/F176A the active site is wide enough not only to accommodate 2-inda-
nol in a catalytically productive orientation, but also to permit a second hydroxylation at the
position adjacent to the first hydroxyl group, as usually observed when ToMO wt acts on its
natural substrates toluene and o-xylene which are respectively converted to 3-/4-methylcate-
chol and 4,5-dimethylcatechol [27].
Fig 4. E103G/F176A ToMO-catalyzed biotransformation of 2-indanol. HPLC chromatogram at λ = 280
nm of an aliquot of the exhausted medium deriving from the 16 hrs, E103G/F176A ToMO-catalyzed
biotransformation of 2-indanol.
doi:10.1371/journal.pone.0124427.g004
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In vitro antioxidant potential of the hydroxylated derivatives of
2-phenoxyethanol, phthalan and 2-indanol
The capacity of the isolated hydroxylated compounds to scavenge the stable radical 2,2-diphe-
nyl-1-picrylhydrazyl (DPPH) was determined spectrophotometrically by measuring the loss of
absorbance of DPPH at λ = 515 nm (see Materials and Methods for details). 0.1 mM DPPH
and different concentrations of each hydroxylated compound were added, in a final volume of
1mL of methanol, in the range 1–200 μM, and the loss of absorbance at 515 nm (from now on
indicated as ABS515) was monitored for 30 min. At this time, the percentage of DPPH effective-
ly reduced (%DPPHred) was calculated evaluating the initial DPPH concentration at t = 0, indi-
cated as [DPPH]t = 0, and the final DPPH concentration at t = 30, referred to as [DPPH]t = 30,
and using the following formula:
%DPPHred ¼ ½1$ð½DPPH&t¼30=½DPPH&t¼0Þ& x 100
The concentration of hydroxylated compound used in each experiment was plotted against
%DPPHred (S7 Fig). The concentration that caused a decrease in the initial DPPH concentra-
tion of 50% was defined as EC50 and was obtained by a non-linear regression of the experi-
mental curves using the Graphpad Prism software (http://www.graphpad.com/). Each EC50 is
the result of at least three independent experiments.
Once obtained the EC50 value for a specific compound we estimated also-at that specific
concentration- the time (expressed in minutes) needed to reach a stable value of the ABS515, a
parameter indicated in literature as TEC50 [37,46]. At this point we calculated what has been
defined [46] as the “antiradical efficiency” (AE) a parameter that is expressed by the following
formula: AE = 1/(EC50 x TEC50). The AE value, taking into account not only the EC50 but
also the reaction time, is more informative than the EC50 value alone on the antioxidant be-
havior of a compound tested with this specific assay [46].
In all the experiments, described in this and in the following paragraphs, natural aromatic
antioxidants such as tyrosol and hydroxytyrosol have also been tested [32–36] as reference
molecules, in parallel with the hydroxylated compounds obtained by ToMO-catalyzed bio-
transformation of 2-phenoxyethanol, phthalan and 2-indanol.
Results are shown in Table 2, where it is evident that some among the phenols and catechols
produced by the ToMO-catalyzed reaction on non-natural aromatic substrates show an AE
value comparable to the strong natural phenolic antioxidant hydroxytyrosol. Interestingly,
compounds such as tyrosol, which has been reported to have antioxidant activity in vivo [47],
3HEP, DHiBF, andDHI (S4 Fig) were almost non responsive to the DPPH assay causing neg-
ligible losses of ABS515 even when used at concentrations up to 2mM (data not shown).
DPPH reduction curves obtained for each compound tested (S7 Fig) and the AE values cal-
culated (Table 2) clearly demonstrate the relevant reducing potential of 2HEP, 4HEP and of
THI compared to hydroxytyrosol activity. Although this could be expected in the case of THI,
Table 2. Evaluation of the antioxidant activity using the DPPH assay.
Compound EC50 (μM Antioxidant/μM DPPH) TEC50 (min) AE
Hydroxytyrosol 0.21 (±0.01) 18.0 (±2.0) 0.27 (±0.01)
4HEP 0.40 (±0.04) 19.0 (±1.0) 0.140 (±0.006)
2HEP 1.00 (±0.02) 25.3 (±2.1) 0.040 (±0.002)
THI 0.40 (±0.01) 15.3 (±2.5) 0.15 (±0.03)
EC50, TEC50 and antioxidant efﬁciencies (AE) values of hydroxytyrosol, 4 HEP, 2HEP and THI. Standard deviations (SD) are reported in parentheses.
doi:10.1371/journal.pone.0124427.t002
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as it shares a catechol moiety with the hydroxytyrosol structure, results obtained from 2HEP
and 4HEP (phenols like tyrosol, DHiBF, andDHI) deserve some comments. In both struc-
tures the aromatic ring hosts two oxygens either in ortho (2HEP) or para (4HEP); thus these
two molecules share an important structural similarity with catechol and hydroquinone, re-
spectively, two known antioxidants [48]. 3HEP, instead, shows the additional atom oxygen in a
meta position respect to the-OH already present on the aromatic ring, thus resembling resor-
cinol. Compared to catechol and hydroquinone, where the-OH group in either ortho or para
position has an electron donating effect, the reaction of resorcinol with a radical such as DPPH
would theoretically be reduced by the electron-withdrawing effect of the-OH group in the meta
position [9]. The same rational seems to apply to the three hydroxylated derivatives we ob-
tained from the biotransformation of 2-phenoxyethanol.
Interestingly, the THI plot shows a sigmoidal profile that was not observed for the other
compounds tested. Although a more detailed investigation would be necessary to account for
such a behaviour, it may be argued that a two-step oxidation path is available for THI as a con-
sequence of the-OH substituted five member ring condensed with the catechol system (S8 Fig
and explicative notes).
Antioxidant potential of 4HEP, 3HEP, 2HEP, DHiBF, DHI, THI in cultured
H9c2 cells
The potential antioxidant activity of the hydroxylated compounds described in this study was
also evaluated testing their effect in a eukaryotic cell system such as the rat cardiomyoblast cell
line H9c2. These latter are non-malignant cardiac-like cells, commonly used to study the mo-
lecular response to oxidative damage [39–40]. We first examined the effect of the hydroxylated
compounds on cell viability, by using the MTT assay (Panel A in S9 Fig), to verify that a cyto-
toxic effect did not occur. To this purpose, cells were cultured for 72 hours under normal
growth conditions in the presence of each purified hydroxylated compound, previously diluted
in the growth medium at optimized concentrations (Materials and Methods). The percentage
of viable cells, compared to the control, never significantly decreased as shown in Panel A in S9
Fig, thus showing that the compounds tested are not cytotoxic on this specific cell line. Indeed,
in the presence of the non-hydroxylated precursors (Panel A in S9 Fig, dark white bars) used as
substrates in the ToMO-catalyzed biotransformations, the percentage of viable cells was almost
close to the 100%. It is worth to note that hydroxytyrosol and tyrosol induced a significant in-
crease of cell survival (Panel A in S9 Fig, black bars) (p value< 0.01). A slight positive effect on
cell viability was also observed when using the hydroxylated products obtained from 2-phenox-
yethanol, with a significant increase of the viable cells number (p value< 0.01 for 4HEP, p
value< 0.05 for 3HEP and 2HEP). Conversely,DHiBF,DHI and THI did not produce any
apparent change in cell viability.
Optimized concentrations obtained in this assay were used in all subsequent experiments
(Materials and Methods). In order to validate the data obtained on cell viability, we investigated
whether the tested compounds had any effect on cell apoptosis. Apoptotic cells were identified
by acridine orange (AO) and ethidium bromide (EB) staining of nuclei [45], as described in
Materials and Methods; results are presented in Panel B and C in S9 Fig When cells were cul-
tured under normal growth conditions, the hydroxylated compounds did not induce an in-
crease in cell apoptosis (Panel C in S9 Fig, white bars). This is consistent with the results
obtained from the MTT assay. Moreover, tyrosol, 3HEP,DHI and THI induced a significant
decrease of the number of apoptotic cells (p value< 0.05 forDHI, p value! 0.01 for the other
compounds; Panel C in S9 Fig). Exposure of H9c2 to 0.25 mM of SA for 90 min induced, per
se, a 37% increase in the percentage of apoptotic nuclei (Panel C in S9 Fig, first black bar).
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Since this stress condition was sufficient to elicit a detectable but still sub-lethal cell stress re-
sponse, it was considered suitable for further experiments aimed at investigating the potential
protective effect of our compounds towards the SA-induced effect. Pretreatment for 3h with
4HEP, 2HEP,DHI and THI resulted in a significant reduced percentage of apoptotic nuclei,
which decreased from 37% of the control to around 20% (Panel C in S9 Fig, black bars) (p
value< 0.05 for 2HEP andDHI,! 0.01 for 4HEP and THI). The other hydroxylated com-
pounds did not significantly alter the sodium arsenite (SA)-induced apoptotic effect.
To better assess a potential antioxidant activity of our hydroxylated compounds, a cell stress
response was analyzed, which is activated under mild stress conditions when a transient trans-
lational arrest occurs. As underlined in the Introduction section, exposure to SA inhibits pro-
tein synthesis and activates multiple stress signaling pathways, including the formation of
stress granules (SGs) [4,41–43]. SGs are cytoplasmic foci composed of 40S ribosomal subunits,
initiation translation factors and their associated mRNA transcripts, which aggregate when
translation initiation is stalled. The SGs formation is reversible and the protein synthesis can be
restored, if the stress condition is recovered. To investigate the potential antioxidant effect of
our hydroxylated compounds, we examined the occurrence and the number of stress granules
(SGs) in H9c2 cells both under normal growth and SA-induced stress conditions. SGs were de-
tected by immunofluorescence and confocal microscopy analysis using the marker PABP
(poly-A binding protein) (Materials and Methods and Fig 5). To estimate the antioxidant
Fig 5. Immunofluorescence assay. Effect of sodium arsenite on the formation of stress granules:
immunofluorescence and statistical analysis. PABPmAb and Cy3-conjugated goat anti-mouse F(ab’)2 were
used to detect SGs in H9c2 cells cultured under normal growth (A) and SA-stress conditions (B). Nuclei are
stained with DAPI. Scale bars: 10μm. (C) Effect of pretreatment with hydroxylated compounds in SA-treated
H92c cardiomyoblasts. The table reports SGs number for cell (Mean ± SEM) that was obtained by using
“Analyze Particles” plugin of the image software ImageJ (pixel unit: 1,5–2,0; Circularity: 0,99–1,00). Statistical
analysis (unpaired t test, two tailed; (*, p! 0.05; **, p! 0.01). Tyr: tyrosol; Hyd: hydroxytyrosol.
doi:10.1371/journal.pone.0124427.g005
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activity, SGs number per cell was calculated by using a statistical analysis, applied to at least
three images acquired analyzing a minimum of 350–400 cells. When H9c2 cells were cultured
under normal growth conditions, in the presence of the hydroxylated compounds, no signifi-
cant change in SGs formation was observed (11.7 ± 4.4) when compared to the control, con-
firming that the compounds tested do not alter the cellular status (data not shown). In SA-
treated cells, SGs were instead easily identified and the statistical analysis revealed the presence
of 55.3 ± 3.7 SGs per cell (Fig 5). When pre-treatment with the hydroxylated compounds was
performed before the SA-induced oxidative stress, a strong and statistically significant decrease
in SGs number was observed (Fig 5). 2HEP and THI, again, showed a higher antioxidant activ-
ity compared to the other hydroxylated compounds. A putative antioxidant activity of the aro-
matic non-hydroxylated substrates used was also evaluated. Their effect on SGs in stressed
H9c2 cells was analyzed (data not shown), and no significant decrease in SGs number was ob-
served, when compared to the control.
Conclusions
Aromatic nuclei are, for their chemical versatility, ideal candidates to create molecules with
multiple pharmacological effects. Phenols and catechols, in particular, are promising starting
points to merge with other pharmacophores thus obtaining multipotent agents with antioxi-
dant effects and beyond. The different studies presented on the ToMOmulticomponent system
in more than a decade [18,20–21,23–31] described the unique versatility of the catalytic activity
of this enzyme, which allows to obtain hydroxylated derivatives from a wide array of aromatic
substrates, highlighting its role as a potential resource for the biosynthesis of phenolic and
catecholic compounds.
We have previously shown that a fine-tuning of the regioselectivity and of the catalytic effi-
ciency of ToMO on 2-phenylethanol, a non-natural substrate, to produce known antioxidants
such as tyrosol and hydroxytyrosol could be achieved by using an optimized computational
model that allows a careful alteration of the shape of the active site [26,18].
In this work we investigated the use of ToMO for the biosynthesis of six aromatic antioxi-
dants, starting from three commercially available aromatic compounds that are non-natural
substrates of the enzyme. By using either the wt enzyme or ToMOmutant E103G/F176A-cata-
lyzed biotransformations, six hydroxylated compounds were obtained. Although not all of
them were able to reduce the DPPH stable radical, a common test system for determining the
scavenging properties of putative antioxidants in vitro, all hydroxylated compounds shared a
common, although differential, antioxidant effect on eukaryotic cells of the H9c2 cell line sub-
jected to a mild oxidative stress induced by sodium arsenite. The discrepancy between the two
assays showed from one side a possible limitation in the use of the DPPH assay as the unique
methodology to assess the in vitro antioxidant potential of hydroxylated aromatic compounds,
and on the other hand confirms that the antioxidant effect of phenols and catechols frequently
observed in cells might not be due to a simple scavenge of free radicals, but might be dependent
on other molecular events that have not been completely elucidated yet.
The availability of the molecules produced under the present study undoubtedly opens new
possibilities for obtaining a whole new set of antioxidant molecules by using the ToMOmulti-
component system as biocatalyst using a wide array of commercially available monocyclic aro-
matic compounds as starting substrates.
Supporting Information
S1 Fig. Bioconversion of 2-phenylethanol.Natural antioxidants tyrosol and hydroxytyrosol
produced from the hydroxylation of 2-phenylethanol catalyzed by ToMOmutants E103G/
Monooxygenase Mediated Biosynthesis of Aromatic Antioxidants
PLOS ONE | DOI:10.1371/journal.pone.0124427 April 27, 2015 15 / 20
F176T and E103G/F176I (Notomista E., Scognamiglio R., Troncone L., Donadio G., Pezzella
A., Di Donato A., and Izzo V. Tuning the specificity of the recombinant multicomponent tolu-
ene o-xylene monooxygenase from Pseudomonas sp. strain OX1 for the biosynthesis of tyrosol
from 2-phenylethanol. Appl. Environ. Microbiol. 2011.77(15): 5428–37. http://aem.asm.org/
content/77/15/5428.full).
(TIF)
S2 Fig. Time course chromatograms. Time course formation of the hydroxylated products
deriving from the ToMO-catalyzed bioconversion of: (Panel A) 2-phenoxyethanol, (Panel B)
phthalan and (Panel C) 2-indanol. Chromatograms were extracted at λ = 280 nm. The 2-inda-
nol bioconversion was performed by using ToMOmutant E103G/F176A.
(TIF)
S3 Fig. NMR analysis. NMR analysis of the isolated products deriving from the ToMO-cata-
lyzed bioconversion of: 2-phenoxyethanol (Compounds 1, 2 and 3), phthalan (Compound 4)
and 2-indanol (Compounds 5 and 6). The structures deduced for each new compound ob-
tained are also presented.
(TIF)
S4 Fig. Mass spectrometry analysis.Mass spectrometry analysis and molecular weights ob-
tained for the isolated products deriving from the ToMO-catalyzed bioconversion of: 2-phe-
noxyethanol (Compounds 1, 2 and 3), phthalan (Compound 4) and 2-indanol (Compounds 5
and 6).
(TIF)
S5 Fig. Estimation of extinction coefficients. For each hydroxylated compound isolated, the
εat λmax of a similar model compound is reported which was used for the determination of the
concentration throughout this study.
(TIF)
S6 Fig. Modelling.Monte Carlo minimized models of the complexes between ToMO or
(E103G,F176A)-ToMO and the arenium intermediates for the toluene/p-cresol (S4M) and the
2-indanol/2,5-dihydroxyindan (25I) reactions. Carbon atoms are shown in green (ToMO/
S4M), magenta (ToMO/25I) and yellow [(E103G,F176A)-ToMO/25I]. Oxygen atoms are
shown in red, nitrogen atoms in blue, sulphur atoms in dark yellow. Hydrogen atoms are not
shown. Iron ions are shown as orange spheres.
(TIF)
S7 Fig. DPPH assay. DPPH reduction (expressed as the percentage of the DPPH effectively
reduced, Y axis) as a function of the μM concentration of the compound tested (X axis). 4-
(2-Hydroxyethoxy)phenol (4HEP); 2-(2-Hydroxyethoxy)phenol (2HEP); 2,5,6-trihydroxyin-
dan (THI); Hydroxytyrosol.
(TIF)
S8 Fig. Oxidation pathway. Two-step oxidation pathway proposed for THI as a consequence
of its peculiar structure showing an-OH substituted five member ring condensed with the cate-
chol moiety. First oxidation step results in the formation of expected orthoquinone moiety
which can itself undergoes tautomerization affording-via transient quinone methides- a cyclo-
pentanone condensed catechol, again susceptible to act as reductant (Pezzella A., Lista L., Na-
politano A., and d’Ischia M. Tyrosinase-catalyzed oxidation of 17beta-estradiol: structure
elucidation of the products formed beyond catechol estrogen quinones. Chem.Res. Toxicol.
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2005.18(9): 1413–9. http://pubs.acs.org/doi/abs/10.1021/tx050060o).
(TIF)
S9 Fig. MTT viability assay and apoptosis assay. (Panel A)H9c2 cells were cultured under
normal growth conditions, incubated in the presence of either the substrates (dark white bars)
or the hydroxylated derivatives (black bars) for 72 hours. Cell viability was determined by
means of ABS570 compared to the control (white bar), that is cells without any treatment. Data
shown are the means ± s.d of at least three repeats, of a representative experiment. A statistical
analysis by two-tailed Student’s t was performed. (Panel B) and (Panel C) Acridine orange
(AO) and ethidium bromide (EB) staining of nuclei to identify apoptotic nuclei. H9c2 cells
were cultured under either normal growth conditions (image on the left, panel B, and white
bars in panel C), or SA-induced oxidative stress (image on the right, panel B, and black bars in
panel C).
(TIF)
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Oxidative stress is generally considered as the consequence of an imbalance between
pro- and antioxidants species, which often results into indiscriminate and global damage
at the organismal level. Elderly people are more susceptible to oxidative stress and
this depends, almost in part, from a decreased performance of their endogenous
antioxidant system. As many studies reported an inverse correlation between systemic
levels of antioxidants and several diseases, primarily cardiovascular diseases, but also
diabetes and neurological disorders, antioxidant supplementation has been foreseen as
an effective preventive and therapeutic intervention for aging-associated pathologies.
However, the expectations of this therapeutic approach have often been partially
disappointed by clinical trials. The interplay of both endogenous and exogenous
antioxidants with the systemic redox system is very complex and represents an issue
that is still under debate. In this review a selection of recent clinical studies concerning
antioxidants supplementation and the evaluation of their influence in aging-related
diseases is analyzed. The controversial outcomes of antioxidants supplementation
therapies, which might partially depend from an underestimation of the patient specific
metabolic demand and genetic background, are presented.
Keywords: vitamins, resveratrol, sirtuins, hormesis, oxidative stress
INTRODUCTION
Reactive oxygen species (ROS) comprise both free radicals such as superoxide (O• 2 ), and non-
radical species such as hydrogen peroxide (H2O2), (Weseler and Bast, 2010; Gülçin, 2012). These
molecules, continuously produced in the cell, are involved in physiological events such as cell
di erentiation, primary immune defense, and signaling (Poli et al., 2004; Shah and Sauer, 2006;
Gülçin, 2012). Indeed, some ROS such as H2O2 are versatile players of the molecular signaling
machinery because they are small, highly di usible, and can be rapidly generated and degraded
(Gough and Cotter, 2011).
Both radical and non-radical ROS are pro-oxidant species capable of oxidizing in the cell
di erent biomolecules (Sies, 1991), which leads to a sequence of chain reactions that may end up
in molecular and cellular damage (Gülçin, 2012).
The balance between beneficial and detrimental e ects of ROS is preserved in the cell by the
activity of a complex array of non-enzymatic and enzymatic detoxificationmechanisms collectively
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known as antioxidants (Sies, 1993; Bast and Haenen, 2015).
Antioxidants are able to counteract, at relatively low
concentrations, the damage induced in cells by ROS, thus
protecting physiological targets such as lipids, DNA and proteins
(Loguercio et al., 2012; Bast and Haenen, 2015). Noteworthy,
antioxidants may also act indirectly by regulating redox-sensitive
signal transduction pathways including transcription factors, and
inhibition of poly (ADP-ribose) polymerase (PARP-1) (Weseler
and Bast, 2010).
An imbalance of either the pro-oxidant and/or the antioxidant
parties is at the origin of a complex physiological status known
as “oxidative stress” (Davies, 1995; Conti et al., 2015a,b), which
may be also favored by external sources, and by the presence
of dietary compounds of pro-oxidant nature such as quinones
(Gülçin, 2012).
Elderly people are more susceptible to oxidative stress
due to a reduction in the e ciency of their endogenous
antioxidant systems. Organs such as heart and brain,
with limited replication rate and high levels of oxygen
consumption, are particularly vulnerable to this phenomenon,
thus explaining almost in part the high prevalence of
neurological and cardiovascular diseases (CVD) in elderly
(Ames et al., 1993; Stadtman and Berlett, 1997; Corbi et al.,
2008).
A substantial body of literature reported an inverse correlation
between serum or plasma total antioxidant capacity and both
the onset and progression of several diseases, primarily CVD
(Ciancarelli et al., 2012), but also diabetes (Opara et al., 1999),
respiratory (Gumral et al., 2009) and neurological disorders
(Schrag et al., 2013).
Consequently, antioxidants supplementation was suggested
as a promising therapy in line with the general acceptance
of the Free Radical Theory of Aging (FRTA) (Harman, 1956,
2006). First presented in Harman (1956), this theory is based
on the assumption that lowering the global level of ROS in
the body might retard aging, increase life span and be e ective
in preventing and treating aging-associated diseases (Sadowska-
Bartosz and Bartosz, 2014). Further refinements of this theory
addressed the roles of other activated oxygen species in aging in
the more generalized Oxidative Stress Theory of Aging (OSTA)
(Bokov et al., 2004; Muller et al., 2007).
This awareness resulted from one side in boosting in the
scientific community the quest for novel natural or synthetic
antioxidants (Donadio et al., 2015), and on the other in
establishing several treatment strategies whose aim was to
counterbalance oxidative stress by supplementing exogenous
antioxidants, either singularly or in combination (Bouayed and
Bohn, 2010).
However, the clinical expectations of antioxidants-based
therapies have been frequently disappointed. The interplay
between endogenous and exogenous antioxidants with the
overall redox system in humans is very complex and represents
a topical issue that is still under debate in the scientific
community.
In this review a selection of recent clinical studies concerning
antioxidants supplementation and the evaluation of their
influence in aging-related diseases is analyzed (Table 1).
NATURAL ANTIOXIDANTS USED IN
RECENT CLINICAL STUDIES
Many natural compounds have been considered, either singularly
or in combination, for supplementation therapies. Among
them, we devoted particular attention to a specific subset of
molecules such as vitamin C, vitamin E, resveratrol, curcumin,
hydroxytyrosol and coenzyme Q10.
Ascorbic acid is the main form of vitamin C in the human
body and acts as the co-substrate for several enzymes that are
important for the organism’s functioning. Its antioxidant activity
relies on the ability to be reversibly oxidized to ascorbyl radical
and then to dehydroascorbate (DHA) (Wells and Xu, 1994).
The distribution and the concentration of vitamin C in
the organs depend on their specific ascorbate requirements
and on the tissue distribution of sodium-dependent vitamin C
transporter 1 and 2 (SVCT1 and SVCT2) (Figueroa-Mendez and
Rivas-Arancibia, 2015).
Vitamin C (ascorbic acid) has di erent important roles in
the cell; as a reducing agent and an antioxidant, ascorbate is
able to react and inactivate ROS and, most importantly, reduces
in membranes LDL and a-tocopheroxyl radicals to regenerate
a-tocopherol (Vitamin E) (Chambial et al., 2013).
One of the several biological functions mediated by ascorbate
is the enhancement of nitric oxide bioavailability, which is
essential to preserve endothelial homeostasis (Carr and Frei,
1999). A recent metanalysis (Ashor et al., 2014) revealed that
vitamin C supplementation counteracts endothelial dysfunction
(ED), which is doubtless one of the major contributors for both
the development and progression of CVDs (Versari et al., 2009;
Conti et al., 2012b, 2013; Corbi et al., 2012; Zhang et al., 2014),
suggesting a clinical impact of supplementation only in subjects
at higher CVDs risk. Antoniades et al. (2004) found that a
vitamin C supplementation of 2 g/day for 4 weeks increased
forearm vasodilator response to reactive hyperemia in patients
with combined diabetes (DM) and coronary artery diseases
(CAD).
An interesting study by Mullan et al. (2002) showed that an
oral administration of ascorbic acid (500 mg/day) for 1 month
lowered blood pressure and reduced systemic arterial sti ness;
conversely, other two randomized controlled trials failed to prove
a blood pressure-lowering e ect of vitamin C supplementation
(Lovat et al., 1993; Ghosh et al., 1994).
However, the role played by vitamin C in aging-associated
diseases has not been adequately investigated in clinical trials
mainly because this antioxidant was often used in combination
with other molecules (Watanabe et al., 1998; Salonen et al., 2003).
When referring to vitamin E, a family of 8 isoforms classified
in two categories is considered: four saturated analogs (a, b,
g, and d) called tocopherols and four unsaturated analogs
indicated as tocotrienols, which di er for the methylation pattern
(Cardenas and Ghosh, 2013). These molecules are hydrophobic
fat-soluble compounds found in a variety of food sources such as
corn oil, peanuts, vegetable oils, fruits and vegetables (Cardenas
and Ghosh, 2013). Most of the studies presented in literature
have been performed using a-tocopherol (Wallert et al., 2014;
Hanson et al., 2015) that is considered the most active isomer
Frontiers in Pharmacology | www.frontiersin.org 2 February 2016 | Volume 7 | Article 24
fphar-07-00024 February 10, 2016 Time: 18:50 # 3
Conti et al. Antioxidant Supplementation in Aging Diseases
TABLE 1 | Clinical studies performed with the main antioxidants.
Antioxidant Disease Primary results Reference
Vitamin C Type 2 DM and CAD " Forearm vasodilator response Antoniades et al., 2004
DM # Arterial blood pressure and improvement of arterial stiffness Mullan et al., 2004
IHD Prevention of nitrate tolerance Watanabe et al., 1998
Vitamin E CAD # Rate of non-fatal MI Stephens et al., 1996
CVD and DM No effect on cardiovascular outcomes Yusuf et al., 2000
Vascular disease and DM " Risk for HF Lonn et al., 2005
Prior MI " Chronic HF in patients with LVD Marchioli et al., 2006
CAD # Plasma biomarkers of oxidative stress and inflammation Devaraj et al., 2007
Resveratrol Hypertension and dyslipidemia # Endothelial dysfunction Carrizzo et al., 2013
DM Improvement of glucose control and insulin sensitivity Liu et al., 2014
Coenzyme Q10 CAD " Antioxidant enzymes activities and #inflammation Lee et al., 2013
Vitamin E and C Hypercholesterolemia # atherosclerotic progression Salonen et al., 2003
Vitamins C, E and
b-carotene (alone
or in combination)
CVD No overall effects on cardiovascular events Cook et al., 2007
DM, diabetes mellitus; CAD, coronary artery disease; IHD, ischemic heart disease; CVD, cardiovascular disease; MI, myocardial infarction; HF, heart failure; LVD, left
ventricular dysfunction.
within this group and the main hydrophobic antioxidant in cell
membranes and circulating lipoproteins. Its antioxidant function
is strongly supported by the regeneration promoted by vitamin
C a-Tocopherol exhibits strong antioxidant capacity in vitro and
has been shown to inhibit LDL oxidation (Wallert et al., 2014).
In addition, a-tocopherol shows a remarkable anti-
inflammatory action by inhibiting, for example, cyclooxygenase-
2 (COX2) (O’Leary et al., 2004). Next to its antinflammatory
and antioxidative properties, vitamin E shows other properties,
such as the modulation of the expression of genes encoding
proteins involved in signaling (Cardenas and Ghosh, 2013). In
addition vitamin E is also involved in the uptake, transport and
degradation of tocopherols, as well as the uptake of lipoproteins
and the storage and export of lipids such as cholesterol (Cardenas
and Ghosh, 2013).
The beneficial e ects of vitamin E dietary intake have been
described (O’Leary et al., 2004; Hanson et al., 2015), whereas
the data concerning vitamin E supplementation are controversial.
An old randomized controlled trial by Stephens et al. (1996)
showed that in patients with CAD, 1 year of a-tocopherol
supplementation reduced the rate of non-fatal myocardial
infarction. However, very few human studies have confirmed
the e cacy of vitamin E supplementation in aging-associated
diseases, and most of them focused on the role of vitamin E
supplementation in influencing aspects of aging phenotypes,
such as oxidative stress and inflammation biomarkers. In this
specific context some investigations, performed both in animals
models and in humans, e ectively demonstrated benefits of
vitamin E supplementation (Iuliano et al., 2000; Navarro et al.,
2005; Abdala-Valencia et al., 2012), while others showed negative
impact (Bjelakovic et al., 2012), or no e ect at all (Morley and
Trainor, 2001; Hemilä and Kaprio, 2011).
Two large randomized trials (Yusuf et al., 2000; Lonn et al.,
2005) investigated the impact of vitamin E supplementation
on CVDs and cardiovascular events in patients at high risk.
The “Heart Outcomes Prevention Evaluation (HOPE)” analyzed
the e cacy of a treatment with vitamin E in preventing
cardiovascular outcomes in 9,541 patients with CVD or diabetes
in addition to at least one other risk factor (Yusuf et al.,
2000). This study, with mean follow-up of 4.5 years, showed
that vitamin E did not reduce the incidence of cardiovascular
events when compared to placebo, thus suggesting the lack of an
evident beneficial e ect exerted by this antioxidant (Yusuf et al.,
2000).
The “HOPE-TOO” (Lonn et al., 2005) an extension of the
HOPE study, was aimed at assessing whether longer duration of
the treatment with vitamin E could prevent cancer and/or CVD
during a follow-up of 7 years. The HOPE-TOO, involving 7,030
patients, confirmed that administration of 400 IU of vitamin
E had no evident impact either on cancer outcomes or on
major cardiovascular events and death. Furthermore, during the
HOPE-TOO study, the investigators advanced the hypothesis
that vitamin E supplementation might even be responsible to
increase the risk of heart failure (Lonn et al., 2005).
Another clinical trial explored the e ect of vitamin E on
the development of chronic heart failure (CHF) in 8,415 post-
infarction patients without CHF at baseline (Marchioli et al.,
2006). The authors found that vitamin E treatment was associated
with a 50% increase of CHF in patients with left ventricular
dysfunction, thus confirming the conclusion raised by the HOPE
trial investigators.
More recently, Devaraj et al. (2007) evaluated the e ect
of a high dose of a-tocopherol (1,200 IU/die for 2 years)
in CAD patients with high levels of oxidative stress. The
authors demonstrated that vitamin E supplementation lowered
plasmatic levels of inflammationmarkers, such as high-sensitivity
C-reactive protein and tumor necrosis factor-alpha, and the
levels of oxidative stress biomarkers, such as plasmatic oxidized
LDL, urinary F2-isoprostanes and monocytes superoxide anion
concentrations (Devaraj et al., 2007). However, a-tocopherol
supplementation failed to induce any change in intima-media
thickness of carotid arteries and no significant di erences in
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cardiovascular events were observed between patients treated
with vitamin E and those with placebo (Devaraj et al.,
2007).
As previously underlined, vitamins E and C have been
frequently used in combination in clinical trials concerning
aging-associated diseases. The “Women’s antioxidant
Cardiovascular Study (WACS)” (Cook et al., 2007) investigated
the e ect of vitamins C, E and b-carotene (alone or in
combination) in preventing cardiovascular events in 8,171
patients with either a history of CVD or at least three
cardiovascular risk factors, and during an average 9.4 year
follow-up (Cook et al., 2007). Results from WACS, as in the
case of other antioxidant trials performed with women, failed
to find any preventive e ects of the antioxidants used on
CVD.
The Physicians’ Health Study II (PHS II) (Sesso et al., 2008)
randomized trial investigated instead the e ects of vitamins E and
C in the prevention of CVD in men during a mean follow-up of
8 years. This trial did not evidence any benefit from antioxidant
supplementation on major CVD outcomes; moreover, vitamin
E was associated with an increased risk of stroke (Sesso et al.,
2008).
In a recent prospective study performed with 3,919 aged
men, Wannamethee et al. (2013) showed that higher plasma
levels of vitamin C, but not those of vitamin E, are inversely
associated with cardiovascular risk factors, including blood
lipids and blood pressure. Notably, whereas the dietary intake
of vitamin C did not exert any influence, the dietary intake
of vitamin E was significantly correlated with increased risk
of HF (Wannamethee et al., 2013). The authors of this
interesting investigation suggested that the reason for the
association between vitamin E intake and HF might depend
by the fact that vitamin E (a-tocopherol) may become a pro-
oxidant in an environment characterized by high oxidative
stress, such as an aged biological system (Wannamethee et al.,
2013).
Resveratrol (3, 40, 5-trihydroxystilbene) is a phytoalexin
that belongs to the stilbene class of compounds, abundant
in many plants, such as peanuts, blueberries, pine nuts and
grapes where it mainly accumulates in a glycosylated form,
and that is synthesized in response to fungal infection and to
some environmental stresses like climate, ozone and ultraviolet
irradiation (Harikumar and Aggarwal, 2008).
Resveratrol appears to modulate numerous cell-signaling
pathways through the regulation of di erent molecular targets
including the AMP-regulated kinase AMPK and the NAD-
dependent deacetylase Sirt-1 (Yun et al., 2014; Conti et al.,
2015a). The variety of molecular mechanisms mediated by
this compound translates into a plethora of biological actions,
primarily, antioxidant and anti-inflammatory e ects. Resveratrol
is a good antioxidant and blocks in vitro LDL oxidation, a
biological phenomenon associated with the risk of coronary
heart disease and myocardial infarction (Khurana et al., 2013).
In rodents, resveratrol supplementation has been shown to
decrease cardiovascular risk factor, including blood lipids and
VCAM-1, to improve cardiovascular function and physical
capacity and to decrease inflammation in the vasculature of aged
animals leading to improved vascular function (Gliemann et al.,
2013).
The anti-inflammatory properties of resveratrol have been
proved by several in vitro experiments. For instance, resveratrol
was showed to suppress NF-kB activity induced by beta-
amyloid in PC12 neuron cell lines, (Jang and Surh, 2003)
and to reduce the production of IL-1 beta and TNF-alpha
induced by LPS or beta-amyloid in the microglia (Capiralla
et al., 2012; Zhong et al., 2012), suggesting a neuroprotective
e ect that has also been confirmed in cellular models of
neurodegenerative disorders, such as Parkinson’s and Alzheimer’s
diseases (Albani et al., 2009). Resveratrol anti-inflammatory e ect
has been demonstrated also in vivo, i.e., in an animal model
of asthma in which this molecule mitigated structural airway
remodeling (Royce et al., 2011) or in rats with LPS-induce
liver failure where resveratrol improved hepatotoxic markers
by multiple mechanisms such as downregulation of NOS-2,
and modification of oxidative stress parameters (Farghali et al.,
2009).
Despite the promising results reported in vitro (Zhang et al.,
2011; Montesano et al., 2013) and in animal models (Saleh et al.,
2014), few studies have been performed directly in humans and
the results obtained are not quite convergent.
Recent studies underlined the importance of patient selection
in evaluating the potential therapeutic e ects of resveratrol.
Recently, Carrizzo et al. (2013) conducted an ex vivo study
to investigate the e ects of resveratrol on superior thyroid
artery obtained from 59 patients (63 years of mean age)
with hypertension and dyslipidemia, and found that resveratrol
reduced ED via modulation of NO metabolism and attenuation
of vascular oxidative stress. Interestingly, resveratrol failed to
exert any e ect in vessels from patients without hypertension
or dyslipidemia (Carrizzo et al., 2013). A di erential e ect
of resveratrol influenced by the initial health status was also
suggested by a recent meta-analysis by Liu et al. (2014) which
highlighted that resveratrol improves glucose control and insulin
sensitivity in diabetic patients but does not a ect glycemic values
in non-diabetic subjects.
In a recent work published by Gliemann et al. (2013), the
authors tested for the first time the combined e ect of exercise
training (ET) and resveratrol on vascular function in aged
humans. In this trial 27 healthy physically inactive aged men
were randomized into 8 weeks of daily intake of either 250 mg of
trans-resveratrol or of placebo andwere subjected to concomitant
high-intensity ET (Gliemann et al., 2013).
The main aim of the study was to confirm if oral
resveratrol supplementation improved the positive
cardiovascular adaptations to ET in aged subjects by
specifically increasing sirtuin 1 (SIRT1) mediated signaling
and by promoting the endogenous antioxidant system.
Interestingly, results showed that, whereas ET e ectively
improved several cardiovascular health parameters in aged
men, concomitant resveratrol supplementation somehow
blunted most of these e ects leading, among others, to a
significantly lower improvement in the training-induced
increase in maximal oxygen uptake (Gliemann et al.,
2013).
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Curcumin is a lipophilic bioactive phenol derived from the
rhizome of Curcuma longa, which shows low solubility and
stability in aqueous solution. It is contained in culinary curry
and used as a coloring agent in food (Bhullar et al., 2013). Orally
ingested curcumin is metabolized into the active metabolite
tetrahydrocurcumin by a reductase found in the intestinal
epithelium (Sadowska-Bartosz and Bartosz, 2014). Extensive
research during the last few decades has suggested a strong
therapeutic and pharmacological potential of this molecule as
antioxidant, antimutagenic, antiprotozoal and antibacterial agent
(Bhullar et al., 2013).
Curcumin strong medicinal properties are also associated
with reported anti-cancer and neuroprotective e ect such
as in Alzheimer disease (Brondino et al., 2014). A hormetic
mechanism of action of this compound is suggested from
studies showing that expression levels of the stress response
protein Heme Oxygenase-1 (HO-1) were increased in cultured
hippocampal neurons treated with curcumin (Scapagnini
et al., 2006). Moreover, this phenolic compound has been
shown to reverse chronic stress-induced impairment of
hippocampal neurogenesis and increase expression of brain-
derived neurotrophic factor (BDNF) in an animal model of
depression (Xu et al., 2007). Several studies also showed that
curcumin interacts with NF-kB, and through this interaction
exerts protective function also in the regulation of T-cell-
mediated immunity (Kou et al., 2013). Recently González-Reyes
et al. (2013) identified curcumin as a neuroprotector against
hemin, the oxidized form of heme, which induced damage in
primary cultures of cerebellar granule neurons of rats. In this
study, a pretreatment of the neurons with 5–30 µM curcumin
increased by 2.3–4.9 fold HO-1 expression and by 5.6–14.3-fold
Glutathione (GSH) levels. Moreover, 15 µM curcumin lowered
by 55% the increase in ROS production, by 94% the reduction of
GSH/glutathione disulfide ratio, and by 49% cell death induced
by hemin. Furthermore, curcumin induced the translocation
into the nucleus of nuclear factor related factor-2 (Nrf2),
thereby stimulating an inflammatory and antioxidant response
against hemin-induced neuronal death (González-Reyes et al.,
2013).
Curcumin e ects on both the arterial endothelial function and
the central arterial compliance was recently evaluated in post-
menopausal women that underwent a daily ingestion of 150 mg
of curcumin (Akazawa et al., 2012). In 32 post-menopausal
women the Flow Mediated Dilation (FMD) measured arterial
endothelial function, before and after 8 weeks of curcumin
ingestion or ET. After this time, the authors observed that
FMD increased significantly both in the exercise and curcumin
groups, whereas no significant change in FMD was detected
in the control group (Akazawa et al., 2012). The results
obtained suggested that a regular ingestion of curcumin could
improve endothelial function andmight be a potential alternative
treatment for patients who are unable to exercise. In a di erent
study performed by the same group (Akazawa et al., 2013)
and involving this time 51 post-menopausal women, the e ects
of curcumin ingestion alone and in combination with aerobic
ET on central arterial compliance were evaluated. In this case
also, the regular ingestion of curcumin, as the ET alone,
significantly increased carotid arterial compliance in the group
analyzed. Interestingly, the combination of ET and curcumin
ingestion, di erently from what observed with resveratrol
(Gliemann et al., 2013), led to a cumulative beneficial e ect in
the improvement of the arterial compliance (Akazawa et al.,
2013).
Hydroxytyrosol is an ortho-diphenol (a catechol) abundant in
olive, fruits and extra virgin olive oil (Waterman and Lockwood,
2007). This compound, due to its catecholic structure, shows a
marked antioxidant activity and is able to scavenge oxygen and
nitrogen free radicals, inhibit LDL oxidation, platelet aggregation
and endothelial cell activation, and protects DNA from oxidative
damage (Waterman and Lockwood, 2007; Notomista et al., 2011;
Bulotta et al., 2014). Hydroxytyrosol is also ametal chelator and is
able to scavenge the peroxyl radicals and break peroxidative chain
reactions producing very stable resonance structures (Bulotta
et al., 2014). Interestingly, scavenging activity of hydroxytyrosol
has also been demonstrated with respect to hypochlorous acid
(HOCl) (Visioli et al., 1998) a potent oxidant produced in vivo
at the site of inflammation, a phenomenon which may be critical
for the protection from atherosclerosis, since HOCl can oxidize
the apoproteic component of LDL. Moreover, it has been recently
reported (Giordano et al., 2014) that hydroxytyrosol is endowed
with the ability to modulate an adaptive signaling pathway
activated after endoplasmic reticulum (ER) stress and to improve
ER homeostasis itself.
The antioxidant activity of hydroxytyrosol seems to be related
in vivo to its high bioavailability: various studies have in fact
documented a high degree of absorption of this compound,
which is fundamental to exert its biological activities (Bulotta
et al., 2014). Several studies, mostly performed in cell and animal
models, have suggested beneficial e ects of hydroxytyrosol in the
prevention or treatment of chronic and degenerative diseases,
especially CVD and cancer (Facchini et al., 2014). Most of the
studies currently presented in literature on hydroxytyrosol are
performed in vitro on cultured eukaryotic cells and very few are
the clinical trials performed in humans and more specifically
on elderly people. One of the main reasons is probably the
fact that purified hydroxytyrosol is still very expensive, which
hampers its use for long-lasting trials. Currently, the attention
of the scientific community is focused more on the e ect of
olive oil supplementation on health, but olive oil is a complex
mixture containing variable amounts of triacylglycerols, fatty
acids and polyphenols (Waterman and Lockwood, 2007), thus no
conclusive hypothesis of the use of purified hydroxytyrosol can
yet be drawn from these studies.
Oliveras-López et al. (2013) evaluated the e ects of daily
consumption of extra virgin olive oil in 62 subjects aged
65–96 years. After a 6-weeks daily intake of polyphenol-
rich olive oil with high oleuropein derivative contents, the
authors found a significant improvement in lipid profiles,
including a reduction of total cholesterol and a significant
increase of HDL levels. Moreover, in the same subjects, an
increase of serum total antioxidant capacity, and a concomitant
significant increase of catalase in erythrocytes and decrease in
superoxide dismutase and glutathione peroxidase activities were
also observed (Oliveras-López et al., 2013).
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Coenzyme Q10 (CoQ10), referred to as ubiquinol in its
most active (95%) and reduced form (Q10H2), is a lipophilic
molecule present in the membranes of almost all human tissues,
and essential for the respiratory transport chain (Onur et al.,
2014). The side chain serves to keep the molecule anchored
in the inner mitochondrial membrane, and the quinone ring,
which is easily and reversibly reduced to the quinol form,
enables it to fulfill its function of transferring electrons from
complexes I and II to complex III in the respiratory chain,
ultimately resulting in the reduction of oxygen to water and
the generation of ATP (Nowicka and Kruk, 2010; Laredj et al.,
2014). CoQ10 is also capable of recycling and regenerating
other antioxidants such as a-tocopherol and ascorbate. CoQ10
has also been identified as a modulator of gene expression,
inflammatory processes and apoptosis (Bhagavan and Chopra,
2007). The quinol prevents lipid peroxidation by inhibiting the
initial formation and propagation of lipid peroxy radicals, and in
the process it is oxidized to the quinone and H2O2 is produced.
In addition, it has been shown to protect proteins from oxidation
by a similar mechanism (Forsmark-Andrée et al., 1995), and to
prevent oxidative DNA damage such as strand breakages. As
well as its role in the cellular membranes, CoQ is also believed
to function in the blood to protect lipoproteins such as very
low density (VLDL), low density (LDL) and high density (HDL)
lipoproteins from oxidation (Bentinger et al., 2007). Current
evidence suggests that CoQ has a number of independent anti-
inflammatory e ects (Schmelzer et al., 2007). It has been shown to
reduce the secretion of pro-inflammatory cytokines inmonocytes
and lymphocytes after an inflammatory stimulus by influencing
the expression of NF-kB-dependent genes (Schmelzer et al., 2009;
Bentinger et al., 2010). Furthermore, dietary supplementation
with CoQ10 has been reported to improve ED in patients
with diabetes by up-regulating nitric oxide production (patients
received 200 mg CoQ10/day for 12 weeks) (Watts et al., 2002),
and to decrease hepatic inflammatory stress caused by obesity in
mice (Sohet et al., 2009).
Coenzyme Q10 supplementation at 300 mg/day was reported
to significantly enhance antioxidant enzymes activities and lower
inflammation in patients who have CAD during therapy with
statins (Lee et al., 2013). Statins can e ectively lower CoQ
synthesis as they inhibit 3-hydroxy-3-methylglutaryl Coenzyme
A reductase (HMG-CoA reductase), the rate-limiting enzyme
in the pathway of cholesterol synthesis which includes the
formation of the isoprenoid units required to produce CoQ
(Goldstein and Brown, 1990). Moreover, CoQ levels may be
pathologically modified in conditions associated with oxidative
stress and in aging (Potgieter et al., 2013; Botham et al.,
2015).
Data presented in literature on CoQ10 supplementation are
heterogeneous and involve a very large number of pathologies. As
for HF, no conclusions can be drawn on the benefits or harms of
coenzyme Q10 as trials published in literature lack fundamental
information concerning clinically relevant endpoints (Madmani
et al., 2014). More in detail, reports on the e ect of CoQ10
in diseases depending on oxidative stress in elderly people are
scarce. In a recent study (Bloomer et al., 2012), 15 exercise-
trained individuals (10 men and 5 women; 30–65 years) received
300 mg of reduced CoQ10 per day or a placebo for 4 weeks in
a random order, double blind, crossover design. Treatment with
CoQ10 resulted in a significant increase in total blood CoQ10
and reduced blood CoQ10, but did not translate into improved
exercise performance or decreased oxidative stress (Bloomer
et al., 2012).
HORMESIS AND GENETIC VARIABILITY
INFLUENCE ON THE OUTCOMES OF
ANTIOXIDANTS SUPPLEMENTATION
As previously reported, clinical trials involving the use of
antioxidants supplementation often show conflicting results and
lead to dangerous misconceptions, either too positive or too
negative, on the use of these molecules in the treatment of
several aging-associated diseases. Amid this debate, the first
aspect that should be considered is that there are several
limitations concerning FRTA, the basic hypothesis on which the
antioxidants supplementation therapies are mainly based. This
theory, as already underlined, suggests a linear dose-response
relationship between increasing amounts of ROS and biological
damages, which potentially culminates in diseases and mortality.
Therefore, oxidative stress should represent the main driving
force of aging and a major determinant of lifespan (Sadowska-
Bartosz and Bartosz, 2014). To date, many investigations have
urged to reexamine FRTA leading to a modernized view of this
theory that takes also in account the so-called “mitohormesis.”
According to this concept, a large amount of ROS causes
detrimental e ects on the cells, whereas low or moderate levels
of ROS may exert an opposite e ect improving biological
outcomes (Ristow and Schmeisser, 2014; Yun and Finkel, 2014).
The beneficial e ects of caloric restriction (CR) and ET are a
good example because they can be considered both as oxidative
stressors or inducer of the endogenous antioxidant system
activation by favoring a transient cellular increase of ROS
(Corbi et al., 2012). Many independent investigations raised
the possibility that an initial induction of ROS triggered by
CR promotes an adaptive stimulation of antioxidant enzymes
at the steady state, consequentially CR is now considered as
the first example of mitohormesis (Agarwal et al., 2005; Schulz
et al., 2007; Mesquita et al., 2010; Zarse et al., 2012). CR
likely induces an adaptive hormetic response through di erent
molecular pathways, one of these involving sirtuins, a family
of NAD+-dependent deacetylases conserved from yeasts to
humans (Banerjee et al., 2012). SIRT1, the first member of
sirtuins characterized in humans, plays a crucial role in inducing
mitochondrial biogenesis andmediating oxidative stress response
through a number of proteins that promote the expression
of antioxidant genes, such as peroxisome proliferator-activated
receptor (PPAR) gamma coactivator-1 alpha 5 (PGC-1a) (St-
Pierre et al., 2006) and Forkhead transcription factors member,
FOXO3a. SIRT1 interacts with FOXO3a in cells in response to
oxidative stress increasing FOXO3 ability to induce cell cycle
arrest and resistance to oxidative stress and, at the same time
inhibiting FOXO3 ability to induce cell death (Brunet et al.,
2004). Ferrara et al. (2008) demonstrated that exercise-induced
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increase in SIRT1 activity in the heart of aged rats caused an
increase in the expression of FOXO3a and an up-regulation
of FOXO3a targets involved in the oxidative stress response,
including SOD and catalase.
Exercise training, as CR, is to date considered an intervention
triggering a cellular hormetic adaptation (Radak et al., 2005;
Ji et al., 2006). Physical inactivity is indeed one of the major
risk factors for CVD, neurodegenerative disorders and many
other diseases; consequentially, regular physical exercise exerts
health promoting e ect on such clinical conditions and in general
on aging-related diseases (Hu et al., 2001; Conti et al., 2012b;
Brown et al., 2013). Exercise is strictly correlated to enhanced
mitochondrial biogenesis and increased production of ROS and
may promote longevity through pathways common to those of
CR (Lanza et al., 2008). However, the benefits linked to ET
strictly depend on the type and workload of exercise and, in
particular, overtraining can result in maladaptation and possibly
cellular damage (Alessio and Goldfarb, 1988; Chevion et al.,
2003; Conti et al., 2012a, 2013). ET has been reported to activate
PGC-1a, which controls mitochondrial gene expression by a
variety of transcription factors (Nikolaidis and Jamurtas, 2009).
This regulation culminates in enhanced oxygen consumption
in muscle fibers, which, in turn, promotes ROS generation.
Moreover, beyond skeletal muscle, other tissues, such as blood,
heart and lung, represent a source of ROS during exercise
(Nikolaidis and Jamurtas, 2009). Concomitantly to enhanced
ROS production, regular exercise leads to the up-regulation
of several antioxidant enzymes, including SODs, catalase and
glutathione peroxidase, reinforcing the concept that a certain
amount of ROS is necessary for exercise health-promoting e ects
(Nikolaidis and Jamurtas, 2009).
It is not surprising, then, that both older and recent studies
showed that purified antioxidants supplementation might be
inadequate or even damaging for athletes, as they seem to
abolish ET benefits, including prevention of certain diseases.
A very interesting study by Ristow et al. (2009) investigated
whether exercise could promote insulin-sensitizing abilities in
a ROS-dependent manner in healthy humans. The authors
measured insulin sensitivity by glucose infusion rate (GIR)
and the amount of ROS within skeletal muscle of trained
subjects (previously untrained) in the presence or absence of
antioxidant supplementation with vitamin E and vitamin C. As
expected, ET induced ROS formation, which was counteracted
by the antioxidant treatment. However, concomitantly to the
increase of TBARs, ET was able to stimulate the expression of
antioxidant molecules, such as SOD and GPx and induced an
increase of GIR; these e ects were also inhibited by antioxidants
supplementation. The conclusion of this study was that a
transient increase of oxidative stress may contribute to prevent
insulin resistance and type 2 diabetes and, most importantly,
antioxidant supplementation may abrogate these results (Ristow
et al., 2009).
In addition to hormesis another aspect that should be
considered for the conflicting results obtained in the clinical
trials is the genetic background of the patients enrolled in the
studies. In the last decade an increasing number of studies have
suggested that longevity depends not only on life style habits
but also on the genetic background. Oxidative stress response
is one of the most evolutionary conserved pathways involved
in determination of lifespan from yeast to humans (Vijg and
Suh, 2005; vB Hjelmborg et al., 2006) and, indeed, genome wide
association studies (GWAS) have identified genetic determinants
associated to the levels of circulating antioxidants, which could
be linked to human diseases (Ahn et al., 2010). A GWAS
authored by Major et al. (2012) revealed that three single
nucleotide polymorphisms (SNPs), two located in genes involved
in vitamin E transport and metabolism (BUD13 and CYP4F2),
and one in NKAIN3, the gene encoding a Na+/K+ transport
membrane protein, are associated with response to vitamin E
supplementation in humans. The authors concluded that genetic
variation contributes to the variability of serologic vitamin E
status and may have potential application in determining the
regimen of antioxidant supplementation required in complex
diseases such as CVD and diabetes (Major et al., 2012). Very
interesting data concern Haptoglobin (Hp), a protein encoded
by a polymorphic gene with 2 common alleles denoted 1 and 2,
which counteracts the increase of ROS induced by hemoglobin
activity (Sadrzadeh et al., 1984). As previously reported, the
HOPE trial, which investigated the potential protective e ect
of vitamin E in cardiovascular patients, showed that treatment
with vitamin E had no e ect on cardiovascular outcomes in
patients at high risk for cardiovascular events (Yusuf et al., 2000).
Later, Milman et al. (2008) verified such results moving from
the hypothesis that HOPE study failed to prove the benefit of
vitamin E supplementation because of the inadequate selection of
patient genotype. To this end, the authors planned a prospective
double-blinded clinical trial in a subgroup of individuals from
the HOPE study with type 2 diabetes and found that vitamin
E supplementation was e ectively able to reduce cardiovascular
events in patients with the Hp 2-2 genotype (Milman et al.,
2008). Other studies confirmed the impact of Hp genotyping
in determining potential benefits from antioxidant therapy, and
strongly supported the e cacy of a pharmacogenomic strategy
to personalize and fine-tune the treatment with vitamin E in
patients with type 2 diabetes (Blum et al., 2010).
CONCLUSION
Redox state homeostasis in living systems is very complex and
life style factors undeniably concur in determining the impact
of changes in oxidative stress response in both unhealthy and
healthy subjects.
A large part of studies investigating the e ectiveness
of antioxidant supplementation therapy in humans raised
contrasting results. This is due to many aspects among which the
often-limited statistic power of the studies, the patient genetic
background, the bioavailability of the molecules used, and the
non-specific e ects that antioxidants might have in the human
body, should be taken into account.
Mainly in the elderly, the clinical trials conducted so far often
su er from an incorrect initial selection of the patients. Further
investigations should be planned to improve patients selection
by performing, for example, quantitative characterizations of the
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redox state for each individual and taking into account both the
individual patient demand and genetic background.
In addition it is worth to underline that, when dealing with
either natural or synthetic antioxidants, clinical trials should
consider other two important aspects. First, antioxidants bearing
di erent functional moieties can be profoundly diverse in terms
of chemical structure and mode of action; therefore, it should be
recommended to identify the right antioxidant to treat a specific
pathological condition (Bast and Haenen, 2013). Secondly, the
validity of the biomarkers used to determine the e ects of
antioxidants on human health are still under debate (van Ommen
et al., 2009). Antioxidants, in fact, might be responsible of subtle
e ects specific for human health optimization and/or disease
prevention, which are processes that can be very di erent inmany
aspects from disease onset and progression.
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a  b  s  t  r  a  c  t
!-l-Rhamnosidases  (!-RHAs)  are  a group  of glycosyl  hydrolases  of  biotechnological  potential  in indus-
trial  processes,  which  catalyze  the  hydrolysis  of  !-l-rhamnose  terminal  residues  from  several  natural
compounds.  A  novel  !–RHA activity  was  identified  in the  crude  extract  of  Novosphingobium  sp. PP1Y,
a  marine  bacterium  able to grow  on a wide  range  of aromatic  polycyclic  compounds.  In this  work,  this
!-RHA  activity  was  isolated  from  the  native  microorganism  and  the corresponding  orf was identified
in  the  completely  sequenced  and  annotated  genome  of  strain  PP1Y. The  coding  gene  was  expressed  in
Escherichia  coli,  strain  BL21(DE3),  and  the  recombinant  protein,  rRHA-P,  was  purified  and  characterized
as  an  inverting  monomeric  glycosidase  of ca.  120  kDa  belonging  to  the  GH106  family.  A  biochemical  char-
acterization  of  this enzyme  using  pNPR  as  substrate  was  performed,  which  showed  that  rRHA-P  had  a
moderate tolerance  to organic  solvents,  a significant  thermal  stability  up  to  45 ◦C  and  a  catalytic  efficiency,
at  pH 6.9,  significantly  higher  than  other  bacterial  !-RHAs  described  in literature.  Moreover,  rRHA-P was
able to  hydrolyze  natural  glycosylated  flavonoids  (naringin,  rutin,  neohesperidin  dihydrochalcone)  con-
taining !-l-rhamnose  bound  to  "-d-glucose  with  either  !-1,2  or !-1,6 glycosidic  linkages.  Data  presented
in  this  manuscript  strongly  support  the potential  use  of RHA-P  as  a biocatalyst  for diverse  biotechnological
applications.
© 2016  Elsevier  B.V.  All rights  reserved.
1. Introduction
!-l-Rhamnosidases (!-RHAs) are a group of glycosyl hydro-
lases (GHs) that catalyze the hydrolysis of terminal residues of
Abbreviations: !-RHAs, !-l-rhamnosidases; GHs, glycosyl hydrolases; GTs,
glycosyl transferases; PPMM, potassium phosphate minimal medium; pNPR,
p-nitrophenyl-!-l-rhamnopyranoside; MOPS, 3-(N-morpholino) propanesulfonic
acid; pNP, p-nitrophenolate; BSA, bovine serum albumin; LB, Luria Bertani medium;
LB-N, Luria Bertani medium containing a final concentration of 0.5 M NaCl; LB-BS,
Luria Bertani medium supplemented with 1 mM of both betaine and sorbitol; LB-
NBS, Luria Bertani medium containing a final concentration of 0.5 M NaCl and 1 mM
of  both betaine and sorbitol; IPTG, Isopropyl "-d-1-thiogalactopyranoside.
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E-mail address: vizzo@unisa.it (V. Izzo).
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!-l-rhamnose from a large number of natural compounds [1]. L-
Rhamnose is widely distributed in plants as component of flavonoid
glycosides, terpenyl glycosides, pigments, signaling molecules, and
in cell walls as a component of complex heteropolysaccharides,
such as rhamnogalacturonan and arabinogalactan-proteins [2–7].
In bacteria, l-rhamnose appears to be included in membrane
rhamnolipids [8,9] and polysaccharides [10]. According to the sim-
ilarities among their amino acidic sequences, !-RHAs are grouped
in the CAZy (carbohydrate-active enzymes) database (www.cazy.
org) into four different families: GH28, GH78, GH106, and NC (non-
classified).
In the last decade, !-RHAs have attracted a great deal of atten-
tion due to their potential application as biocatalysts in a variety of
industrial processes and in particular in the food industry [1]. Sev-
eral dietary products are rich in glycosylated flavonoids that show
the presence of either a rutinoside (6-!-l-rhamnosyl-"-d-glucose)
http://dx.doi.org/10.1016/j.molcatb.2016.10.002
1381-1177/© 2016 Elsevier B.V. All rights reserved.
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or a neohesperidoside (2-!-l-rhamnosyl-"-d-glucose) disaccha-
ridic unit. In particular, naringin, hesperidin and rutin, flavanone
glycosides found in grapefruit juices, lemons, sweet oranges and
vegetables, have gained increasing recognition for their potential
antioxidant, antitumor and anti-inflammatory properties [11–14].
The ability to hydrolyze glycosylated flavonoids has been used
to mitigate the bitterness of citrus juices, which is primarily caused
by naringin. Rhamnose removal from naringin allows softening the
bitter taste of citrus juice [15,16]. Moreover, the corresponding
de-rhamnosylated compound, prunin, is endowed with antimicro-
bial properties [14], and shows an improved intestinal assimilation
when compared to naringin. Other applications of !-RHAs are gain-
ing popularity in the oenological industry, where these enzymes are
used to hydrolyze terpenyl glycosides and enhance aroma in wine,
grape juices and derived beverages [17–19].
Application of !-RHAs to improve flavonoids bioavailability has
also been recently described [20]. In humans, flavonoids absorp-
tion occurs primarily in the small intestine where the attached
glucose (or possibly arabinose or xylose) is removed by endoge-
nous "-glucosidases [21–23]. Terminal rhamnose is not a suitable
substrate for human "-glucosidases. Therefore, unabsorbed rham-
nosylated flavonoids arrive unmodified in the colon, where they
are hydrolyzed by !-rhamnosidase activities expressed by the local
microflora [24]. To improve intestinal absorption of rhamnosylated
flavonoids, and thus their bioavailability in humans, a removal of
the terminal rhamnose group catalyzed by !-RHAs would be indeed
beneficial [25–27].
The absence of human !-RHAs has been the key to the devel-
opment of a novel targeted drug delivery strategy, indicated as
LEAPT (Lectin-directed enzyme activated prodrug therapy) [28,29],
a bipartite system based on the internalization of an engineered
!-RHA bearing a glycosidic moiety that is recognized by specific
lectins present on the surface of different eukaryotic cell lines. In the
LEAPT system, the intake of a rhamnosylated prodrug, which can-
not be processed by mammalian enzymes, allows a site-selective
action of the drug in cells where the engineered !-RHA has been
prelocalized.
To date, microbial !-RHAs have been mainly purified from fun-
gal strains such as Penicillium and Aspergillus [30–32]; only one
example of !-RHA isolated from a viral source has been described
[33], and it is noteworthy that only a limited number of bacte-
rial rhamnosidases has been fully characterized [34–39]. One of
the main differences between fungal and bacterial !-RHAs is their
different optimal pH values, with the fungal enzymes showing
more acidic pH optima when compared to the bacterial counter-
parts, for which neutral and alkaline values have generally been
described. This characteristic suggests diverse applications for fun-
gal and bacterial enzymes, making bacterial !-RHAs suitable in
biotechnological processes requiring good activity in more basic
solutions such as, for example, the production of L-rhamnose from
the hydrolysis of naringin or hesperidin, flavonoids whose solubil-
ity strongly increases at higher pH values [40]. In addition, bacterial
rhamnosidases could be ideal candidates for dietary supplements
having activity across the entire gastrointestinal (GI) tract, and
more specifically in the small intestine where flavonoids absorp-
tion should mostly occur to enhance the beneficial effect of these
molecules on human health.
In order to elucidate the real biotechnological potential of bac-
terial !-RHAs, further investigation is undoubtedly needed. Few
details on the catalytic mechanism of bacterial !-RHAs are avail-
able, and most importantly, to the best of our knowledge, no
attempt to improve the catalytic efficiency or modify substrate
specificity of these enzymes by mutagenesis has been performed
yet. This is in part consequential to the fact that only a very limited
number of crystal structures of !-RHAs are currently available, such
as the !-l-rhamnosidase B (BsRhaB) from Bacillus sp. GL1 [41], and
the !-l-rhamnosidase from Streptomyces avermitilis [42]. There-
fore, it is evident that bacterial !-RHAs represent a yet unexplored
reservoir of potential biocatalysts for which more functional and
structural data are required.
A member of the order of the Sphingomonadales, recently iso-
lated and microbiologically characterized, Novosphingobium sp.
PP1Y [43,44], appears to be a valuable source for the isolation
of !-RHA activities. Sphingomonadales are a group of Gram-
negative !-proteobacteria whose genomes show the presence of
a great abundance of both glycosyl hydrolases (GHs) and gly-
cosyltransferases (GTs). These activities are probably involved in
the biosynthesis of complex extracellular polysaccharides and
microbial biofilms [45]. The interest for Novosphingobium sp. PP1Y
carbohydrate-active enzymes has grown as the sequencing and
annotation of the whole genome, recently completed, allowed the
identification of a great number of genes encoding for both GHs (53
orfs) and GTs (57 orfs) [46].
Recently, a !-RHA activity in Novosphingobium sp. PP1Y crude
extract was described, which showed an alkaline pH optimum and
a moderate tolerance to organic solvents [47]. Novosphingobium sp.
PP1Y crude extract expressing this enzymatic activity was used for
the bioconversion of naringin, rutin and hesperidin. Based on these
preliminary results, a more detailed biochemical characterization
of the !-RHA activity was essential.
In this work, the isolation, recombinant expression and par-
tial characterization of a !-RHA from Novosphingobium sp. PP1Y is
reported. This enzyme, named RHA-P, belongs to the GH106 family
[48], a subgroup for which, according to our knowledge, no crystal
structure is available yet. As evident from our analyses, RHA-P is a
promising candidate for several biotechnological applications.
2. Materials and methods
2.1. Generals
General molecular biology techniques were performed accord-
ing to Sambrook et al. [49]. Bacterial growth was  followed by
measuring the optical density at 600 nm (OD600). pET22b(+)
expression vector and E. coli strain BL21(DE3) were from Amersham
Biosciences; E. coli strain Top10 was purchased from Life Technolo-
gies. N. sp. PP1Y was isolated from polluted seawater in the harbor
of Pozzuoli (Naples, Italy) as previously described [43].
The thermostable recombinant DNA polymerase used for PCR
amplification was  TAQ Polymerase from Microtech Research Prod-
ucts. dNTPs, T4 DNA ligase, and the Wizard PCR Preps DNA
purification system for elution of DNA fragments from agarose gels
were purchased from Promega. The QIAprep Spin Miniprep Kit for
plasmid DNA purification was  from QIAGEN. Enzymes and other
reagents for DNA manipulation were from New England Biolabs.
Oligonucleotides synthesis and DNA sequencing were performed
by MWG-Biotech. N-terminus of rRHA-P was  sequenced by Pro-
teome Factory AG. The presence and location of a potential signal
peptide cleavage site on the amino acidic sequence of RHA-P was
analyzed using SignalP 4.1 server (http://www.cbs.dtu.dk/services/
SignalP).
Q-Sepharose Fast Flow and p-nitrophenyl-!-l-
rhamnopyranoside (pNPR) were from Sigma Aldrich; Sephacryl
S200 High Resolution was purchased from Amersham Biosciences.
IPTG (isopropyl "-d-1-thiogalactopyranoside) was obtained from
Applichem.
Solvents used in enzymatic assays were either from Applichem
(DMSO) or from Romil (acetone). TLC silica gel plates were from E.
Merck (Darmstadt, Germany).
138 F. De Lise et al. / Journal of Molecular Catalysis B: Enzymatic 134 (2016) 136–147
2.2. Growth of Novosphingobium sp. PP1Y cells
N. sp. PP1Y cells were grown in Potassium Phosphate Minimal
Medium (PPMM)  at 30 ◦C for 28 h under orbital shaking at 220 rpm.
A pre-inoculum in LB was  prepared by transferring 50 #L from a
glycerol stock stored at − 80 ◦C to a 50 mL  Falcon tube containing
12.5 mL  of sterile LB. The pre-inoculum was allowed to grow at
30 ◦C O/N under orbital shaking and then used to inoculate 1 L of
PPMM at an initial cell concentration of 0.01- 0.02 OD600. 0.3 mM
naringine was added to the medium and used as an inducer of the
!-RHA activity, as previously described [47].
2.3. Cloning of orfPP1Y RS05470 and construction of the
pET22b(+)/rha-p expression vector
Genomic DNA was extracted from a 50 mL  saturated culture
of N. sp. PP1Y as described elsewhere [44]. OrfPP1Y RS05470
coding for the !-RHA activity was amplified in two contigu-
ous fragments, owing to the considerable length of the orf
(3441 bp). The first fragment, named rha-up (1816 bp), was
amplified using an internal downstream primer, RHA-Intdw (5′-
AGGCGGCCATGGGAATGT-3′), which included an internal NcoI site
already present in orfPP1Y RS05470, and an upstream primer, RHA-
up (5′-GGGAATTCCATATGCCGCGCCTTTCGCT-3′), designed to add
a NdeI restriction site at 5′ of orfPP1Y RS05470. The second half
of the gene, named rha-dw (1625 bp), was amplified using the
upstream primer RHA-Intup (5′-ACATTCCCATGGCCGCCT-3′), com-
plementary to RHA-Intdw, and the downstream primer RHA-dw
(5′-AAAACCGAGCTCTCAATGCCCGCCCGTG-3′) that was  intended to
incorporate a SacI restriction site downstream of the amplified orf.
The amplified fragments, rha-up and rha-dw, were purified from
agarose gel, digested, respectively, with NdeI/NcoI and NcoI/SacI,
and individually cloned in pET22b(+) vector previously cut with
the same enzymes.
Ligated vectors were used to transform E. coli, strain Top10,
competent cells. The resulting recombinant plasmids, named
pET22b(+)/rha-up and pET22b(+)/rha-dw,  were verified by DNA
sequencing. Next, the construction of complete rha-p gene in
pET22b(+) was performed. First, both pET22b(+)/rha-dw and
pET22b(+)/rha-up were digested with NcoI/SacI restriction endonu-
cleases to obtain, respectively, fragment rha-dw and linearized
pET22b(+)/rha-up.
Digestion products were purified from agarose gel electrophore-
sis, eluted and ligated. Ligation products were used to transform E.
coli Top10 competent cells and the resulting recombinant plasmid,
named pET22b(+)/rha-p was verified by DNA sequencing.
2.4. ˛-l-Rhamnosidase recombinant expression
Protein expression was carried out in E. coli BL21(DE3) strain
transformed with pET22b(+)/rha-p plasmid.
All the media described in this paragraph contained 100 #g/mL
of ampicillin.
2.4.1. Analytical expression
E. coli BL21(DE3) competent cells transformed with plasmid
pET22b (+)/rha-p were inoculated in a sterile 50 mL  Falcon tube
containing 12.5 mL  of either LB [50] or LB containing a final con-
centration of 0.5 M NaCl (LB-N). Cells were grown under constant
shaking at 37 ◦C up to 0.6–0.7 OD600. This preinoculum was  diluted
1:100 in 12.5 mL  of either one of the four following media: LB, LB-N,
LB supplemented with 1 mM of both betaine and sorbitol (LB-BS), or
LB containing a final concentration of 0.5 M NaCl and 1 mM of both
betaine and sorbitol (LB-NBS). Cells were grown under constant
shaking at 37 ◦C up to 0.7–0.8 OD600. RHA-P recombinant expres-
sion was induced with 0.1 mM IPTG at either 23 ◦C or 37 ◦C; growth
was continued in constant shaking for 3 h. Cells were collected
by centrifugation (5,524 × g for 15 min  at 4 ◦C) and suspended in
25 mM MOPS pH 6.9 at a final concentration of 14 OD600. Cells were
disrupted by sonication (12 times for a 1-min cycle, on ice) and an
aliquot of each lysate was  centrifuged at 22,100 × g for 10 min  at
4 ◦C. Both soluble and insoluble fractions were analyzed by SDS-
PAGE. The soluble fraction was  assayed for the presence of !-RHA
enzymatic activity.
2.4.2. Large scale expression
Fresh transformed cells were inoculated into 10 mL of LB-N and
incubated in constant shaking at 37 ◦C O/N. The preinoculum was
diluted 1:100 in four 2 L Erlenmeyer flasks containing each 500 mL
of LB-NBS and incubated in constant shaking at 37 ◦C up to 0.7–0.8
OD600.
Expression of the recombinant protein, named rRHA-P, was
induced with 0.1 mM IPTG and growth was  continued for 3 h at
23 ◦C. Cells were collected by centrifugation (5,524 × g for 15 min
at 4 ◦C) and stored at − 80 ◦C until needed.
2.5. Native and recombinant ˛-l-rhamnosidase purification
Both native and recombinant RHA-P were purified following
three chromatographic steps. Cell paste was suspended in 25 mM
MOPS pH 6.9, 5% glycerol (buffer A), at a final concentration of 100
OD600 and cells were disrupted by sonication (10 times for a 1-
min  cycle, on ice). Cell debris were removed by centrifugation at
22,100 × g for 60 min  at 4 ◦C and the supernatant was collected and
filtered through a 0.45 #m PVDF Millipore membrane.
Afterwards, cell extract was loaded onto a Q Sepharose FF col-
umn  (30 mL)  equilibrated in buffer A. The column was washed with
50 mL  of buffer A, after which bound proteins were eluted by using a
300 mL  linear gradient of buffer A from 0 to 0.4 M NaCl at a flow rate
of 15 mL/h. The chromatogram was obtained by analyzing fractions
absorbance at $ = 280 nm and the presence of the recombinant !-
RHA activity was  detected using the pNPR assay. Relevant fractions
were analyzed by SDS-PAGE, pooled and concentrated at a final vol-
ume  of ∼ 0.5 mL  using a 30 kDa Amicon ultra membrane, Millipore.
The sample was then loaded onto a Sephacryl HR S200 equilibrated
with buffer A containing 0.2 M NaCl (buffer B).
Proteins were eluted from the gel filtration column with 250 mL
of buffer B at a flow rate of 12 mL/h. Fractions were collected, ana-
lyzed and screened for the presence of !-RHA activity as previously
described. At this stage, NaCl was removed from pooled fractions
by repeated cycles of ultrafiltration and dilution with buffer A. The
sample was then loaded on a Q Sepharose FF column (30 mL)  equi-
librated in buffer A. The column was  washed with 50 mL  of buffer
A, after which bound proteins were eluted with 300 mL  of a linear
gradient of buffer A from 0 to 0.25 M NaCl at a flow rate of 13 mL/h.
Fractions were collected, analyzed by SDS-PAGE and screened for
the presence of !-RHA activity. Relevant fractions were pooled,
concentrated, purged with nitrogen, and stored at − 80 ◦C until use.
2.6. Analytical gel filtration
Analytical gel-filtration experiments were carried out as fol-
lows: 100 #L of a 40 pM protein sample was  loaded on a Superdex
200 HR 10/300 column previously equilibrated in buffer B, installed
on an AKTATMFPLCTM (GE Healthcare Life Science). Samples were
eluted isocratically at RT at a flow rate of 0.5 mL/min. Protein elu-
tion was  monitored at $ = 280 nm.  A molecular weight calibration
was performed in the same buffer with the following proteins of
known molecular weight: "-amylase (200 kDa), glyceraldehyde-3-
phosphate dehydrogenase (143 kDa), carbonic anhydrase (29 kDa).
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2.7. Enzyme activity assays
!-RHA activity was determined using pNPR as substrate (pNPR
assay). Otherwise stated, all activity assays were performed
at RT. The reaction mixture contained, in a final volume of
0.5 mL  of 50 mM MOPS pH 6.9, pNPR at a final concentration of
600 #M and variable amounts of the sample tested. The reac-
tion was blocked after 10 and 20 min  by adding 0.5 M Na2CO3;
the product, p-nitrophenolate (pNP), was detected spectropho-
tometrically at $= 405 nm.  The extinction coefficient used was
%405 = 18.2 mM− 1 cm− 1. One unit of enzyme activity was defined
as the amount of the enzyme that releases one micromole of pNP
per min.
2.7.1. Kinetic parameters determination
Kinetic parameters were obtained at pH 6.9 using a pNPR con-
centration in the range 0.025–1 mM.  All kinetic parameters were
determined by a non-linear regression curve using GraphPad Prism
(GraphPad Software; www.graphpad.com).
2.7.2. pH optimum
pH optimum for !-RHA activity was determined in the range
4.7–8.8. Enzyme assays were performed as described above, using
the following buffers: 50 mM potassium acetate (pH 4.7–5.7),
50 mM MOPS/NaOH (pH 5.7–7.7) and 50 mM Tris/HCl (pH 7.7–8.8).
2.7.3. Temperature optimum and stability
Optimum temperature was evaluated by performing the stan-
dard pNPR assay and incubating the reaction mixture at different
temperatures, in the range 25–55 ◦C.
The thermal stability of the enzyme was determined by incubat-
ing the enzyme for one and 3 h at 30, 40, 50, 60 ◦C and measuring,
after each incubation, the residual specific activity.
2.7.4. Organic solvents tolerance
The tolerance of the enzymatic activity to the presence of
organic solvents in the reaction mixture, such as DMSO, acetone
or ethanol, was evaluated by performing the standard pNPR assay
in 50 mM MOPS pH 6.9 to which either 10% or 50% of solvent was
added.
2.8. Substrate specificity
Reactions were carried out in 0.6 mL  of 50 mM Na-phosphate
buffer pH 7.0 under magnetic stirring at 40 ◦C in the presence of
20 mM of either aryl glycoside and 0.25 U of rRHA-P. Reactions
were monitored over time (0–24 h) by TLC analysis (system sol-
vent: EtOAc:MeOH:H2O 70:20:10). Compounds on TLC plates were
visualized under UV light or charring with !-naphthol reagent.
Hydrolysis reactions of maltose, pullulan, starch, amylopectin,
sucrose, raffinose, lactose, xylan from birchwood, xylan from oat
spelt, hyaluronic acid, ! −  cellulose, cellobiose, chitosan, "-Glucan
from barley, laminarin, curdlan, fucoidan from Fucus versiculo-
sus, rhamnogalacturonan, rutinose were performed using 2.5 mg
of each substrate, which was suspended in 0.5 mL  of 50 mM Na-
phosphate buffer pH 7.0. The reaction was carried out at 40 ◦C under
magnetic stirring, in the presence of 0.25 U of rRHA-P. Hydrol-
ysis products were monitored by TLC analysis (system solvent
HCOOH:HAc:H2O:2-propanol: EtOAc:1:10:15:5:25).
Flavonoidic compounds such as naringin, rutin, neohesperidin
dihydrochalcone, were screened as possible substrates. In this case,
a 6 mM solution of each compound in a final volume of 1 mL  of
50 mM Na-phosphate buffer pH 7 was incubated at 40 ◦C in the
presence of 0.25 U of rRHA-P. Reactions were checked over time
by TLC analysis (t = 0, 15′, 30′, 60′, 90′, 120′, 150′, 180′, 24 h) with
the following solvent system: EtOAc:MeOH:H2O 70:20:10. An addi-
tional hydrolysis reaction of naringin was performed in conditions
similar to those reported above in the presence of 10% DMSO, and
the reaction was monitored over time.
In all experiments, TLC standard solutions of pure reagents and
products were used for comparison.
2.9. Mass spectrometry analysis
Identification of native and recombinant RHA-P by mass spec-
trometry was performed by enzymatic digestion, either in solution
or in situ after separation by SDS-PAGE.
When digesting in solution, the protein sample was lyophilized
and then dissolved in denaturing buffer (300 mM Tris/HCl pH
8.8, 6 M urea, 10 mM EDTA). Cysteines were reduced with 10 mM
dithiothreitol in denaturing buffer at 37 ◦C for 2 h, and then car-
bamidomethylated with 55 mM iodoacetamide dissolved in the
same buffer at RT for 30 min, in the dark. Protein sample was
desalted by size exclusion chromatography on a Sephadex G–25 M
column (GE Healthcare, Uppsala, Sweden). Fractions containing
RHA-P were lyophilized and then dissolved in 10 mM NH4HCO3
buffer (pH 8.0). Enzyme digestion was performed using proteases
with different specificity such as trypsin, chymotrypsin and endo-
proteinase GluC (V8-DE) (Sigma), using a protease/RHA-P ratio of
1:50 (w/w) at 37 ◦C for 16 h.
For the enzymatic digestion in situ, Coomassie blue stained
bands excised from polyacrylamide gels were destained by
several washes with 0.1 M NH4HCO3 pH 7.5 and acetonitrile. Cys-
teines were reduced for 45 min  in 100 #L of 0.1 M NH4HCO3,
10 mM dithiothreitol, pH 7.5. Carbamidomethylation of thiols was
achieved after 30 min  in the dark by adding 100 #L of 55 mM
iodoacetamide dissolved in the same buffer. Enzymatic digestion
was carried out on different bands of RHA-P by using 100 ng of
proteases with different specificity (same as above) in 10 mM
NH4HCO3 buffer, pH 7.5. Samples were incubated for 2 h at 4 ◦C.
Afterwards, the enzyme solution was removed and a fresh pro-
tease solution was  added; samples were incubated for 18 h at 37 ◦C.
Peptides were extracted by washing the gel spots/bands with ace-
tonitrile and 0.1% formic acid at RT, and were filtered using 0.22 um
PVDF filters (Millipore) following the recommended procedures.
Peptide mixtures were analyzed either by matrix-assisted laser-
desorption/ionization mass spectrometry (MALDI-MS) or capillary
liquid chromatography with tandem mass spectrometry detection
(LC–MS/MS).
MALDI-MS experiments were performed on a 4800 Plus MALDI
TOF/TOF mass spectrometer (Applied Biosystems, Framingham,
MA)  equipped with a nitrogen laser (337 nm). The peptide mixture
(1 #L) was  diluted (1:1, v/v) in acetonitrile/50 mM citrate buffer
(70:30 v/v) containing 10 mg/mL  of !-cyano-4-hydroxycinnamic
acid. Mass calibration was  performed using external peptide stan-
dards purchased from Applied Biosystems.
Spectra were acquired using a mass (m/z) range of
300–4000 amu  and raw data were analyzed using Data Explorer
Software provided by the manufacturer. Experimental mass
values were compared with calculated masses derived from an in
silico digestion of RHA-P obtained with different proteases, using
MS-Digest, a proteomics tool from Protein Prospector software
(prospector.ucsf.edu/).
Peptide mixtures were analyzed by nanoLC–MS/MS on a CHIP
MS  6520 QTOF equipped with a capillary 1200 HPLC system and a
chip cube (Agilent Technologies, Palo Alto, Ca). After sample load-
ing, the peptide mixture was first concentrated and then washed at
4 nL/min in a 40 nL enrichment column (Agilent Technologies chip)
with 2% acetonitrile + 0.1% formic acid.
The sample was  then fractionated on a C18 reverse-phase cap-
illary column at a flow rate of 400 nL/min by using a two-solvents
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system consisting of 2% acetonitrile + 0.1% formic acid (solvent A)
and 95% acetonitrile + 0.1% formic acid (solvent B). Separation was
carried out with a 50 min  linear gradient from 5 to 60% of solvent
B.
Peptide analysis was performed using data-dependent acquisi-
tion of one MS  scan (mass range from 300 to 2,000 m/z) followed
by MS/MS  scans of the five most abundant ions in each MS  scan.
MS/MS  spectra were acquired automatically when the MS  sig-
nal detected upraised the threshold of 50,000 counts. Double and
triple charged ions were isolated and fragmented. The acquired
MS/MS  spectra were transformed in Mascot Generic format (.mgf)
and used to query either a NCBInr 02-2015 (21,322,359,704 amino
acid sequences; 10,835,265,410 residues) or a N. sp. PP1Y (4635
aminoacid sequences; 1,493,994 residues) sequence database.
A licensed version (2.4.0.) of MASCOT software
(www.matrixscience.com) was used with the following search
parameters: trypsin, chymotrypsin or GluC endoproteinase as
enzyme; 3 or 2 as allowed number of missed cleavages; car-
bamidomethylation of cysteines as fixed modification; 10 ppm
MS  tolerance and 0.6 Da MS/MS  tolerance; peptide charge from
+2 to +3. Oxidation of methionine and formation of pyroglutamic
acid from glutamine residues at the N-terminal position of pep-
tides were considered as variable modifications. Ions score is
− 10*Log(P), where P is the probability that the observed match is a
random event. Individual ions score >14 indicate identity or exten-
sive homology (p < 0.05). Protein scores derive from ion scores
as a non-probabilistic basis for ranking protein hits. Individual
ion score threshold provided by MASCOT software, necessary to
evaluate the quality of matches in MS/MS  data and to calculate
protein score, was 52 in NCBInr database and 14 in PP1Y Database.
In Table 1 only peptides with ion score ≥ 10 are reported.
2.10. NMR  Analysis
All the experiments were performed at 298 K on a Bruker
600 MHz  DRX spectrometer equipped with a cryo probe. pNPR was
dissolved in D2O to a final concentration of 3 mM in a 5-mm NMR
tube. The ligand proton resonances were assigned by a combina-
tion of 1D and 2D NMR  experiments including COSY, TOCSY and
HSQC. 1H NMR  spectra were acquired with 32 k data points. Dou-
ble quantum-filtered phase sensitive COSY and TOCSY experiments
were performed by using data sets of 2096 × 256 (t1 x t2) points.
Total Correlation Spectroscopy (TOCSY) spectrum was recorded
with a spin lock time of 100 ms.  Heteronuclear single quantum
coherence (HSQC) experiment was measured in the 1H-detected
mode via single quantum coherence with proton decoupling in
the 13C domain, by using data sets of 2048 × 256 points. Experi-
ments were carried out in the phase-sensitive mode according to
the method of States and coworkers [51]. In all homonuclear spec-
tra the data matrix was zero-filled in the F1 dimension to give a
matrix of 4096 × 2048 points and resolution was enhanced in both
dimensions by a cosine-bell function before Fourier transformation.
After the acquisition of the initial spectra of the ligand alone,
rRHA-P was added to a final concentration of ∼1 #M (∼60 #g) in
the NMR  tube from a ∼5.9 #M solution in 25 mM MOPS contain-
ing 5% glycerol. The NMR  sample was immediately placed in the
spectrometer probe to record experiments on the mixture.
Data acquisition and processing were performed with TOPSPIN
2.1 software.
2.10. Analytical methods
Protein concentration was measured using the Bio-Rad Pro-
tein System [52] using bovine serum albumin (BSA) as standard.
Polyacrylamide gel electrophoresis was carried out using standard
techniques [53]. SDS–PAGE 15% Tris–glycine gels were run under
denaturing conditions and proteins were stained with Coomassie
brilliant blue G-250. “Wide range” (200–6.5 kDa) molecular weight
standard was from Sigma (ColorBurstTM Electrophoresis Marker).
3. Results
3.1. Isolation and identification of a ˛-RHA from
Novosphingobium sp. PP1Y
In a previous work [47], a !-RHA activity was detected in the
crude extract of N. sp. PP1Y grown in minimal medium and in the
presence of 0.3 mM naringin. In order to identify and characterize
this enzymatic activity, N. sp. PP1Y cells were grown under the same
experimental conditions described by the authors [47]. Cells were
collected by centrifugation after 24 h of growth in PPMM (optical
density of ∼1 OD600) at 5,524 × g for 15 min  at 4 ◦C. !-RHA purifi-
cation was  carried out following the procedures described in this
work in Materials and Methods. In all three chromatographic steps
used for the purification of N. sp. PP1Y crude extract, a unique peak
of !-RHA activity was always detected, but no major protein band
was ever evident from the SDS-PAGE analysis of the corresponding
active fractions (data not shown).
Peak fractions obtained from the first two chromatographic
steps were digested with trypsin and analyzed by LC–MS/MS
analysis. Raw data were used to search NCBI database (Bacte-
ria as taxonomy restriction) with the MS/MS  ion search program
of Mascot software. Among the identified proteins, a mem-
ber of the glycoside hydrolase family (Novosphingobium sp.
PP1Y:WP 013837086.1) was  identified with 10 (20% of sequence
coverage) and 32 peptides (46% of sequence coverage) in the first
and in the second chromatographic step, respectively (data not
shown). The putative MW,  deduced from the amino acid sequence,
was of 124,225 Da.
Peak fractions obtained from the last chromatographic step (Q-
sepharose) showed the presence of a relatively limited number of
protein bands (Fig.S1, Supplementary material). Five bands migrat-
ing as expected for proteins of MW higher than 100 kDa were
selected and excised from the polyacrylamide gel stained with Col-
loidal Coomassie Blue. Bands were digested in situ with trypsin,
and the resulting peptides mixture was analyzed by LC–MS/MS.
Raw data were used to search NCBI database (Bacteria as taxonomy
restriction) with MASCOT software.
One of the protein bands analyzed, indicated in Fig. S1 by a
red arrow, was  identified (52 peptides, 71% sequence coverage,
Table 1) as the protein encoded by the orfPP1Y RS05470; this latter
is located in one of the extrachromosomal elements of N. sp. PP1Y,
the Megaplasmid referred to as Mpl  [44]. This protein, from now
on indicated as RHA-P, had been previously annotated as a mem-
ber of the GHs family and is composed by 1,146 aa for a calculated
molecular weight of about 124,225 Da.
3.2. Cloning, recombinant expression and purification of
recombinant RHA-P
The recombinant plasmid pET22b(+)/rha-p (Materials and
Methods), in which orf PP1Y RS05470 was cloned, was  used to
transform E. coli BL21(DE3) strain. First attempts of expression of
the recombinant protein at 37 ◦C showed the presence of a protein
band with the expected molecular weight of recombinant RHA-P
(rRHA-P) almost exclusively in the insoluble fraction of the induced
culture (Fig. S2). As evident from Fig. S2 of the Supplementary mate-
rial, when E. coli was instead induced at 23 ◦C [54], the presence of
a protein band with the expected MW for rRHA-P in the soluble
fraction (lane 5) appeared to be markedly increased when com-
pared to the soluble fraction obtained after an induction performed
F. De Lise et al. / Journal of Molecular Catalysis B: Enzymatic 134 (2016) 136–147 141
Table  1
Identification of native RHA-P by in situ digestion followed by LC–MS/MS analysis.
Protein [Species] NCBInr
Accession number
Mass Protein score Sequence coverage (%) n◦ of peptides Ion scorea and peptide sequence
Glycoside hydrolase family
protein [Novosphingobium sp.
PP1Y]
gi|334145605|ref|
WP  013837086.1|
124,225 2318 71 52 34 R.TGDAIK.A
31 R.VGGFYGK.G
38 R.GVVQNEK.R
28 R.LDNELVR.G
21 R.GPEIEPVK.A
11 R.VLPITGRK.A
19KVGSKNEPR.G
37 R.AVAEAAFDK.V
42 R.GVVQNEKR.Q
48KLSSPNAMALR.A
13KLSSPNAMALR.A+Oxidation (M)
37  R.DITDQVPVLR.L
13 R.ITVVGDITMDR.L
41 R.ITVVGDITMDR.L+Oxidation (M)
32 R.LGRPEDYYVK.L
17KAPIVSVTLYYK.V
24KVEKWFGQIPR.G
55KVGLHILGGLASSR.L
52 R.VKAQAEAELAQK.L
61 R.LDATAIAEAQER.L
35 R.TFVVSAPVQADR.T
28 R.MGWLLPAVTQDK.L
15 R.MGWLLPAVTQDK.L+Oxidation (M)
27 R.KAPIVSVTLYYK.V
52 R.DLAAMAALTPAQVK.A
70 R.DLAAMAALTPAQVK.A+Oxidation (M)
74 R.AVVSTLSGEIGGLER.V
32 R.LKPMLEQAFGAWK.A
31 R.LKPMLEQAFGAWK.A+Oxidation (M)
74KGATLAEGQVYSDDPAK.Y
28 R.RAVVSTLSGEIGGLER.V
50KFVLANGLTTIVHTDR.K
18KSAAPVKPLGAAVPAAQGR.I
23 R.NWTAPGINDPDTPALK.V
37 R.MGWLLPAVTQDKLDK.Q
33 R.MGWLLPAVTQDKLDK.Q+Oxidation (M)
47 R.AVAEAAFDKVLADYLR.D
65 R.ALPNQFETNAAVQAAIR.K
25KGWSYGVYSSVTQPTGPR.T
29KWMSRPVYALNVVPGPR.T
26KWMSRPVYALNVVPGPR.T+Oxidation (M)
20 R.TFVVSAPVQADRTGDAIK.A
18KGATLAEGQVYSDDPAKYK.R
36 R.IVLIDRPNSPQSVIMAGR.V
43 R.IVLIDRPNSPQSVIMAGR.V+Oxidation (M)
58KADTEALGLANDVLGGGFLSR.L
47 R.GPEIEPVKAGPVTLPAPLSR.D
55 R.HATIGSMADLDAATLTDVRK.W
56 R.HATIGSMADLDAATLTDVRK.W+Oxidation (M)
21 R.EEKGWSYGVYSSVTQPTGPR.T
46KAIIADVGAFPGQKPITQEELQR.V
70 R.TNYVETVPTGALDLALFMESDR.M
50 R.AIEASANEFLRPGGMTYVVVGDR.K
59 R.AIEASANEFLRPGGMTYVVVGDR.K+Oxidation (M)
65 R.AIEASANEFLRPGGMTYVVVGDRK.I
54 R.QGDNQPYGLFDYAQADGLLPVGHPYR.H+
Gln->pyro-Glu (N-term Q)
71 R.QGDNQPYGLFDYAQADGLLPVGHPYR.H
23 R.LNKDLREEKGWSYGVYSSVTQPTGPR.T
38KWFTEHYGPNNVVLVLSGDIDAATARPK.V
35KIVEPQLEGLGLPIDVQQAPQAAADDQSVE.-
55 R.KIVEPQLEGLGLPIDVQQAPQAAADDQSVE.-
40 R.ALGSTLFGQHPYAQPTDGLGNAASLAALTPAALR.A
a In the table only peptides with ion score ≥10 are reported.
at 37 ◦C (lane 3). Neither the use of different IPTG concentrations
nor the variation of the induction time seemed to improve rRHA-P
solubility.
To increase the yield of active rRHA-P in the soluble fraction of
cell cultures induced at 23 ◦C, a novel set of analytical expression
experiments using either LB or LB-N (Materials and Methods) sup-
plemented with 1 mM of both betaine and sorbitol (two osmolytes),
were performed. Data in literature suggest that the addition of
these molecules to the growth medium of induced recombinant
cells of E. coli might increase protein solubility. This effect should
be improved by the co-presence in the medium of a high salt con-
centration (LB-N medium), which might i) increase the uptake rate
in the cytoplasm of betaine and sorbitol from the extracellular
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Table 2
Purification Table of rRHA-P.
Total Unitsb Specific Activity
(Units/mg)b
P.F.a Yield (%)
Cell lysate 13,728.8 49.8
I  Q-Sepharose 5,939.6 54.7 1.1 43.3
Gel  filtration 1,370.6 66.1 1.3 9.9
II  Q-Sepharose 920.9 346.9 6.9 6.7
a Purification Factor.
b Standard deviations, expressed as percentage errors, were always within 20%.
Fig. 1. SDS-PAGE analysis of rRHA-P purification steps. Lane 1: MW standard. Lane
2:  cell lysate of E. coli strain BL21(DE3). Lane 3: peak fraction after the first Q-
sepharose. Lane 4: peak fraction after S200-gel filtration chromatography. Lane 5:
purified rRHA-P; the red arrow in this line indicates the contaminant protein found
at  the end of purification. For each sample an amount of ca. 4 #g of total proteins
was  loaded. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
environment [55], and/or ii) induce the expression of additional
heat-shock proteins assisting in protein folding [56].
For these experiments, IPTG concentration and induction time
were respectively 0.1 mM and 3 h. Activity assays showed that the
best expression of active rRHA-P was obtained inducing the cul-
tures at 23 ◦C and using LB-NBS (LB-N to which 1 mM of both
betaine and sorbitol were added) as growth medium. In this case,
specific activity of cell extract was 46 times higher than what
obtained with the soluble fraction of recombinant cells grown in
LB and induced at 37 ◦C.
Large-scale recombinant expression was performed by using the
optimized conditions suggested by the analytical experiments.
rRHA-P purification was carried out following three different
chromatographic steps. The purification table (Table 2) showed a
final purification factor (PF) of 6.9. SDS-PAGE analysis of peak frac-
tions representative of each purification step (Fig. 1) showed in the
final purified sample of rRHA-P the additional presence of a major
contaminant protein with an approximate MW of ∼35 kDa.
The 35 kDa protein band was excised, digested in situ with
trypsin and analyzed by LC–MS/MS. The protein, identified by
searching the E. coli sequence database (Materials and Methods),
resulted to be glyceraldehyde 3-phosphate dehydrogenase, as iden-
tified by 17 peptides matches for a sequence coverage of 71%.
Purified rRHA-P amino acidic sequence was verified up to a
94% coverage, by MS  Mapping analysis carried out by MALDI-TOF
and LC–MS/MS. However, it is worth noting that the protein N-
terminus, detected by MS  analysis, lacks the first 23 amino acids
from the expected cloned sequence (Fig. 2 and Fig. S3).
To confirm the lack of the putative N-terminal peptide, purified
rRHA-P was subjected to both a MALDI-TOF and LC–MS/MS analysis
after an in situ digestion with either trypsin or chymotrypsin, and
to the N-terminus sequencing. Mass spectrometry analysis allowed
the identification of peptides 23ESRDDAAEVAPSTRPEPSLEQAF45
(MH+ 2502.17 ppm) and 23ESRDDAAEVAPSTR36 (MH+ 1503.70)
when rRHA-P was digested with chymotrypsin or trypsin, respec-
Table 3
TLC results of RHA-P-catalyzed reaction using different pNP-!- and pNP-"- deriva-
tives as substrates.
Substratesa Hydrolysis Transglycosylation
3 h 20 h 3 h 20 h
1 pNP-!-d-Glcp – – – –
2  pNP − "-d-Glcp – – – –
3  pNP − !-d-Galp – – – –
4  pNP − "-d-Galp – – – –
5  pNP − !-d-Manp – – – –
6  pNP − "-d-Manp – – – –
7  pNP − "-d-Xylp – – – –
8  pNP − !-l-Fucp – – – –
9  pNP − "-d-Fucp – – – –
10  pNP − !-l-Araf – – – –
11  pNP − "-l-Araf – – – –
12  pNP − !-l-Rhap + + – –
13  pNP "-GlcAp – – – –
14  pNP "-d-NAGlcp – – – –
15  pNP "-d-NAGalp – – – –
a Ara, arabinose; Fuc, fucose; Gal, galactose; Glc, glucose; Man, mannose; NAGlc,
N-acetylglucosamine; NAGal: N-acetylgalactosamine, GlcA: glucuronic acid, Rha,
Rhamnose; Xyl, xylose.
tively. This evidence was  also confirmed by N-terminus sequencing
results, which showed that the first 5 amino acids of the recom-
binant protein are ESRDD. Interestingly, also in native RHA-P the
same N-terminal peptide, obtained by fragmentation spectrum of
the triple charged ion at 834.73 m/z from the in situ digestion of the
protein with chymotrypsin (Fig. S4), had been detected in the first
place. The scarce amount of native protein, however, did not allow
us to confirm the effective lack of the N-terminus peptide by direct
amino acidic sequencing.
3.3. Biochemical characterization of rRHA-P
3.3.1. Analytical gel filtration
The oligomeric state of rRHA-P was  verified by analytical gel
filtration using a Superdex 200 analytical column; the protein
eluted as a single peak with an apparent molecular weight of
101,500 ± 5,000 Da, which indicates that rRHA-P is a monomer.
3.3.2. Substrate specificity
To investigate rRHA-P substrate specificity in hydrolysis and
self-condensation processes, several pNP-!- and pNP-"- deriva-
tives were used as substrates in enzymatic assays performed as
described in Materials and Methods. Reactions were followed over
time by TLC analysis and data are reported in Table 3. As evident
from Table 3, the purified enzyme showed activity only on pNPR,
confirming that rRHA-P is indeed a !-l-rhamnosidase. Moreover,
no activity on pNP-"-d-Glc was detected, excluding that rRHA-P
might act as a naringinase, a class of glycosyl hydrolase having both
!-l-rhamnosidase and "-d-glucosidase activities [40]. Further-
more, oligo- and polysaccharides such as rutinose, maltose, sucrose,
lactose, pullulan, starch, amylopectin, raffinose, xylan from birch-
wood, xylan from oat spelt, hyaluronic acid, !-cellulose, cellobiose,
chitosan, "-Glucan from barley, laminarin, curdlan, fucoidan from
Fucus versiculosus, were also tested as substrates for rRHA-P. TLC
analysis of all these reactions, performed as described in Materials
and Methods, showed the lack of activity of this enzyme on any of
these compounds.
3.3.3. Mechanism of action
To understand whether rRHA-P behaves as an inverting or a
retaining glycosidase [1], 1H NMR  spectroscopy was used to mon-
itor the stereochemical course of pNPR cleavage. As shown in
Fig. 3, after the addition of the enzyme, a mixture of ! and "
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Fig. 2. rRHA-P sequence coverage by MS  analysis. Highlighted in grey are the peptides, identified by MS  analysis (MALDI-TOF and/or LC–MSMS), of the enzymatic digestions
of  rRHA-P carried out either in situ or in solution with proteases of different specificity: trypsin, chymotrypsin and endoproteinase GluC (V8-DE). A global sequence coverage
of  94% was  obtained. Crossed is the N-terminus sequence expected for rRHA-P (reference sequence WP 013837086.1) and not retrieved, either by N-terminus or by MS
analysis.
Fig. 3. 1H NMR  analysis of pNPR after rRHA-P catalyzed hydrolysis. A. Spectrum of the ligand alone in solution (3 mM). B. Spectrum following the addition of the enzyme to
the  NMR  tube (∼60 #g), which showed the appearance of CH3 signals relative to !- and "-anomers. C. Spectrum obtained after a 30 min  reaction; a mixture of !- and "-
anomers  with a different relative ratio was observed due to emiacetal equilibrium.
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Fig. 4. rRHA-P kinetic behavior. Reaction rate expressed in #M/min  is plotted as a
function of pNPR concentration.
rhamnose anomers was observed in solution, as evident from the
presence of two different methyl group resonances. TOCSY spec-
trum allowed the assignment of both ! and " spin systems up to
the methyl group resonances located at position 6 of each rhamnose
residue. Therefore, the less shielded methyl signal was assigned to
"-rhamnose. The analysis of the intensity of the different methyl
proton signals showed that the thermodynamically unfavorable "-
rhamnose prevailed soon after the addition of rRHA-P (Fig. 3B).
Afterwards, as a consequence of the equilibrium established by a
reducing monosaccharide in water, the relative ratio of the two
peaks changed up to the point in which the ! anomeric product was
predominant (Fig. 3C). Hence, the data suggested that rRHA-P acts
as an inverting enzyme as it cleaves the !-glycoside ligand yielding
a "-anomer, which in water solution equilibrates according to the
anomeric effect.
3.3.4. Enzymatic characterization
All enzymatic assays described in this subsection are detailed
in Materials and Methods section and were performed using pNPR
as substrate. Kinetic constants on pNPR were determined using a
substrate concentration ranging from 0.025 to 1 mM.  The reaction
rate (#M/min), plotted as a function of the substrate concentration
(#M),  showed a typical Michaelis-Menten trend and is reported in
Fig. 4. KM constant was of 160.2 (±17.3) #M,  a value significantly
lower than most other !-RHAs described in literature [32,57],
indicating a higher affinity of rRHA-P for pNPR. A Vmax of 21.1
(±8.0) #M/min, a kcat of 734.4 (±212.9) sec− 1and a Ks of 4.6 (±1.7)
sec− 1#M− 1were obtained.
Fig. 6. rRHA-P tolerance to organic solvents. Data are reported as percentage of
residual specific activity (S.A.) compared to the control (25 mM MOPS, pH 6.9). MOPS
buffer is used at a final concentration of 25 mM and at pH 6.9.
rRHA-P revealed an optimal activity in the range 6.0-7.5 with an
optimum at pH 6.9 (Fig. 5A), retaining 47% and 36% of activity at pH
7.9 and 8.8, respectively. In addition, rRHA-P activity was assayed
in the temperature range 25 ◦C–55 ◦C. Data are presented in Fig. 5B
and show an optimal activity temperature at ca. 40.9 ◦C, with a 44%
retaining of its initial value up to 50 ◦C. To evaluate the thermal
stability of rRHA-P in the same range used to determine the optimal
temperature, an incubation of the purified protein for either one
or 3 h was performed at different temperatures; afterwards, the
residual rhamnosidase activity of the enzyme was  calculated (Fig.
S5). The enzymatic activity appeared to be stable between 25 and
40 ◦C, independently from the duration of the incubation. At 40 ◦C,
corresponding to the temperature optimum, the activity is stable
up to 24 h (data not shown).
In order to establish the tolerance of the enzymatic activity
of rRHA-P to the presence of organic solvents, pNPR assay in
50 mM MOPS pH 6.9 containing 10% or 50% of either DMSO, ace-
tone or ethanol was  performed (Fig. 6). While activity dramatically
decreased in all concentration of acetone and in 50% of ethanol and
DMSO, a 66% of activity was  still recovered in the presence of 10%
of either DMSO or ethanol.
3.3.5. Activity on flavonoids
The ability of rRHA-P to hydrolyze natural flavonoids was  eval-
uated. Enzymatic assays using naringin, rutin and neohesperidin
Fig. 5. rRHA-P activity assays. pH (A) and temperature (B) optimum curves. In both graphs specific activity (S.A.) is plotted as a function of pH and temperature, respectively.
The  maximum value of S.A. obtained is reported in both graphs and indicated by a black arrow.
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dihydrochalcone were performed and followed by TLC analysis,
as described in Materials and Methods. To this purpose, a 6 mM
solution of each compound was incubated with purified rRHA-P
in 50 mM Na-phosphate buffer pH 7.0 at 40 ◦C, and the reaction
was monitored by TLC analyses over time. After 3 h of incubation,
TLC analysis of the reaction mixtures showed a 40–60% hydrolysis
of neohesperidin dihydrochalcone and rutin in the corresponding
derhamnosylated neohesperidin dihydrochalcone and quercetin-
3-"-glucopyranoside (isoquercitrin). Besides, a total conversion of
naringin was observed as the corresponding products, rhamnose
and prunin, were the only compounds observed on the TLC plate.
Reaction on naringin was also carried out in the presence of 10%
DMSO. In this case, in our experimental conditions, the complete
conversion of naringin in prunin and rhamnose occurred after just
1h.
4. Discussion
!-RHAs are a group of glycosyl hydrolases (GHs) that have
attracted a great deal of attention due to their potential appli-
cation as biocatalysts in a variety of industrial processes. These
enzymes are of particular interest for the biotransformation of
several natural compounds used in pharmaceutical and food indus-
try. Enzymatic derhamnosylation catalyzed by !-RHAs can be
used, for example, in functional foods and beverages contain-
ing molecules with enhanced health-related properties. Some
examples encompass the biotransformation of natural steroids,
antibiotics, flavonoids, and terpenyl glycosides responsible for wine
aromas [2,40].
Bacterial !-RHAs are still poorly characterized, but their
biochemical properties might be of key importance for bio-
transformation processes involving reactions conditions that are
unfavorable for fungal rhamnosidases. In this work, we  have
successfully expressed and partially characterized a novel recom-
binant !-RHA from Novosphingobium sp. PP1Y, named RHA-P. The
!-RHA activity has been isolated from the native source and the
corresponding protein sequence was verified by MS  analysis. The
sequence was used for a BLAST search against all protein databases,
and resulted to be homologous to GHs present in the genomes
of several Sphingomonads; among these, a 48% sequence identity
of RHA-P with the !-RHA (rhaM) from Sphingomonas paucimobilis
FP2001, was retrieved [58]. Noteworthy, an analysis of the amino
acidic sequence of RHA-P highlighted the presence of a 23 amino
acids long signal peptide [59] located at the N-terminus of the pro-
tein.
The new !-RHA identified is encoded by orfPP1Y RS05470, a
3,441 bp gene located in Megaplasmid Mpl  of N. sp. PP1Y [44],
which was amplified and cloned into pET22b (+) plasmid to
allow for the recombinant expression in E. coli BL21(DE3) strain.
First attempts of expression of the recombinant protein, rRHA-P,
resulted in the foremost presence of the protein in the insoluble
portion of the induced cultures. A lower induction temperature,
shifted from 37 ◦C to 23 ◦C, along with the use of a high-salt LB for-
mulation containing both betaine and sorbitol, which presumably
act as “chemical chaperones”, efficiently concurred in improving
the yield of soluble, active rRHA-P [54–56].
rRHA-P was purified following a three-step purification proto-
col. The relatively poor yield obtained at the end of the purification
was not unexpected at this stage, as we chose after each step to
avoid collecting rRHA-P active fractions that showed the presence
of too many protein contaminants.
Purified rRHA-P sequence was verified by MS  mapping. It is
interesting to underline that the protein N-terminus expected from
the cloned sequence was never detected, either by MS  analysis
(both native and recombinant RHA-P) or by N-terminus sequenc-
ing (only recombinant RHA-P). The lack of this peptide, which
had been expected by a preliminary analysis of the amino acidic
sequence, confirmed the presence of a signal peptide presumably
cleaved through a post-translational proteolytic processing. A sim-
ilar evidence has been described for the !-RHA isolated from S.
paucimobilis FP2001 and recombinantly expressed in E. coli [58].
Takeshi M.  and coworkers reported in this case the presence of a
putative signal peptide cleaved between positions A24 and N25
[58]. Similarly, in rRHA-P the cleavage site is located between A23
and E24. The amino acidic sequence of the N-terminus of both
!-RHA from strain FP2001 and strain PP1Y revealed several pecu-
liarities owned by bacterial signal peptides, such as the presence of
a charged region (2–5 residues) followed by a hydrophobic stretch
of ∼ 12 aa, along with the presence of small and apolar residues
located 1 and 3 aa upstream of the cleavage site [60]. The func-
tional role of this cleavage, as well as the possible sorting of these
processed proteins in the periplasmic space of the native bacteria,
needs to be further investigated.
A preliminary structural characterization showed that rRHA-P
is a monomeric protein with an approximate molecular weight of
101,500 ± 5,000 Da. Mechanism of action, kinetic parameters and
optimum reaction conditions were determined using a synthetic
substrate, pNPR.
As for the reaction mechanism, GHs are generally grouped in two
main classes, inverting and retaining. A typical inverting glycosi-
dase requires the presence of a catalytic acid residue and a catalytic
basic residue, whereas a typical retaining glycosidase contains a
general acid/base residue and a nucleophile. These different hydrol-
ysis mechanisms lead, respectively, to an inversion or to a retention
of the anomeric oxygen configuration in the product compared to
the substrate [61]. NMR  experiments showed that rRHA-P acts as
an inverting GH; further investigation will give additional insights
in identifying residues in the active site of this enzyme, which are
directly involved in catalysis.
rRHA-P catalytic efficiency, defined by a Ks value of
4.6 s− 1#M− 1, underlined that the activity of this enzyme resulted
to be comparable or even higher than that of other bacterial
!-RHAs described in literature. When clearly reported, such as
in lactic acid bacteria Lactobacillus plantarum, and Pediococcus
acidilactici, Ks values on pNPR range in fact from 0.01 s− 1#M− 1
to 0.019 s− 1#M− 1 [38,39]. In addition, Ks of rRHA-P resulted to
be approximately 3 times higher than the Ks of 1.74 s− 1#M− 1
reported for the !-RHA isolated from S. paucimobilis FP2001
[57]. The comparison among the KM values present in literature,
ranging from 1.18 mM for S. paucimobilis FP 2001 to 16.2 mM for
the !-RHA isolated from P. acidilactici,  showed a higher apparent
affinity of rRHA-P for pNPR (KM of 160 #M),  which might be in part
responsible for the great differences found in KS values.
To investigate the effective potential of using rRHA-P in biotech-
nological processes involving the biotransformation of flavonoids,
optimal reaction conditions in terms of pH, temperature and pres-
ence of organic solvents were evaluated. In particular, rRHA-P, in
line with other bacterial !-RHAs [34–38,55], has an optimal activity
at pH 6.9, a value that highlights a marked difference with fun-
gal !-RHAs acting at pH values ranging from 4 to 5 [17,31,32].
rRHA-P shows an optimal activity at 40.9 ◦C and a significant overall
thermal stability, retaining ∼66% of the activity up to 45 ◦C, a tem-
perature range mainly used in most industrial processes. In this
respect, also a great majority of other fungal and bacterial enzymes
exhibit similar values of temperature stability and optimal activity
[17,32,34,37,38,55], whereas only a limited number of !-RHAs is
more thermophilic and has an optimum of temperature at ca. 60 ◦C
[31,36,37,39]. rRHA-P has a moderate tolerance to organic solvents,
usually employed for the biotransformation of flavonoids that are
poorly soluble in water, retaining the 66% of activity on pNPR in
solutions containing 10% of either DMSO or ethanol. Naringin con-
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version is even faster in 10% DMSO than in the absence of this
solvent, probably owing to the fact that this flavonoid is more sol-
uble in the presence of DMSO. Noteworthy, flavonoids conversion
catalyzed by other !-RHA has been described in the presence of
2–5% DMSO [37–39]; higher concentration of DMSO, as the one
used for our bioconversion, might further increase the solubility
of many flavonoids of commercial interest. These data altogether
suggest a higher tolerance of rRHA-P to the presence of solvents
compared to !-RHAs described in literature for which a residual 20
−  30% activity in 12% ethanol and a 24% activity in 25% DMSO has
been reported [17,39]. It is worth mentioning that rRHA-P residual
activity in ethanol-containing buffers might be of additional impor-
tance as many biologically relevant rhamnosylated flavonoids are
found in wine and possibly citrus derived alcoholic beverages.
As previously underlined, the kinetic data obtained so far for
this enzyme undoubtedly encourage its use for the bioconversion
of glycosylated natural flavonoids that are more soluble at high
temperature (ca. 50 ◦C) [62], basic pH values, and in the pres-
ence of organic solvents. In this context, experiments to verify the
hydrolytic properties of rRHA-P on few natural flavonoids contain-
ing either !-1,2 or !-1,6 glycosidic linkages between !-l-rhamnose
and "-d-glucose were performed. TLC analysis on naringin (!-1,2),
rutin (!-1,6) and neohesperidin (!-1,6) showed a total conversion
of naringin in the corresponding prunin and rhamnose, while a
partial hydrolysis of rutin and neohesperidin was observed, thus
confirming the ability of this enzyme to hydrolyze both !-1,2 and
!-1,6 linkages. Likewise, the majority of other bacterial and fun-
gal !-RHAs exhibit similar substrate specificity, even though these
enzymes often show a slight preference for the hydrolysis of !-1,6
linkages [31,32,37–39].
In conclusion, the results described in this work boost the
interest toward a further biochemical characterization of RHA-P
activity using for example a wide array of glycosylated flavonoids,
to investigate the effective potential of this novel enzyme for vari-
ous biomass and food-processing applications aimed at recovering
high-value added compounds from complex vegetable matrixes.
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Abstract: Background: Cardiovascular disease is the leading cause of morbidity and 
mortality worldwide in developed countries, and its social and economic burden is 
expected to increase dramatically over the next decades. Despite significative im-
provement in the pharmacological treatment, and the huge advances in prevention, the 
quest for new molecular targets and for novel, more efficient and personalized thera-
pies is still a priority for this group of pathologies.  
Objective: The paramount complexity of the metabolic networks responsible for the 
onset and progression of cardiovascular disease is highlighted by the wide and diverse 
array of new molecular targets recently described in literature. In this brief review, we 
focused our interest on a subset of promising molecular targets for the development of 
new pharmacological treatments specific for cardiac diseases such as coronary artery 
disease, heart failure and myocardial infarction.  
Conclusions: The global quest for new molecular targets for the treatment of cardiac dis-
eases is leading to an impressive amount of records in the more recent literature. Although 
several promising molecular pathways have been identified so far, great caution should be 
used in considering all these targets effective in promoting the production of new drugs. 
The identification of suitable therapeutic targets is in fact an ongoing challenge that 
often lacks enough pre-clinical and clinical studies, which hinders the effective utili-
zation of several new drugs due to a lack of efficacy or induction of safety liabilities.  
Keywords: Cardiovascular disease, coronary artery disease, heart failure, myocardial infarction, drug discovery, 
drug targets. 
INTRODUCTION 
The cardiovascular system (CVS) is responsible to 
transport oxygen and nutrients, remove metabolic 
waste, and carry endocrine factors and immune cells 
throughout the body.  
Cardiovascular pressure/volume complex homeo-
stasis mainly depends upon the tight regulation of a 
neurohormonal system, which involves the interplay 
between the renin-angiotensin-aldosterone system 
(RAAS) and the sympathetic nervous system (SNS), 
together with the cardiac natriuretic peptides and the 
arginine vasopressin-mediated action [1].  
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Cardiovascular disease (CVD) is currently the leading 
cause of mortality and morbidity worldwide and is 
caused by a wide array of dysfunctions affecting the 
heart and/or blood vessels, which include aging, hyper-
tension, diabetes, atherosclerosis and coronary artery 
disease (CAD) [2]. In September 2016, the World 
Health Organization (WHO) has estimated that more 
than 17 million people die annually from CVD and has 
launched the “Global Hearts” initiative, aimed at facing 
the global threat of these diseases [3].  
Early onset of CVD involves complex cellular and 
molecular signaling cascades that regulate, among oth-
ers, cardiac myocytes growth, electrical conduction, 
contractility, redox balance, metabolic homeostasis, 
extracellular matrix remodeling (EMR), necrosis and 
apoptosis [4-6].  
CAD is the result of a progressive narrowing and 
damage of blood vessels that supply blood to the heart 
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muscle and it is usually caused by atherosclerosis, a 
process of hardening of arteries due to the buildup of 
an atheromatous plaque inside the artery walls. CAD 
include less severe manifestations, such as stable an-
gina (SA) or unstable angina (UA) and more severe 
forms like acute coronary syndrome (ACS) and myo-
cardial infarction (MI).  
Heart Failure (HF) is the final endpoint of many 
heart diseases [7], and is characterized by several 
hemodynamic abnormalities, ultimately leading to an 
inadequate systemic perfusion that does not respond to 
the body metabolic demand in conditions of stress or 
increased activity [8]. In the early onset of HF, com-
pensatory neurohormonal mechanisms are activated to 
maintain cardiovascular homeostasis; however, an in-
crease in cardiac mass along with alterations in the ex-
tracellular matrix (ECM) later drive the alteration in 
heart function and structure, usually referred to as 
“cardiac remodeling”. The late stage of HF is clinically 
characterized by cardiac enlargement and by a pro-
gressive worsening of the contractile function [7, 8]. 
Age, male sex, left ventricular hypertrophy (LVH), 
MI, CAD, valvular heart disease, obesity, and diabetes 
are among the main risk factors described so far for HF 
development [7, 9]. Among others, hypertension, a 
multifactorial disease characterized by high blood pres-
sure and involving both genetic and environmental fac-
tors, is a major contributor to the population burden of 
HF because of its great prevalence [7, 10]. Hyperten-
sion is characterized by high arterial pressure resulting 
from increased peripheral vascular resistance, which 
can be consequent to both enhanced contractility of 
vascular smooth muscle cells (VSMCs) and arterial 
wall remodeling. Systemic hypertension induces LVH, 
fibrosis and diastolic dysfunction, increases the risk of 
CAD, which leads to congestive HF. 
Elevated cholesterol levels are recognized as an im-
portant independent risk factor for the onset of CAD; 
therefore, dyslipidemia is also directly linked to the 
development of HF. It is worth noting that elevated 
levels of total cholesterol are not a strong predictor of 
new-onset HF, whereas an increased ratio of total cho-
lesterol to HDL cholesterol seems to be effectively as-
sociated with high HF risk [7].  
Despite a substantial progress in the treatment of HF 
with the all-time classics angiotensin-converting-enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARB), 
diuretics, beta blockers and aldosterone antagonists, no 
further improvement has been observed in the late 10 
years for patients prognosis [7]. HF remains a deadly 
clinical syndrome and a major public health concern for 
western countries, being the most frequent reason for 
hospitalization in elderly patients; both the prevalence of 
this disorder and the cost of healthcare are expected to 
dramatically increase over next decades [11-15]. 
HF patients are frequently re-hospitalized and gen-
erally experience a very poor quality of life. Thus, 
there is undoubtedly an urgent need of identifying new 
targets for the development of innovative pharmacol-
ogical treatments for HF. Insights into the molecular 
and cellular determinants responsible for the develop-
ment of HF are shedding light on several anomalies in 
cell function and signaling that could be used as po-
tential therapeutic targets in the near future [8, 13]. 
MI  is  an  irreversible  damage  of  myocardial  tis-
sue, which occurs as a consequence of myocardial cell 
death due to protracted ischemia and hypoxia. This 
most commonly happens when blood flow is blocked 
by the occlusion of a coronary artery, possibly occur-
ring as the consequence of the rupture of an athero-
sclerotic plaque that leads to the formation of a blood 
clot. Major modifiable risk factors of MI are hyperten-
sion, high blood cholesterol level, diabetes (mellitus), 
smoking/tobacco use, obesity, poor nutrition/diet, 
physical inactivity, stress, and the exposure to danger-
ous conditions at work [16]. The major non-modifiable 
risk factors for MI include age, family history, and 
race. Likely, combinations of these risk factors, which 
appear to be different in men and women, are important 
in the aetiology of the disease [16].  
After MI, necrotic cardiac myocytes trigger the on-
set of an inflammatory response, which might be bene-
ficial in terms of wound healing, but is responsible to 
further damage the left ventricule. A complex tissue 
remodeling follows MI event, which involves both cel-
lular and ECM components [17]. The initial loss of 
cardiomyocytes in MI, due to the primary ischemic 
event, directly affects the survival and long-term prog-
nosis of the patient, which may experience arrhyth-
mogenesis, adverse remodeling and contractile dys-
function. The fast recovery of coronary blood flow us-
ing percutaneous coronary intervention (PCI) as pri-
mary state care remains of utmost importance to pre-
serve myocardial viability in patients with MI. How-
ever, PCI can also trigger molecular events that con-
tribute to the process known as "ischemic/ reperfusion” 
(I/R) injury [17, 18]. In this process, the restoration of 
blood flow boosts the over-production of reactive oxy-
gen species (ROS) [19], an intracellular Ca2+ overload, 
and the up-regulation of pro-inflammatory molecules 
triggering cell death in vital spared myocytes, thus 
leading to additional cardiac damage and complications 
[20]. 
In conclusion, clinical evidence suggests for several 
CVDs the growing need of identifying novel targets to 
improve the pharmacotherapy efficiency. It should be 
underlined that, for the complexity of the metabolic 
pathways involved, multiple molecular targets, and not 
single molecules, should be considered for future
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Fig. (1). A schematic and simplified view of the molecular targets described in this paper highlighting their interconnections 
in cardiac myocyte and their role in either promoting or preventing cardiac diseases. 
 
therapeutic management.This approach, along with the 
characterization of the genetic background of the pa-
tient, will concur in developing in the near future a far 
more personalized approach in the treatment of these 
diseases. In this brief review, we focused our interest 
on a subset of promising molecular targets (Fig. 1), 
recently described in the literature, for the development 
of new pharmacological treatments specific for cardiac 
diseases such as atherosclerosis, CAD, HF and MI.  
NOVEL MOLECULAR TARGETS FOR THE 
TREATMENT OF CARDIAC DISEASES.  
ROS Metabolism, Oxidative Stress and I/R Injury 
ROS include several oxygen and nitrogen-derived 
species such as superoxide (O2•−), hydroxyl radical 
(•OH), hydrogen peroxide (H2O2), and peroxynitrite 
(ONOO−) [19]. An imbalance between ROS production 
and the cell/systemic antioxidant defense capacity is 
responsible for the onset of the metabolic condition 
generally called “oxidative stress” [19, 21]. ROS are a 
double-edged sword as they are undoubtedly essential 
in cell signaling, proliferation, and differentiation 
pathways, but if their levels increase in an unregulated 
manner they are responsible for cell damage, necrosis, 
and apoptosis via oxidation of lipids, proteins, and 
DNA [22, 23]. Physiology and pathophysiology of 
CVD are clearly related to both oxidative stress and 
ROS, even though not all molecular details have been 
fully elucidated yet. The multiple effects of ROS are 
particularly evident, for example, in the different stages 
underlying I/R injury [24, 25]. In this case, during 
ischemia, ROS-producing enzymes are activated and 
up-regulated, and hypoxia is responsible to decrease 
ATP production and uncouple the electron transport 
chain. During the reperfusion phase, the re-
establishment of the blood supply abruptly restores mo-
lecular oxygen, thus resulting in a sharp increase of 
ROS generation. ROS trigger a cascade of molecular 
events involving the expression of proinflammatory 
stimuli, the expression of adhesion molecules by endo-
thelial cells and leukocytes, which contribute to the 
infiltration and activation of neutrophils, T cells and 
monocytes. In the third stage, after early reperfusion, 
tissue repair takes place. At this stage, low levels of 
ROS are generated, which act as signaling molecules to 
activate the transcription of growth factors and promote 
cell proliferation, differentiation and migration. The 
result of this repair stage is tissue and vascular remod-
eling, which helps restoring organ function, but at the 
same time causes tissue fibrosis, which eventually con-
tributes to HF onset.  
Reactive Nitrogen Species (RNS) derived from ni-
tric oxide (NO), also play a central role in the cellular 
and systemic response to I/R. Indeed, interactions be-
tween ROS and RNS are responsible to influence the 
extent of injury via the production of reactive nitrogen 
oxide species (RNOS), such as ONOO−. RNOS are 
responsible for several detrimental effects at this stage 
including damage/modification of macromolecules, 
induction of death of endothelial and/or parenchymal 
cells, stimulation of production/release of pro-inflam- 
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matory mediators and of adhesion molecules support-
ing leukocyte/lymphocyte-endothelial cell adhesive 
interactions, along with a diminished global availability 
of protective NO [25].  
It is evident that the interplay between ROS (and 
RNS) homeostasis and CVD is quite complex, and this 
is probably one of the main reasons explaining the con-
flicting results often described in literature when gen-
eral antioxidant treatments are used to mitigate CVD 
[19, 24]. Nonetheless, ROS redox therapy still shows 
promising signs of being a possible treatment option, as 
long as new molecular details of this complex relation-
ship continue to be unraveled. 
Peroxisome proliferator activated receptors (PPARs) 
are involved in several biological processes such as en-
ergy homeostasis, cell proliferation and differentiation, 
fatty acid catabolism, and adipogenesis [26]. Among the 
three PPAR isotypes identified, PPARδ is the predomi-
nant subtype in cardiac cells and is involved in the regu-
lation of cardiac lipid metabolism. There is a great inter-
est for this nuclear receptor due to its important role in 
apoptotis and cell proliferation, and for its function as a 
key regulator of fatty acid metabolism [26]. In the 
framework of the inflammatory response following car-
diac I/R it is worth to note that PPARδ activation by one 
of its synthetic ligand, GW610742, reduces inflamma-
tory cytokine expression, ending up in a reduction of 
plasma levels of interleukin-6 (IL-6) and interleukin-8 
(IL-8) [26]. Recently, the therapeutic effects of 
GW610742 treatment on cardiac healing in post-MI rats 
was investigated [27]. Interestingly, GW610742 treat-
ment promoted the onset of cardiac fibrosis and angio-
genesis in the early infarct site after MI. The prolonged 
pharmacological PPARδ activation did not lead to bene-
ficial effects on cardiac function in that specific study, 
despite the histological advance of the healing process in 
the early phase after MI [27]. 
Recently, cardiac troponin I-interacting protein 
kinase (TNNI3K), a cardiomyocyte-specific kinase 
over-expressed in patients with HF, was shown to pro-
mote I/R injuries through the onset of a marked oxida-
tive stress, thereby promoting the death of cardiomyo-
cytes [28, 29]. To shed light on the significance of this 
increased expression, a pre-clinical study based on ro-
dent models was conducted [29]. In TNNI3K overex-
pressing mice, ischemic injury was worsened and car-
diomyocyte death was promoted; this was driven by an 
increase in O2•−production and a stimulation of the mi-
togen-activated protein kinase (MAPK) p38, an en-
zyme that responds to stress signals in cells (Fig. 1). 
The combination of both activities stimulated mito-
chondrial death pathway in cardiac cells, which wors-
ened I/R injury. Conversely, in loss-of-function mice, 
O2•−production and p38 activation were markedly re-
duced and heart lesion, dysfunction and fibrosis were 
limited [29]. Active site-binding small molecules that 
selectively inhibited TNNI3K, when delivered at reper-
fusion, decreased infarct size and significantly reduced 
ROS [29]. Results on TNNI3K are encoura- 
ging especially because this kinase appears to be car-
diospecific, thus the use of inhibitors should produce 
limited negative effects on systemic kinase inhibition. 
TNNI3K inhibition might represent a novel pharma-
cological option after coronary angioplasty in acute 
state of MI, and in chronic coronary syndromes, char-
acterized by the frequent occurrence of multiple epi-
sodes of I/R injury. However, further studies in pre-
clinical animal models are still required to better detail 
the signaling pathways effectively involved [30].  
Mitochondrial Metabolism  
Mitochondria play a very important role in the regu-
lation of cardiovascular cell function and, conse-
quently, in the onset of CVD [24, 25]. The high ener-
getic demand of the cardiac tissue mainly relies on the 
metabolism of mitochondria, which show a critical role 
in regulating cardiomyocyte apoptosis as well. Conse-
quently, the high consumption of oxygen in cardio-
myocytes can potentially prompt the cells to oxidative 
stress. Mitochondria are an important source of ROS, 
which has profound implications for the cardiovascular 
system. Mitochondrial metabolic impairment can be 
associated with abnormal mitochondrial dynamics, in-
creased oxidative stress and abnormal Ca2+ handling, 
and seems to play a critical role in the myocardial re-
modeling process responsible for HF onset [31]. Some 
of the recently published strategies for the treatment of 
CVD encompass the exploitation of different mito-
chondrial targets. 
During the last decades, several evidences have 
shown that mitochondria are quite “dinamic” organ-
elles as their morphology, subcellular distribution and 
activity can be modified according to the cell metabolic 
status [32]. Mitochondria continually divide (fission) 
and fuse, even in resting cells, and several reports have 
demonstrated a direct correlation between the extent of 
mitochondrial fusion and the capacity for oxidative 
phosphorylation [33]. Tissues with high energy re-
quirements (e.g. heart and skeletal muscle) show a pre-
dominantly fused mitochondrial morphology with 
tightly packed cristae [33]. A fine-tuned interplay be-
tween mitochondrial fission and fusion guarantees a 
proper mitochondrial function, and a close relationship 
between a remodeling of mitochondrial architecture 
and the changes in metabolism does exist [32].  
Dynamin-related GTPases mitofusins (MFN1, 
MFN2) and optic atrophy protein 1 (OPA1), respec-
tively expressed in the outer and inner mithocondrial 
membrane, are the main regulators of mitochondrial 
fusion [33, 34], whereas mitochondrial fission 1 protein 
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(Fis1) and Dynamin-related protein 1 (DRP1) are 
mostly responsible for mitochondrial fission [33].  
Data in literature support the idea that changes in 
mitochondrial morphology may be relevant to various 
aspects of CVD, including I/R injury, HF, and dilated 
cardiomyopathy, where disorganized small mitochon-
dria have been retrieved [35].  
Mitochondria observed in failing hearts of rats are 
small and fragmented, which is consistent with a de-
creased fusion rate. HF in both human and rat cardio-
myocites is characterized by a marked decrease in 
OPA1 levels, which leads to cell apoptosis [35, 36]. In 
some HF models, levels of OPA-1 are reduced but 
there is no change in the amount of MFN1, MFN2, 
DRP1, or Fis1. Expression of OPA1 mRNA does not 
seem to be directly influenced, thus indicating that the 
decrease of OPA-1 proteins might be likely due to 
post-transcriptional modification or degradation [35, 
36]. Deficiency of this protein, which normally pre-
vents release of cytochrome c from the mitochondria, is 
related to mitochondrial respiratory dysfunction [36]. 
Ong and coworkers [37] observed that transfection of 
HL-1 cells with MFN1 or MFN2 supported mitochon-
drial elongation and reduced cell death following simu-
lated ischaemia; transfection with the mitochondrial 
fission protein Fis1 promoted instead mitochondrial 
fragmentation and increased cell death. These data 
suggest that prevention of ischaemia-induced mito-
chondrial fragmentation might be cardioprotective [37]. 
In conclusion, therapeutic approaches aimed at either 
inhibiting mitochondrial fission or stimulating mito-
chondrial fusion might protect the heart from failure 
and ischemia. 
As previously underlined, mitochondria are a site of 
massive production of free radicals, and are conse-
quently one of the first molecular targets for oxidative 
damage [38]. During cardiac remodeling and HF, both 
cytosolic and mitochondrial ROS are unbalanced, thus 
leading to oxidative damage, mitochondrial dysfunc-
tion and ultimately cell death [38]. Since mitochondrial 
ROS are involved in cardiac hypertrophy and remodel-
ing, several groups have developed specific strategies 
for the targeted delivery of antioxidants to mitochon-
dria, as an innovative therapeutic approach to prevent 
cardiac failure. As an example, Dai and coworkers 
demonstrated that mitochondrial-targeted catalase par-
tially protects the heart from failure [39]. They used the 
mitochondrial-targeted antioxidant peptide Szeto-
Schiller (SS-31) to reduce mitochondrial oxidative 
stress in hypertensive cardiomyopathy [40]. SS-31 pep-
tide belongs to a family of aromatic cationic peptides 
that selectively target the mitochondrial inner mem-
brane and are endowed with the ability to scavenge 
H2O2, ONOO- and •OH, and to inhibit lipid peroxida-
tion. These peptides reduce mitochondrial ROS, thus 
inhibiting cytochrome c release and preventing oxi-
dant-induced cell death. Preclinical studies strongly 
support the use of these peptides in case of I/R injury 
and neurodegenerative disorders [41]. Among others, 
peptide SS-31 reduced Ang II-induced NOX4 up-
regulation and prevented apoptosis. Experimental re-
sults highlighted that SS-31 is a multifunctional mito-
protective compound that promotes bioenergetics, re-
ducing ROS production, scavenging excess ROS, in-
hibiting cardiolipin peroxidation, and preserving mito-
chondrial structure, all properties that are particularly 
effective in minimizing I/R injury. However, further 
pre-clinical and clinical studies are still required in or-
der to evaluate the efficacy and toxicity of mitochon-
drial-targeted antioxidants. 
In the last two decades a new role of Ca2+ in pro-
gramming reactive hypertrophic signaling has emerged 
[42]. Ca2+ is stored mainly in the sarcoplasmic reticu-
lum (SR), which regulates its release into the cyto-
plasm. The main regulative Ca2+ channels involved in 
this function are the inositol 1,4,5-triphosphate receptor 
(InsP3R) and the ryanodine receptor (RyR). Following 
a release, low cytoplasmic concentration of Ca2+ is pre-
served because Ca2+ ions are rapidly pumped back 
through the action of the sarcoendoplasmic reticulum 
Ca2+ ATPase (SERCA) [42]. Mitochondrial Ca2+ is also 
important for cell bioenergetics; an increase in mito-
chondrial Ca2+ concentration is responsible for stimu-
lating Krebs Cycle activity and increasing NADH lev-
els, thus leading to a global increase in ATP synthesis 
[43]. 
Cytoplasmic Ca2+ increase activates the Ca2+-
calmoduline dependent protein II (CAMKII), cal-
cineurin (CaN) and protein kinase C (PKC), which in 
turn induce a characteristic genetic program involved 
in the development of cardiac hypertrophy. Moreover, 
the activation of CAMKII and CaN promotes mito-
chondrial fission and, consequently, cardiomyocyte 
apoptosis.  
Several reports focused their attention on the varia-
tion of mitochondrial mitochondrial Ca2+ metabolism 
in HF [44]. Interestingly, cardiomyocytes from failing 
hearts show a reduced mitochondrial Ca2+ sensitivity 
that might be directly responsible for the reduction in 
mitochondrial metabolism. Therefore, the stimulation 
of mitochondrial Ca2+ has been investigated as a poten-
tial therapeutic strategy to prevent HF [44]. In this con-
text, insulin-like growth factor-1 (IGF-1) was reported 
to prompt mitochondrial Ca2+ uptake and mitochondrial 
respiration and to prevent a fall in ATP synthesis, thus 
reducing cell death [45].  
Future studies aimed at elucidating the interplay be-
tween mitochondrial morphology, metabolism, and 
cardiac function will undoubtedly provide new interest-
ing insight for the prevention and treatment of CVD. 
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Cholesterol Metabolism 
CVD, like atherosclerosis, is closely related to al-
terations in cholesterol metabolism. Innovative phar-
macological approaches aiming at counteracting cho-
lesterol imbalance show a promising therapeutic poten-
tial. Some therapeutic agents are already used to at-
tenuate atherogenesis such as niacin, fibrates and stat-
ins; these latter often fail to achieve treatment goals, 
and residual CVD risk remains high.  
HDL cholesterol has numerous anti-atherosclerotic 
properties [46]; a key function of HDL is in fact to 
promote reverse cholesterol transport from the periph-
ery to the liver, thus removing excess cholesterol from 
membranes of peripheral cells, macrophages and foam 
[47, 48]. Cholesterol efflux by HDL is also important 
for lipoprotein signaling in endothelial cells, which 
leads to the activation of endothelial nitric oxide syn-
thase (eNOS), thus supporting endothelial repair and 
inducing angiogenesis [49, 50]. Structural and func-
tional changes of HDL, which may affect their anti-
atherogenic properties, have been reported in the 
chronic inflammatory process of atherosclerosis and in 
pathological states such as oxidative stress, inflamma-
tion and diabetes [51, 52].  
Therapeutic interventions aimed at preventing athe-
rosclerosis and CVD should not only focus on raising 
HDL levels, but should also address the improvement 
of their structural and functional properties [52]. Apol-
ipoproteins Apo A-I and A-II are major protein com-
ponents of human HDL. The cycling of Apo A-I be-
tween lipid-poor and lipid-rich forms of HDL plays a 
key role in the transport of cholesterol by these parti-
cles. Beneficial effects of raising Apo A-I levels on the 
anti-atherosclerotic properties of HDL are validated by 
experiments of transgenic overexpression or intrave-
nous infusion of Apo A-I in mice models, which re-
sulted in a marked reduction of atherosclerosis [53]. 
Promising research has also been performed on the 
therapeutic effect of mimetic peptides structurally re-
lated to Apo A-I, but further studies need to be per-
formed in this direction [54]. 
Reducing circulating levels of low-density lipopro-
teins (LDL) is clearly another important aspect in the 
development of new therapies to countervail athero-
sclerosis. In this framework an interesting target is the 
serine protease proprotein convertase subtilisin/kexin 
type 9 (PCSK9), which binds and vehiculate to the 
lysosome for degradation the LDL receptor (LDLR) 
[55]. The decreased number of LDLR available on the 
cell surface leads to an increase in circulating LDL par-
ticles. Among the specific inhibitors recently discussed 
in literature, antibodies directed against PCSK9 are 
probably the most promising ones, with multiple phase 
III and cardiovascular endpoint trials already underway 
[55]. These fully human monoclonal antibodies have 
shown to be effective in subjects with statin intoler-
ance, as adjuvant to statin therapy, as monotherapy and 
in patients with familial hypercholesterolemia [55].  
Epicardial Adipose Tissue  
The perivascular adipose tissue (PVAT) is the adi-
pose tissue that virtually surrounds all large arteries in 
the body and is an active endocrine and paracrine organ 
influencing vascular homeostasis through the produc-
tion of local cytokines and chemokines, collectively 
known as adipokines [56, 57]. An impairment in the 
secretion of these molecules leads to multiple patho-
logical conditions such as atherosclerosis and CAD 
[58, 59].  
Recently, the attention has been specifically focused 
on the adipose tissue present on the surface of the heart 
surrounding large coronary arteries and on the surface 
of the ventricles, known as epicardial perivascular adi-
pose tissue (EAT), whose dysfunction has been in-
volved in the onset of the inflammatory burden affect-
ing coronary plaque development and phenotype [58, 
59]. EAT, in physiologic conditions, has several pro-
tective functions for the heart [56, 57]; however, it is 
known that EAT might produce several pro-
inflammatory and pro-atherogenic cytokines, such as 
Tumor Necrosis Factor α (TNF-α), Monocyte chemoat-
tractant protein-1 (MCP-1), IL-6, Interleukin 1β (IL-
1β), plasminogen activator inhibitor-1 (PAI-1), resistin, 
leptin, visfatin and chemerin [57]. Noteworthy, in CAD 
patients local levels of these inflammatory mediators 
do not correlate with plasma concentrations of circulat-
ing cytokines and are independent of several clinical 
variables, such as obesity, and diabetes [58]. Not all 
adipokines are pro-inflammatory and pro-atherogenic; 
adiponectin, as an example, has been associated with 
endothelial improvement and vascular protection [56]. 
More specifically, adiponectin stimulates NO produc-
tion in vascular endothelial cells and seems to amelio-
rate endothelial function through eNOS-dependent 
pathways [56]. Thus, there is a substantial body of evi-
dence showing that several adipokines might effec-
tively represent novel therapeutic targets for the treat-
ment of CAD. It is still quite unclear, however, whether 
future therapies should aim at either increasing anti-
atherogenic adipokine or inhibiting pro-atherogenic 
adipokine levels or combining both strategies [56]. 
Endoplasmic Reticulum Metabolism  
The endoplasmic reticulum (ER) plays a crucial role 
in the folding of secretory and membrane proteins, cal-
cium homeostasis, and lipid biosynthesis [60]. ER 
function can be hindered in response to a wide variety 
of stressors, which leads to the accumulation of un-
folded and misfolded proteins, thus activating tran-
scriptional and translational pathways known as the 
unfolded protein response (UPR) [61].  
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Adaptive and pro-apoptotic pathways of UPR have 
been related to the pathophysiology of human diseases, 
including CVD, neurodegenerative diseases, diabetes 
mellitus, obesity, and liver diseases. Advanced athero-
sclerotic plaques can cause ER stress and activate UPR 
pathways [62, 63], thus inducing oxidized lipids pro-
duction, inflammation cascade and metabolic stress 
[64]. A growing number of evidences indicates that the 
ER stress-induced macrophage apoptosis is a key cellu-
lar event in the conversion of benign to vulnerable 
atherosclerotic plaques. Moreover, a strong association 
between ER stress markers such as CHOP 
(CCAAT/enhancer binding protein (C/EBP) homolo-
gous Protein) and Glucose-regulated protein 78 
(GRP78) and ruptured atherosclerotic plaques in hu-
man coronary artery lesions was retrieved [65], sug-
gesting that ER stress is likely involved in the devel-
opment of plaque rupture in humans. Pharmacological 
agents that directly activate or deactivate UPR compo-
nents will be potentially useful in treating CVD. Poten-
tial components of the UPR, such as Activation Tran-
scription Factor 6 (ATF6), inositol-requiring enzyme 1 
(IRE1), spliced X-Box binding Protein 1 (XBP1), 
PERK, eukaryotic initiation factor 2 (eIF2), and the 
proteasome, could be initial targets for therapeutic de-
sign. In several studies, activation of ATF6 had cardio-
protective effects against I/R injury [66, 67]. 
CHOP is a pro-apoptotic transcription factor; dele-
tion of the gene encoding for this protein protects 
against cell death induced by a pharmacological ER 
stressor [68]. CHOP inhibitors might attenuate cardiac 
hypertrophy and failure and prevent atherosclerosis. 
GRP78 is a Heat shock protein 70 (HSP70)-like chap-
erone, which recognizes and binds exposed hydropho-
bic residues in misfolded or denatured proteins; over-
expression of GRP78 attenuates ER stress and cardiac 
damage by I/R or proteasome inhibition [69]. In this 
framework, it would be interesting to determine 
whether chemical chaperones, which have been suc-
cessfully used in other animal models of UPR-
associated diseases, might have a beneficial effect on 
advanced atherosclerotic lesion progression [70].  
Other Targets  
GRK2. G-protein-coupled receptors (GPCRs) are 
the largest superfamily of cell surface receptors; they 
are crucial molecular sensors for many physiological 
processes and represent the clinical target of a signifi-
cant percentage of all drugs currently used [71]. Ago-
nist binding promotes interaction of the GPCR with 
heterotrimeric G proteins, which initiates the classical 
intracellular signaling cascade. Drugs targeting GPCRs 
either directly block the ligand-receptor access or 
modulate the production of the target GPCR ligand. 
The majority of GPCRs are regulated by agonist-
promoted desensitization and downregulation [72]. At 
the molecular level, this process is triggered by the 
phosphorylation of the receptor catalyzed by GPCR 
kinases (GRKs), followed by the binding of β-arrestins 
(βarrs); βarrs uncouple the receptor from its cognate G 
proteins, sterically hinder its further binding to them, 
thus targeting the receptor for internalization into en-
dosomes [73]. GRKs are serine-threonine protein 
kinases comprising seven isoforms (GRK1-7), among 
which GRK2 is mainly expressed in the heart. GRK2 
is a cytoplasmic protein in its inactive state, which rec-
ognizes, binds and phosphorylates agonist-bound 
GPCR, including β- and α2-adrenergic receptors (β-
ARs and α2-ARs) and angiotensin II type 1 receptor 
(AT1Rs) [73]. During HF different neurohormonal sys-
tems are hyperactive, which leads to a marked increase 
in circulating levels of catecholamines such as adrena-
line and noradrenaline. This overstimulation of the β-
adrenergic system, which is of course part of a com-
pensatory mechanism, is responsible at the same time 
to produce toxic effects on the heart on the long run 
and plays a key pathogenic role in HF progression. 
GRK2 is upregulated in several different pathologic 
conditions, such as cardiac ischemia, hypertrophy, and 
hypertension, in line with a protective mechanism 
whose aim is to counteract the effects of an excessive 
catecholaminergic stimulation by reducing signaling 
through βARs [74]. Moreover, in HF, cardiac GRK2 
protein levels are increased in the early stages of the 
disease and an increasing body of evidence suggests 
that this protein can be considered as a potential novel 
biomarker of cardiac dysfunction in human [74-76]. In 
line with this, the prognostic value of GRK2 to predict 
cardiovascular death and all-cause mortality was re-
cently assessed [75, 76].  
GRK2 upregulation is detrimental for the heart and 
provokes the functional uncoupling of βAR in vivo. An 
ever-growing body of pre-clinical evidence presented 
in literature supports cardiac GRK2 inhibition as a 
valid pharmacological approach to improve cardiac 
function and reduce the cardiac damage in patients with 
HF [77-82]. Studies in knock-out mice using a GRK2 
inhibitor peptide, known as bARKct, revealed a benefi-
cial effect on cardiac function in several other animal 
models [77, 78]. The use of a wide array of small 
molecules and peptides to inhibit GRK2 is currently 
under investigation [80, 81] and will certainly offer in 
the near future many advantages for the patient suffer-
ing from HF.  
Interestingly, adrenal glands were recently pin-
pointed as a possible target organ for GRK2 therapy; 
adrenal GRK2, indeed, seems to play an important role 
in regulation of heart sympathetic stimulation and in 
HF damages [73]. The inhibition, via adenoviral-
mediated βARKct adrenal-specific gene delivery, led to 
a marked reduction in catecholamines circulating lev-
els, restoring both adrenal and cardiac functions [73]. 
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Among others, the serotonin reuptake inhibitor 
(SSRI) paroxetine showed strong affinity for GRK2 
and revealed significant inhibitory properties on GRK2 
both in vitro and in vivo [79]. Paroxetine binds in the 
active site of GRK2 and stabilizes the kinase domain in 
a novel conformation, in which a unique regulatory 
loop forms part of the ligand-binding site [79]. A major 
limitation for the use of this drug, however, is the re-
quirement of a  very high dosage to inhibit the kinase. 
The effective doses exceed those approved for the use 
of paroxetine in humans, provoking unavoidable ef-
fects on the central nervous system [8].  
All these data strongly support the use of inhibition 
mechanisms on GRK2 activity in HF treatment [82]. 
However, the incoming evidence about the multiple 
role of GRK2 in cellular physiology is prompting fur-
ther studies to identify its subcellular localization and 
function in the different organelles, thus better detailing 
the molecular determinants of its inhibition.  
ACE2. Angiotensin-converting enzyme (ACE), a 
dipeptidyl carboxypeptidase, is a key enzyme in the 
renin–angiotensin system (RAS) and is involved in the 
conversion of the inactive decapeptide, angiotensin I 
(Ang I; or Ang 1-10), to the active octapeptide Ang II 
(or Ang 1–8), and in the inactivation of the vasodilator 
bradykinin [83]. The canonical view of RAS has been 
confronted by the recent discovery of the enzyme 
ACE2, a monocarboxypeptidase that converts Ang II 
into angiotensin 1-7 (Ang 1-7), which counteracts the 
molecular and cellular effects of Ang II [84]. It has 
been proposed that ACE2, widely expressed in cardio-
myocytes, cardiofibroblasts, and coronary endothelial 
cells, might protect against blood pressure increase 
caused by Ang II action [83]. Indeed, recent preclinical 
translational studies confirmed that an increase of 
ACE2 level prevents and reverses the HF phenotype. 
Recombinant human ACE2 has been shown to effec-
tively lower plasma levels of Ang II and to increase 
Ang 1-7 levels, and, most importantly, was considered 
safe in both phase I and II of clinical trials [84]. 
RhoA/ROCKpathway. Rho-kinases (ROCKs) are 
the first and the best-characterized effectors of the 
small G-protein RhoA, and play important roles in 
many intracellular signaling pathways [85-89]. ROCK 
are serine/threonine kinases for which two isoforms, 
ROCK1 and ROCK2 have been identified in humans 
[86]. The RhoA/ROCK pathway has been so far well 
described in endothelial cells and in VSMCs, where a 
large number of ROCK targets are related to actin-
filament dynamics, organization of the cytoskeleton 
and regulation of contractility [87]. The Rho/ROCK 
cascade seems to be interacting with other signaling 
cascades, like NO-signaling, that are also important 
regulators of vascular smooth muscle contractility [85]. 
ROCKs activity regulates major morphogenetic events 
during embryonic development including cardiomyo-
cyte differentiation [85].  
Several studies have clearly shown an important 
pathophysiological involvement of this pathway in the 
cardiovascular system and in diseases such as athero-
sclerosis, I/R injury, hypertension, HF and stroke [85-
89]. Among others, the interplay between ROCKs acti-
vation and ROS production plays a crucial role in myo-
cardial damage after I/R. Pretreatment with the ROCK 
inhibitor Fasudil before reperfusion prevented endothe-
lial dysfunction and reduced the extent of MI in several 
animal models [87].  
Among others, increased activity of the Rho/Rho-
kinase pathway has also been shown to have an impor-
tant role in the development and maintenance of hyper-
tension [85-87]. Modifications in the RhoA/ROCK 
pathway are likely related to an upstream event in the 
hypertensive state. One upstream signaling molecule 
possibly involved is Ang II and its receptor type 1 
(AT1R). Interestingly, another upstream event that is 
linked to activation of RhoA and ROCKs in hyperten-
sion is the formation of ROS [86].  
ROCKs specific inhibitors, such as Fasudil and Y-
27632, inhibit kinase activity by competing with ATP 
at the Rho-binding site [87]. Since the two ROCK iso-
forms seem to have different functions in smooth mus-
cle cells under different conditions, clinical applica-
tions require more specific ROCK inhibitors, which 
might have multiple beneficial effects on vascular 
function.  
 Even though the use of ROCKs inhibitors have 
drawn much attention in cardiovascular medicine, their 
use should be avoided during pregnancy due to the cru-
cial role of ROCKs in cardiac development [87]. 
Moreover, it should be also taken in account that sev-
eral medications, including statins, calcium channel 
blockers and eicosapentaenoic acid share an indirect 
inhibitory effect on Rho-kinase.  
Recently, it was shown that Arhgef1 is the RhoA 
guanine exchange factor responsible for angiotensin II-
induced activation of RhoA signaling in arterial smooth 
muscle cells [88, 89]. The authors showed that control 
of RhoA signaling through Arhgef1 is central to the 
development of angiotensin II-dependent hypertension 
and identify Arhgef1 as a potential target for the treat-
ment of hypertension [88, 89].  
PTX3. Pentraxine (PTXs) superfamily includes 
evolutionary conserved proteins involved in the acute 
inflammatory phase [90]. Among them, particular at-
tention has been focused on pentraxine 3 (PTX3); this 
protein regulates the inflammatory response and is also 
involved in several important mechanisms, including 
the onset of vascular diseases. Indeed, during inflam-
mation, blood vessels produce a large amount of PTX3; 
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these high levels are also detected in several pathologi-
cal conditions affecting the cardiovascular system [91]. 
Furthermore, the protein is abundantly expressed in the 
endothelial cells in advanced atherosclerotic lesions 
and in patients with vasculitis [91]. This suggests that 
PTX3 is involved in a variety of molecular mechanisms 
leading to vascular damage; in addition, it has been 
shown that its elevated plasma levels might effectively 
represent a predictor of fragility in hypertensive pa-
tients [92, 93]. Interestingly, recent work by Bonacina 
and coworkers showed that PTX3 produced by vascu-
lar cells plays a protective role in arterial thrombosis, 
reducing collagen and fibrinogen induced platelet ag-
gregation. Injection of recombinant PTX3 restored, at 
least partially, phenotype observed in PTX3-deficient 
knockout mice and had beneficial effects on cardiovas-
cular dysfunctions in wild-type mice [94]. 
miRNA. miRNAs, small non-coding RNAs of 20-
25 nucleotides, are a group of key regulators that 
modulate the development of various diseases, includ-
ing CVD. Considering the role of miRNA in gene regu-
lation, MiRNAs may thus be deeply involved in car-
diac hypertrophy and HF and show a great potential for 
diagnostic and therapeutic utilization [95-98]. MiRNAs 
modulate gene expression at the posttranscriptional 
level through several mechanisms [99], and are ex-
tremely abundant in humans; it has been estimated that 
these molecules, whose expression seems to be tissue 
specific, participate in modulating the expression of 
more than 60% of protein-coding genes [100, 101]. 
MiRNAs downregulate gene expression by either 
cleaving and degrading mRNA or blocking translation 
through different mechanisms such as inhibition of 
mRNA translation, de-adenylation and sequestration 
[102].  
Generally, a mature miRNA regulates gene expres-
sion by binding motifs in the 3' UTR sequences, but 
recent studies suggest that miRNA may also target 5' 
UTR or exons and may potentially undergo base pair-
ing with regulatory-DNA sequences to modulate tran-
scription [102].  
 As already underlined in this review, CVD is the 
result of cardiac remodeling involving several proc-
esses such as cardiomyocyte hypertrophy, cardiomyo-
cyte apoptosis, interstitial fibrosis and aberrant cardiac 
conduction. All these processes, ultimately, impair the 
myocardium electromechanical performance. Patho-
logical cardiac hypertrophy is characterized by an in-
crease in cell size, enhanced protein synthesis, and 
heightened organization of the sarcomere. In vivo and 
in vitro studies in cardiac hypertrophy models have 
reaveled both up- and down- regulation of miRNAs 
responsible for either positive or negative regulatory 
effects on cardiac hyperthrophic pathways. In litera-
ture, several studies show the involvement of miR-
1/miR133 cluster in hypertrophy remodeling [103, 
104]. It has been shown that they are downregulated in 
cardiac disease and cardiac hypertrophy models [104]. 
Futhermore, miR-1/miR133 cluster participates in hy-
pertrophic program because they repress CaN/NFAT 
(Nuclear Factor of activated T-cells) and IGF signaling 
pathways, a key regulator of cardiomyocytes growth 
and differentiation [103]. Even though the precise role 
of miR-1 remains to be defined, the observed effects in 
vitro and in vivo of these molecules suggest that their 
pharmacological potential might be of preventing car-
diac hypertrophy during cardiac diseases [105]. 
To date, more than 11 miRNAs have been experi-
mentally established to be involved in the pathogenesis 
of CVD; among these, the best characterized are miR-
1, 133, 129, 18b, 195, 21, 23a, 23b, 24, 208, and 212 
[106]. Down-regulation of miR-1 has been for example 
identified in three different hypertrophic models, in-
cluding transverse aortic arch-constricted mice, trans-
genic mice with selective cardiac overexpression of a 
constitutively active mutant of the Akt kinase, and ex-
ercised rats [107, 108]. MiR-1 was also reported to 
negatively regulate the expression of hypertrophy-
associated genes, myocyte enhancer factor-2 (Mef2a) 
and transcription factor Gata4, and to attenuate cardio-
myocyte hypertrophy in cultured neonatal rat cardio-
myocytes and in the intact adult heart [109]. Increasing 
evidence indicates that miRNAs such as miR-1/106, 
miR-133, miR-21, miR-320, miR-199a and miR- 92a, 
are also implicated in CAD. It was recently shown that 
miR-1 level is markedly elevated in ischemic myocar-
dium where apoptotic cell death plays an important role 
in the detrimental changes of the diseased heart [110]. 
Aberrant proliferation of VSMCs and the formation of 
neointimal lesion is a key pathological process of a va-
riety of proliferative vascular diseases, such as athero-
sclerosis, CAD, postangioplasty restenosis and trans-
plantation arteriopathy [111]. It was suggested that 
miR-21, miR-221, and miR-222 were significantly 
upregulated in carotid arteries after angioplasty and the 
depletion of the aberrantly overexpressed miR-21, 
miR-221, or miR-222, via antisense-mediated knock-
down, has a significantly negative effect on neointimal 
lesion formation in rat artery after angioplasty, forced 
overexpression of these miRNAs promotes instead 
VSMCs proliferation [112].  
For those miRNAs that are aberrantly upregulated 
and play a causal role in disease states, the anti-miRNA 
techniques suppressing their expression are an appeal-
ing therapeutical approach. The inhibition of miRNAs 
expression can be achieved by using antisense inhibitor 
oligonucleotides (AMO) technique, thus designing oli-
gonucleotides fully complementary to their target 
miRNAs (antagomiR), which block the targeted miR-
NAs with unknown mechanisms [113, 114]. Several 
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studies have validated so far the therapeutic effects of 
antagomiR in cardiac hypertrophy and infarction [115].  
CONCLUSION 
CVD is globally recognized as the leading cause of 
human morbidity and mortality in developed countries, 
although a profound gap still exists between high-
income countries and low and middle-income countries 
in terms of major and fatal clinical events [116]. 
Despite the existence of well-established therapies 
for these dysfunctions, their social and economic bur-
den, due to high mortality and morbidity rates, contin-
ues to increase and, as a very limited number of new 
drugs survive phase III trials, there is a critical need for 
safer and more effective therapies. 
Aim of this brief review has been to describe some 
among the most interesting molecular targets currently 
investigated for the development of new therapeutics 
for cardiac diseases. 
The global quest for new molecular targets is lead-
ing to an impressive amount of records in the more re-
cent literature. However, great caution should be used 
in considering all these targets effective in promoting 
the production of new drugs, as past lessons have 
shown the fail in clinical development of several new 
molecules due to a lack of efficacy or induction of 
safety liabilities [117]. The drawbacks responsible for 
discontinuing the pipeline to the development of com-
mercially available drugs are different and include, 
among others, a very high bar of the existing medicines 
and the increasing cost of mega-trials. In addition, sev-
eral studies lack independent and large-scale popula-
tion studies from which novel targets with strong corre-
lation to clinical phenotypes should be inferred, and do 
not show the fundamental pre-clinical and clinical vali-
dations. Furthermore, many molecular targets for CVD 
treatment are correctly selected, based on their in-
volvement in critical metabolic pathways in cellular 
models but, since they play functional roles in other 
biological processes outside the cardiovascular system, 
they lack specificity.  
Lastly, but most importantly, the complexity of 
CVD -caused by interconnected multiple genetic, envi-
ronmental and physiological factors- cannot be ad-
dressed by a single “magic bullet”. To maximize the 
chance for successful clinical drug development, CVD 
onset should be analyzed based on the entire body of 
genetic and biochemical knowledge associated with the 
clinical traits, even though today it is still very impor-
tant to add further details to the cellular and molecular 
basis of cardiovascular dysfunctions.  
In this light, an increasing interest has been aroused 
in “omics” sciences, which allow performing the un-
targeted investigation of complex biological systems. 
In particular, proteomic approaches are very attractive 
to CVD research, since these multifactorial pathologies 
depend on alterations involving large protein networks. 
Proteomics emerged as one of the most powerful tools 
to identify biomarkers for early diagnosis of CVD and 
risk prediction [118], responsible to identify tens of 
new promising candidates both in plasma and urine. 
Moreover, it could provide information concerning the 
proteins playing key roles in the onset and progression 
of CVD, also unveiling the relationships occurring 
among proteins affecting different pathways [119]. 
Therefore, proteomics-based studies could lead to the 
identification of new therapeutic targets, possibly con-
sisting of groups of proteins [120, 121].  
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